etoposide has been researched along with camptothecin in 659 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (1.06) | 18.7374 |
| 1990's | 159 (24.13) | 18.2507 |
| 2000's | 259 (39.30) | 29.6817 |
| 2010's | 219 (33.23) | 24.3611 |
| 2020's | 15 (2.28) | 2.80 |
| Authors | Studies |
|---|---|
| Bisagni, E; Croisy, A; Janin, YL; Riou, JF | 1 |
| Baguley, BC; Deady, LW; Denny, WA; Finlay, GJ; Kaye, AJ | 1 |
| Artico, M; Costi, R; De Montis, A; Di Santo, R; Greco, G; La Colla, P; Marongiu, ME; Massa, S; Novellino, E; Tramontano, E | 1 |
| Bigg, DC; Camara, J; Demarquay, D; Harnett, J; Kasprzyk, PG; Lavergne, O; Lesueur-Ginot, L; Pla Rodas, F; Pommier, J; Pons, D; Prévost, G; Rolland, A; Schiano-Liberatore, AM; Ulibarri, G | 1 |
| Almerico, AM; Barraja, P; Cirrincione, G; Diana, P; La Colla, P; Lauria, A; Marongiu, ME; Minnei, C; Murtas, P; Musiu, C; Pani, A; Passannanti, A | 1 |
| Corbett, TH; Edelstein, M; Hazeldine, ST; Horwitz, JP; Kushner, J; Palomino, E; Paluch, J; Polin, L; White, K | 1 |
| Furbacher, TR; Gunatilaka, AA | 1 |
| Alvarez-Pedraglio, A; Colmenarejo, G; Lavandera, JL | 1 |
| Baguley, BC; Deady, LW; Denny, WA; Rodemann, T; Zhuang, L | 1 |
| Abdel-Aziz, M; Matsuda, K; Okawara, T; Otsuka, M; Suzuki, K; Uyeda, M | 1 |
| Hwang, HJ; Kim, JS; Kim, YS; Lee, EJ; Lee, SK; Park, HJ; Ryu, CK; Suh, ME; Yi, YJ | 1 |
| Itoh, A; Kumashiro, T; Mizushina, Y; Nagakura, N; Nishi, T; Tanahashi, T; Yamaguchi, M | 1 |
| Benel, L; Bertrand, V; Delfourne, E; Legentil, L; Lesur, B | 1 |
| Choo, HY; Kim, JS; Lee, HJ; Lee, IK; Lee, SK; Park, HJ; Rhee, HK; Ryu, CK; Suh, ME | 1 |
| Choo, HY; Lee, CO; Lee, SK; Park, HJ; Rhee, HK | 1 |
| Austin, CA; López-Lazaro, M; Willmore, E | 1 |
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Chan, YL; Chen, HW; Chen, WR; Guh, JH; His, CP; Hsin, LW; Kao, PH; Lee, CH; Lee, O; Li, TK; Wang, HP; Yang, MS | 1 |
| Austin, CA; Curtis, H; Gilroy, KL; Jobson, A; López-Lázaro, M; Padget, K; Willmore, E | 1 |
| Jahng, Y; Jung, MJ; Kang, DH; Kim, JS; Kwon, Y; Lee, ES; Na, Y | 1 |
| Dassi, C; David-Cordonnier, MH; Depauw, S; Lemster, T; Lenglet, G; Pindur, U | 1 |
| Ahmad, KF; Badria, FA; Bar, FM; El Sayed, KA; Elnagar, AY; Khanfar, MA; Liu, H; Raisch, KP; Sylvester, PW; Zaghloul, AM | 1 |
| Austin, CP; Fidock, DA; Hayton, K; Huang, R; Inglese, J; Jiang, H; Johnson, RL; Su, XZ; Wellems, TE; Wichterman, J; Yuan, J | 1 |
| Choo, HY; Jung, MJ; Kim, MH; Kwon, Y; Lim, SY; Rhee, HK | 1 |
| Cho, HJ; Jung, MJ; Kwon, Y; Na, Y | 1 |
| Jahng, Y; Jung, MJ; Karki, R; Kwon, Y; Lee, ES; Na, Y; Nam, JM; Thapa, P; Thapa, U | 1 |
| Basnet, A; Cho, WJ; Choi, H; Choi, JH; Jahng, Y; Jeong, BS; Karki, R; Kwon, Y; Lee, CS; Lee, ES; Na, Y; Thapa, P; Yun, M | 1 |
| Bodner, A; Chee, GL; Hasinoff, BB; Wu, X; Yalowich, JC | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Cho, HJ; Jung, MJ; Kim, J; Kwon, Y; Lee, ES; Na, Y; Woo, S | 1 |
| Cho, WJ; Choi, H; Choi, JH; Jeong, BS; Jung, MJ; Karki, R; Kwon, Y; Lee, ES; Na, Y; Nam, JM; Thapa, P; Yun, M | 1 |
| Das, B; Jakka, NM; Laxminarayana, K; Mahender, I; Raju, TV; Rao, JV; Reddy, PR; Srinivas, Y; Sudhakar, C | 1 |
| Cho, WJ; Jeong, TC; Kang, MJ; Karki, R; Kim, HL; Kwon, Y; Lee, ES; Na, Y; Nam, JM; Thapa, P | 1 |
| Ha, EM; Kang, DH; Kwon, Y; Lee, CS; Lee, ES; Na, Y; Nam, JM; Woo, S | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Agrawal, SK; Chashoo, G; Kamal, A; Kumar, BA; Saxena, AK; Singh, SK; Suresh, P | 1 |
| Calvo, A; Font, M; Ibáñez, E; Palop, JA; Plano, D; Prior, C; Sanmartín, C | 1 |
| Na, Y; Nam, JM | 1 |
| Arefolov, A; Clardy, J; Clarke, AS; Ishihara, K; Marks, KM; Park, ES; Pelish, HE; Ring, JE; Russo, K | 1 |
| Jun, KY; Jung, MJ; Kwon, Y; Lee, ES; Lee, EY; Lee, OH; Na, Y; Park Choo, HY | 1 |
| David-Cordonnier, MH; Depauw, S; Genès, C; Lenglet, G; Michel, S; Nhili, R; Porée, FH; Prado, S; Tillequin, F | 1 |
| Chen, SB; Gu, LQ; Huang, SL; Huang, ZH; Huang, ZS; Li, D; Ou, JB; Ou, TM; Shen, LL; Tan, JH; Wu, WB | 1 |
| Cho, WJ; Choi, JH; Ha, EM; Jahng, Y; Jeon, KH; Karki, R; Kwon, Y; Lee, E; Lee, ES; Na, Y; Thapa, P; Thapa, U; Yun, M | 1 |
| Jeong, YT; Kim, SK; Pallela, R; Park, DH; Parthiban, P | 1 |
| Encío, I; Font, M; Lamberto, I; Moreno, E; Palop, JA; Plano, D; Sanmartín, C | 1 |
| Busonera, B; Caboni, P; Casu, L; Cottiglia, F; Farci, P; Floris, C; Leonti, M; Ouhtit, A; Sanna, G | 1 |
| Cho, WJ; Choi, H; Jeon, KH; Kadayat, TM; Karki, R; Kwon, Y; Lee, E; Lee, ES; Na, Y; Park, PH; Thapa, P; Yoo, HY | 1 |
| Bose, DS; Idrees, M; Jakka, NM; Rao, JV; Todewale, IK | 1 |
| Imthiajali, S; Kamal, A; Lavanya, A; Mallareddy, A; Pal-Bhadra, M; Pushpavalli, SN; Ramaiah, MJ; Suresh, P | 1 |
| Cho, WJ; Jeong, BS; Kadayat, TM; Karki, R; Kim, ND; Kwon, HB; Kwon, Y; Lee, E; Lee, ES; Na, Y; Thapa, P; Yun, M | 1 |
| Cheng, YC; Gullen, EA; Jiang, ZL; Kim, SW; Lee, KH; Leung, CH; Morris-Natschke, SL; Park, SY; Shi, Q; Ye, D; Zhu, H | 1 |
| Jahng, Y; Kwon, Y; Liang, JL; Park, SE | 1 |
| Dong, G; Guo, Z; Miao, Z; Sheng, C; Wang, S; Yao, J; Zhang, W; Zhang, Y | 1 |
| Ellis, KC; Hiasa, H; Nguyen, T; Oppegard, LM | 1 |
| Batista-Gonzalez, A; Brunhofer, G; Fallarero, A; Gopi Mohan, C; Karlsson, D; Shinde, P; Vuorela, P | 1 |
| Banerjee, UC; Baviskar, AT; Das, D; Guchhait, SK; Kandekar, S; Kashyap, M; Kundu, CN; Mohapatra, P; Preet, R; Satapathy, SR; Siddharth, S | 1 |
| Chen, Z; Qian, X; Tan, S; Xu, Y; Yin, H | 1 |
| Bielawska, A; Bielawski, K; Lepiarczyk, M; Maciorkowska, E; Siwek, A; Trotsko, N; Wujec, M | 1 |
| Baek, KH; Kim, SH; Kwon, HB; Kwon, Y; Lee, E; Lee, ES; Na, Y; Woo, H | 1 |
| Font, M; Ibáñez, E; Lizarraga, E; Palop, JA; Plano, D; Sanmartín, C | 1 |
| Imthiajali, S; Kamal, A; Kapavarapu, RK; Lakshminarayan Reddy, T; Pal-Bhadra, M; Pushpavalli, SN; Ramaiah, MJ; Rao, BN; Shankaraiah, N; Srinivasa Reddy, T; Suresh, P | 1 |
| Banerjee, UC; Baviskar, AT; Gupta, M; Gupta, MK; Khullar, M; Kumar, R; Kumar, S; Raut, SK; Singh, R; Singh, S | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chang, IH; Jun, KY; Kwon, Y; Lee, E; Lee, ES; Na, Y; Park, SE | 1 |
| Abdel-Aziz, M; Abuo-Rahma, Gel-D; Kwon, Y; Park, SE; Sayed, MA | 1 |
| Carbone, M; Ciavatta, ML; Cirillo, I; Gavagnin, M; Guo, YW; Kiss, R; Mathieu, V; Mollo, E; Wang, JR | 1 |
| Abdel Bar, F; Amer, M; Ashour, A; Bang, TH; El-Sharkawy, S; Katakura, Y; Kondo, R; Miyamoto, T; Shimizu, K; Toyota, N | 1 |
| Cho, WJ; Jeong, HM; Jin, Y; Khadka, DB; Kwon, Y; Lee, ES; My Van, HT; Woo, H; Yang, SH; Youl Lee, K; Zhao, C | 1 |
| Chang, LC; Goto, M; Hung, HY; Kuo, DH; Kuo, SC; Lee, KH; Liu, YQ; Morris-Natschke, SL; Nan, X; Pan, SL; Qian, K; Teng, CM; Wang, CY; Wang, MJ; Wu, TS; Wu, YC; Yang, JS; Yang, L; Yang, XM; Zhao, XB; Zhao, YL | 1 |
| Jee, JG; Jun, KY; Kadayat, TM; Karki, R; Kwon, Y; Lee, ES; Lee, JH; Park, C; Thapa, P | 1 |
| Chen, W; Li, Z; Lu, C; Shen, Y; Zhang, M | 1 |
| Bist, G; Jun, KY; Kadayat, TM; Kwon, Y; Lee, ES; Magar, TB; Park, C; Yoo, HY | 1 |
| Chen, SB; Gu, LQ; Huang, SL; Huang, ZS; Li, D; Mai, YW; Ou, TM; Tan, JH; Wang, HG; Xie, HT; Yao, BL; Yao, PF | 1 |
| Chen, CL; Chen, TC; Huang, HS; Lee, CC; Wu, CL; Yu, DS | 1 |
| Chen, W; Dong, G; He, S; Huang, Y; Jiang, Y; Li, Z; Liu, N; Miao, Z; Sheng, C; Wang, Z; Yao, J; Zhang, W | 1 |
| Bist, G; Kadayat, TM; Karki, R; Kwon, Y; Lee, ES; Magar, TB; Na, Y; Shrestha, A; Song, C | 1 |
| Bist, G; Kadayat, TM; Kwon, Y; Lee, ES; Magar, TB; Na, Y; Shin, S; Shrestha, A; Song, C; Thapa, P | 1 |
| Alex, JM; Amrutkar, SM; Banerjee, UC; Baviskar, AT; Joshi, G; Kumar, R; Negi, A; Singh, S | 1 |
| Cao, HT; Chau, MV; Cho, WJ; Jin, Y; Khadka, DB; Kwon, Y; Le, TN; Nguyen, HT; Shin, S; Tran, GH; Van, HT; Zhao, C | 1 |
| Bist, G; Jun, KY; Kadayat, TM; Kwon, Y; Lee, ES; Na, Y; Park, C; Shrestha, A; Thapa Magar, TB; Thapa, P; Zheng, Z | 1 |
| Caneschi, W; Couri, MRC; da Silveira, LS; de Almeida, MV; de Oliveira, PF; de Souza Fernandes, F; Diniz, CG; Fernandes, TS; Le Hyaric, M; Lourenço, MCS; Martins, SPL; Pereira, DE; Tavares, DC | 1 |
| Dezhenkova, LG; Kalinina, AA; Kaluzhny, DN; Kubbutat, M; Luzikov, YN; Pommier, Y; Preobrazhenskaya, MN; Romanenko, VI; Schols, D; Shchekotikhin, AE; Shtil, AA; Tatarskiy, VV; Treshalin, MI; Treshalina, HM; Tsvetkov, VB; Volodina, YL | 1 |
| Bist, G; Jun, KY; Kadayat, TM; Kwon, Y; Lee, ES; Magar, TB; Na, Y; Park, S; Shrestha, A | 1 |
| Bist, G; Jun, KY; Kadayat, TM; Karki, R; Kwon, Y; Lee, ES; Na, Y; Shin, S; Shrestha, A; Thapa Magar, TB | 1 |
| Abdel-Aziz, HA; Ahmad, P; Jun, KY; Kadi, AA; Kwon, Y; Rahman, AF; Woo, H | 1 |
| Ayad, T; Fahy, J; Maillos, P; Perez, M; Poughon, V; Ratovelomanana-Vidal, V | 1 |
| Amrutkar, S; Banerjee, UC; Guchhait, SK; Kundu, CN; Nayak, A; Priyadarshani, G | 1 |
| Hong, E; Jun, KY; Kwak, SY; Kwon, Y; Lee, ES; Na, Y; Park, S | 1 |
| Bist, G; Jun, KY; Kadayat, TM; Kwon, Y; Lee, ES; Park, S; Shrestha, A; Thapa Magar, TB | 1 |
| Islam, MS; Kadi, AA; Kwon, Y; Park, S; Rahman, AF; Song, C | 1 |
| Jeon, KH; Kwak, SY; Kwon, Y; Na, Y; Yu, HB | 1 |
| Amrutkar, SM; Banerjee, UC; Das, S; Guchhait, SK; Kundu, CN; Nayak, A; Priyadarshani, G | 1 |
| Bist, G; Kadayat, TM; Kwon, Y; Lee, ES; Lee, HJ; Park, S; Shrestha, A; Thapa Magar, TB | 2 |
| Bist, G; Kwon, Y; Lee, ES; Park, S; Shrestha, A; Song, C; Thapa Magar, TB | 1 |
| Ding, Q; Han, X; Li, S; Liu, Z; Qi, H; Qiao, X; Song, Y; Zhong, Y; Zhou, G | 1 |
| Cho, WJ; Han, J; Jin, Y; Khadka, DB; Kwon, Y; Park, S | 1 |
| Das, BB; Das, SK; Ghosh, A; Halder, N; Paul Chowdhuri, S; Rath, H; Rehman, I; Sahoo, KC; Sengupta, S | 1 |
| Chen, HX; Dong, CZ; Du, ZY; Huang, ZS; Jiang, H; Li, PH; Li, YL; Tang, YD; Zhang, LY; Zhang, WJ; Zhao, MC; Zhou, W | 1 |
| Jo, H; Kwon, Y; Lee, ES; Shrestha, A | 1 |
| Bist, G; Jo, H; Kadayat, TM; Katila, P; Kwon, Y; Lee, ES; Magar, TBT; Seo, SH; Shrestha, A | 1 |
| David-Cordonnier, MH; Depauw, S; Ilić, N; Jambon, S; Karminski-Zamola, G; Kraljević Pavelić, S; Markova-Car, E; Sović, I | 1 |
| Chen, HX; Dong, CZ; Du, ZY; Jiang, H; Li, PH; Wang, J; Zhang, K; Zhang, WJ | 1 |
| Chen, H; Dong, C; Du, Z; Jiang, H; Li, P; Li, Y; Zhang, K; Zhang, W | 1 |
| Arepalli, SK; Jo, H; Jun, KY; Jung, JK; Kang, JS; Kwon, Y; Lee, C; Lee, H; Lee, K; Sim, S | 1 |
| Jang, HJ; Katila, P; Kwon, Y; Lee, ES; Park, S; Shrestha, A; Shrestha, R | 1 |
| An, LK; Hao, XJ; Jin, LY; Khan, A; Liu, H; Liu, HY; Qin, XJ; Yan, H; Yu, Q | 1 |
| Bhattacharya, D; Das, BB; Das, SK; Ghosh, A; Kundu, B; Mukherjee, A; Pal, S; Paul Chowdhuri, S; Sarkar, D; Talukdar, A | 1 |
| He, C; He, M; Li, L; Liang, X; Luan, S; Lv, C; Song, X; Wu, Q; Yin, L; Yin, Z; Yuan, Z; Zhang, W; Zou, Y | 1 |
| Capuzzi, SJ; Chang, LC; Goto, M; Hsieh, KY; Hsu, PL; Lee, KH; Li, J; Li, KP; Morris-Natschke, SL; Zhang, YC | 1 |
| Hwang, SY; Jeon, YH; Jeong, TC; Jo, H; Kadayat, TM; Katila, P; Kim, KS; Kim, SK; Koh, WS; Kwon, Y; Lee, ES; Nepal, MR; Noh, K; Park, S; Shrestha, A; Shrestha, R | 1 |
| Liu, Y; Xu, Z; Zhao, SJ | 1 |
| Dou, Z; He, S; Jin, H; Wang, N; Xiong, Z; Yan, X; Zhang, B | 1 |
| Chen, S; Dong, G; Li, X; Liu, D; Ma, Z; Sheng, C; Wu, S | 1 |
| Andreev, EN; D'yakonov, VA; Dzhemilev, UM; Dzhemileva, LU; Makarov, AA; Makarova, EK | 1 |
| Chen, S; Dong, G; Huang, Y; Liu, D; Ma, Z; Sheng, C; Wan, K; Zhu, F | 1 |
| Bist, G; Hwang, SY; Jang, H; Jeon, KH; Kadayat, TM; Kim, S; Kunwar, S; Kwon, Y; Lee, ES; Park, S; Seo, M; Sheen, N; Shrestha, A | 1 |
| Deng, X; Jiang, W; Li, Y; Liu, L; Luo, T; Wang, Z; Xie, L; Zhang, X | 1 |
| Przybylski, P; Łowicki, D | 1 |
| Adamson, RH; Mead, JA; Sieber, SM | 1 |
| Carter, SK; Muggia, FM; Rozencweig, M; Slavik, M | 1 |
| Beck, H; Capranico, G; Gazdar, AF; Giaccone, G; Zunino, F | 1 |
| Barley, LR; Chang, JY; Cheng, YC; Dethlefsen, LA; Zhou, BS | 1 |
| Andoh, T; Ishida, R; Ishimi, Y | 1 |
| Bertrand, R; Kerrigan, D; O'Connor, PM; Pommier, Y | 1 |
| Kohno, K; Kuwano, M; Matsuda, T; Matsuo, K; Takano, H | 1 |
| Sumner, AT | 1 |
| Cimoli, G; Conte, P; Conzi, G; Noviello, E; Orengo, G; Pagnan, G; Parodi, S; Russo, P; Schenone, F; Venturini, M | 1 |
| Adachi, S; Akiyama, Y; Hashimoto, H; Kasai, Y; Kubota, M; Mikawa, H; Sano, H; Shimizu, T | 1 |
| Bryant, PE; Johnston, PJ | 1 |
| Beck, WT; Danks, MK | 1 |
| Banáth, JP; Durand, RE; Evans, HH; Olive, PL | 1 |
| Beardmore, C; D'Arpa, P; Liu, LF | 1 |
| Kaufmann, SH | 2 |
| Fujita, H | 1 |
| Chou, S; Kaneko, M; Nakamura, Y; Nakaya, K | 1 |
| Shin, CG; Snapka, RM; Strayer, JM; Wani, MA | 1 |
| Hsu, MT; Wong, ML | 1 |
| Andersson, BS; Ling, YH; Nelson, JA | 1 |
| Andrews, PA; Howell, SB; Katz, EJ; Kling, KM; Vick, JS | 1 |
| Musk, SR; Steel, GG | 1 |
| Shin, CG; Snapka, RM | 1 |
| Covey, JM; Holm, C; Kerrigan, D; Pommier, Y | 1 |
| Covey, JM; Kao-Shan, CS; Kerrigan, D; Pommier, Y; Whang-Peng, J | 1 |
| Duguet, M; Jaxel, C; Mirambeau, G; Panijel, J; Portemer, C; Taudou, G | 1 |
| Powelson, MA; Snapka, RM; Strayer, JM | 1 |
| Kato, M; Takada, S; Takayama, S | 1 |
| Fukuoka, M; Hirashima, T; Kudoh, S; Kusunoki, Y; Masuda, N; Matsui, K; Nakagawa, K; Takada, M; Tsukada, H; Yana, T | 1 |
| Bjornsti, MA; Evans, DL; Hall, DJ; Logan, TJ; Mercer, WE | 1 |
| Dubrez, L; Genne, P; Goldwasser, F; Pommier, Y; Solary, E | 1 |
| Arioka, H; Eguchi, K; Karato, A; Kunikane, H; Nishio, M; Ohe, Y; Oshita, F; Sasaki, Y; Shinkai, T; Tamura, T | 1 |
| Kataoka, S; Kawai, H; Mashima, T; Naito, M; Tsuruo, T | 1 |
| Higashide, K; Kikkawa, F; Maeda, O; Misawa, T; Obata, NH; Suganuma, N; Tomoda, Y | 1 |
| Ikeda, T; Nakaike, S; Nakane, S; Ohsawa, M; Suzuki, H; Yamagishi, T | 1 |
| Benchokroun, Y; Larsen, AK; Lelièvre, S | 1 |
| Capranico, G; D'Incalci, M; Garattini, S; Giaccone, G; Zunino, F | 1 |
| Kim, K | 1 |
| Kohn, KW; O'Connor, PM; Pommier, Y; Shimizu, T | 1 |
| Berger, NA; Chatterjee, S; Cheng, MF | 1 |
| Bosl, GJ; Chou, TC; Motzer, RJ; Tong, Y | 1 |
| Ishihara, H; Itamochi, H; Kigawa, J; Minagawa, Y; Terakawa, N | 1 |
| Arioka, H; Eguchi, K; Karato, A; Nakashima, H; Ohe, Y; Oshita, F; Shinkai, T; Tamura, T; Uenaka, K; Yamamoto, N | 1 |
| Ellis, AL; Nowak, B; Plunkett, W; Zwelling, LA | 1 |
| Bussey, AM; Ng, CE; Raaphorst, GP | 1 |
| Iwai, H; Kariya, K; Lee, E; Miura, M; Yoshinari, M | 1 |
| Cassidy, J | 1 |
| Eguchi, K; Kanzawa, F; Karato, A; Kubota, N; Nishio, K; Ohe, Y; Saijo, N; Sasaki, Y; Shinkai, T; Tamura, T | 1 |
| Inaba, M; Kawada, S; Mitsuhashi, J; Nakano, H | 1 |
| Marples, B; Skov, K; Zhou, H | 1 |
| Hashimoto, S; Jing, Y; Nakajo, S; Nakaya, K | 1 |
| Nakane, S; Suzuki, H | 1 |
| Akiyaya, S; Ito, K; Kodera, Y; Kondou, K; Nagai, S; Satta, T; Takagi, H; Yamauchi, M | 1 |
| Hsiung, Y; Liu, YX; Nitiss, JL | 1 |
| Azuma, Y; Kizaki, H; Mizuno, Y; Onishi, Y; Sato, Y; Tadakuma, T | 1 |
| Duguet, M; Jaxel, C; Portemer, C; Taudou, G | 1 |
| Kohno, K; Kuwano, M; Matsuo, K; Sato, S; Tanimura, H; Uchiumi, T; Yamada, Y | 1 |
| Bertrand, R; Kohn, KW; Pommier, Y; Solary, E | 1 |
| Auclair, C; Carteau, S; Goulaouic, H; Mouscadet, JF; Subra, F | 1 |
| Dilworth, A; Myers, CE; Sinha, BK; Yamazaki, H | 1 |
| Astaldi Ricotti, GC; Evans, HH; Lanza, A; Pedrini, AM; Ricanati, M; Stefanini, M; Tornaletti, S | 1 |
| Ariyoshi, Y; Hida, T; Miyara, H; Morishita, M; Nishida, K; Sugiura, T; Takahashi, T; Ueda, R | 1 |
| Bertoglio, J; Bréard, J; Issaad, C; Léglise, MC; Pallardy, M; Roger, R; Turhan, AG | 1 |
| Hidaka, K; Hirohashi, Y; Hisatsugu, T; Kohno, K; Kuwano, M; Sato, S | 1 |
| Andoh, T; Aratani, Y; Koyama, H | 1 |
| Beere, HM; Chresta, CM; Hickman, JA | 1 |
| Smith, CD; Zhang, X | 1 |
| Cotter, TG; Samali, A | 1 |
| Kinzler, KW; Lengauer, C; Vogelstein, B; Waldman, T | 1 |
| Frei, H; Würgler, FE | 1 |
| Hasumi, K; Shimizu, Y; Umezawa, S | 1 |
| Nakaya, K | 1 |
| Creus, A; Marcos, R; Ribas, G; Xamena, N | 1 |
| Báez, A; Casiano, CA; Pommier, Y; Tan, EM; Torres, K | 1 |
| Bertrand, R; Dubrez, L; Eymin, B; Pommier, Y; Solary, E | 1 |
| DeVore, R; Glick, J; Hutson, P; Johnson, D; Kim, K; Schiller, JH; Stewart, J | 1 |
| Ardouin, P; Bénard, J; Bissery, MC; Boland, I; Bressac-de-Paillerets, B; Gouyette, A; Gyergyay, F; Morizet, J; Terrier-Lacombe, MJ; Vassal, G; Vénuat, AM | 1 |
| Hidaka, H; Minamino, T; Miyamoto, K; Nakamura, S; Nomura, M; Wakusawa, S | 1 |
| Pommier, Y; Shao, RG; Shimizu, T | 1 |
| Jasti, R; Kalemkerian, GP; Kaufmann, SH; Mabry, M | 1 |
| Levac, P; Moss, T | 1 |
| Fossella, FV; Glisson, BS; Hong, WK; Lee, JS; Murphy, WK; Perez-Soler, R; Shin, DM | 1 |
| Hwang, A; Janss, A; Maity, A; McKenna, WG; Muschel, RJ; Phillips, P | 1 |
| Kizaki, H; Onishi, Y | 1 |
| Nitiss, JL; Wang, JC | 1 |
| Piette, J; Piret, B | 1 |
| Erusalimsky, JD; Hong, Y; John, J; Moore, M | 1 |
| Adjei, PN; Gores, GJ; Kaufmann, SH; Leung, WY; Mao, F | 1 |
| Chatterjee, D; Pantazis, P; Wyche, JH | 1 |
| Ganapathi, R; Grabowski, D | 1 |
| Bonner, JA; Kozelsky, TF | 1 |
| Abe, S; Fujita, A; Hayashi, I; Kawakami, Y; Kurita, Y; Matsuda, T; Nakabayashi, T; Nishiwaki, Y; Noda, K; Oshita, F; Saijo, N; Suzuki, S; Takahashi, S; Tamura, T; Tobise, K; Tsuchiya, S | 1 |
| Fostel, JM; Shen, LL | 1 |
| Mashima, T; Seimiya, H; Toho, M; Tsuruo, T | 1 |
| Kojima, Y; Kotake, T; Maeda, O; Miki, T; Nonomura, N; Okuyama, A; Saiki, S; Sawada, M | 1 |
| Allouche, M; Dubrez, L; Eymin, B; Solary, E | 1 |
| Cowan, KH; Fukuda, M; Ikeda, K; Kohno, S; Matsuo, I; Nakano, R; Narasaki, F; Oka, M; Soda, H; Takatani, H; Terashi, K; Tomonaga, M | 1 |
| Mashima, T; Miller, DK; Naito, M; Nicholson, DW; Noguchi, K; Tsuruo, T | 1 |
| Berger, NA; Gordon, NH; Mackay, W; Whitacre, CM; Zborowska, E | 1 |
| Kizaki, H; Oguro, M; Onishi, Y | 1 |
| Furukawa, M; Harada, T; Kuwano, M; Tanaka, T | 1 |
| Sun, Y | 1 |
| Johnson, N; Ng, TC; Parkin, JM | 1 |
| Frey, T | 1 |
| Basi, GS; Earnshaw, WC; Eischen, CM; Kaufmann, SH; Kottke, TJ; Leibson, PJ; Martins, LM; Tung, JS | 1 |
| Falaschi, A; Ochem, A; Phan, TN; Tuteja, N; Tuteja, R | 1 |
| Brooker, DL; Ikegami, R; Rivera-Bennetts, AK; Yager, TD | 1 |
| Akiyama, Y; Furusho, K; Kataoka, A; Koishi, S; Kubota, M; Lin, YW; Sawada, M; Usami, I; Watanabe, Ki | 1 |
| Harstrick, A; Kasimir-Bauer, S; Stahl, M | 1 |
| Murray, N | 1 |
| Campbell, LE; Christenson, E; DeMaggio, AJ; Hoekstra, MF; Knippschild, U; Meek, DW; Milne, DM | 1 |
| Negoro, S | 2 |
| Gupta, E; Ibrahim, N; Li, XG; Mendoza, J; Pantazis, P; Patel, M; Rubin, EH; Saleem, A | 1 |
| Akiyama, Y; Furusho, K; Kataoka, A; Kitoh, T; Koishi, S; Kubota, M; Lin, YW; Sawada, M; Usami, I; Watanabe, K | 1 |
| Cao, CX; Pommier, Y; Shao, RG | 1 |
| Ando, M; Eguchi, K; Hojo, N; Kakinuma, R; Kasai, T; Kodama, T; Kubota, K; Kurata, T; Matsumoto, T; Nishiwaki, Y; Ohe, Y; Ohmatsu, H; Saijo, N; Sekine, I; Shinkai, T; Tamura, T; Yamamoto, N | 1 |
| Aoyagi, K; Aoyagi, Y; Asao, T; Okazaki, S; Sano, M; Utsugi, T; Wierzba, K; Yamada, Y | 1 |
| Joshi, B; Li, L; Tang, DG; Zhu, Z | 1 |
| Bloom, SE; Muscarella, DE; Rachlinski, MK; Sotiriadis, J | 1 |
| Cheng, X; Irie, T; Itamochi, H; Kanamori, Y; Kigawa, J; Minagawa, Y; Terakawa, N | 1 |
| Sakata, Y; Tsushima, K | 1 |
| Allavena, P; Broggini, M; Colella, G; D'Incalci, M; Giardina, G; Sen, S | 1 |
| DeJesus, A; Early, J; Giovanella, B; Pantazis, P | 1 |
| Araki, S; Asakura, R; Hojo, K; Itoh, A; Kawahara, M; Konishi, T; Nouchi, T; Takeda, Y; Teruya, M | 1 |
| Phan, TN; Tuteja, N | 1 |
| Chang, L; Ogita, S; Tanaka, T; Umesaki, N | 1 |
| Rowinsky, EK; Siu, LL | 1 |
| Creus, A; Marcos, R; Torres, C | 1 |
| Carabillò, M; Giuliano, M; Lauricella, M; Tesoriere, G; Vassallo, E; Vento, R | 1 |
| Fan, S; Nesbit, CE; Prochownik, EV; Zhang, H | 1 |
| Emanuele, S; Giuliano, M; Lauricella, M; Tesoriere, G; Vento, R | 1 |
| Ara, G; Chan, V; Eder, JP; Northey, D; Rizvi, N; Teicher, BA; Wong, J; Wong, YW | 1 |
| Adhikari, D; Banerjee, D; Bertino, JR; Fu, JZ; Schnieders, B; Zhao, SC | 1 |
| Igarashi, T; Kobayashi, Y; Murayama, T; Ohtsu, T; Sasaki, Y; Tobinai, K | 1 |
| Hill, BT; van Hille, B | 1 |
| Cnaan, A; Janss, AJ; Levow, C; Phillips, PC; Shpilsky, A; Sutton, L; Zhao, H | 1 |
| Fukuoka, M; Hirashima, T; Kawase, I; Kobayashi, M; Kusunoki, Y; Masuda, N; Matsui, K; Negoro, S; Sawaguchi, H; Tada, T; Takeda, K; Takifuji, N; Ushijima, S; Yana, T | 1 |
| Abe, S; Hayashi, I; Kawakami, Y; Kurita, Y; Matsuda, T; Nakabayashi, T; Nishiwaki, Y; Saijo, N; Suzuki, S; Takahashi, T; Tamura, T; Yamamoto, N | 1 |
| Bhalla, K; Bullock, G; Huang, Y; Maria Ibrado, A; Miyashita, T; Ray, S; Reed, J | 1 |
| Cheshire, PJ; Hallman, JD; Houghton, JA; Houghton, PJ; Li, Y; Luo, X; Lutz, L | 1 |
| Ajani, JA | 1 |
| Chanock, SJ; Hiraoka, W; Nieves-Neira, W; Pommier, Y; Vazquez, N | 1 |
| Carabillò, M; Emanuele, S; Giuliano, M; Lauricella, M; Tesoriere, G; Vento, R | 1 |
| Armand, JP; Couteau, C | 1 |
| Cao, CX; Kohn, KW; Pommier, Y; Shao, RG; Wold, MS; Zhang, H | 1 |
| Corey, EJ; Martinez, EJ; Owa, T; Schreiber, SL | 1 |
| Ciesielski, MJ; Fenstermaker, RA | 1 |
| Fujiwara, Y; Isobe, T; Katoh, O; Kurata, T; Miyazaki, M; Oguri, T; Ohashi, N; Takahashi, T; Yamakido, M; Yokozaki, M | 1 |
| Eckardt-Schupp, F; Friedl, AA; Jaspers, NG; Klein, B; Kraakman-van der Zwet, M; Lohman, PH; Midro, AT; Overkamp, WJ; Verhaegh, GW; Zdzienicka, MZ | 1 |
| Anthony, ML; Brindle, KM; Zhao, M | 1 |
| Adami, GR; Buehler, PW; Negrusz, A; Robles, SJ | 1 |
| Leung, LK; Wang, TT | 1 |
| Ekimoto, H; Mashiba, H; Matsumoto, S; Okamoto, K | 1 |
| Cruz, M; Eneroth, P; Sidén, A; Vargas, VI; Yakisich, JS | 1 |
| Hunter, N; Meyn, RE; Mirkovic, N; Story, MD | 1 |
| Kamiya, A; Sekimoto, J; Siddique, T; Suzuki, K; Uyeda, M | 1 |
| Cogoni, C; Macino, G | 1 |
| Johnson, MA; Jones, NJ | 1 |
| Ishiura, S; Koriyama, H; Kouchi, Z; Momoi, T; Saido, TC; Suzuki, K; Umeda, T | 1 |
| Groshen, S; Keshelava, N; Reynolds, CP | 1 |
| Alexandre, S; Nguyen-Ba, G; Rast, C; Vasseur, P | 1 |
| Boisdron-Celle, M; Boulanger, N; Gamelin, E | 1 |
| Aller, P; de Blas, E; Galán, A; Garcia-Bermejo, L; Vilaboa, NE | 1 |
| Bonnefoy-Berard, N; Ferraro, C; Fournel, S; Prigent, AF; Quemeneur, L; Revillard, JP | 1 |
| Barret, JM; Etiévant, C; Hill, BT; Imbert, T; Kruczynski, A; Perrin, D; van Hille, B | 1 |
| Cotter, TG; Knox, KA; McGahon, AJ; McKenna, SL; O'Gorman, DM | 1 |
| Bonnefoy-Berard, N; Ferraro, C; Prigent, AF; Quemeneur, L; Revillard, JP; Taverne, C | 1 |
| Choi, CH; Chung, MH; Jeong, JH; Kim, HS; Kim, MS; Kweon, OS; Lee, TB; Lim, DY; Min, YD; Rha, HS; You, HJ | 1 |
| Falck, J; Helin, K; Hofland, K; Jensen, PB; Petersen, BO; Sehested, M | 1 |
| Bigg, DC; Bronckart, Y; Chaboteaux, C; da Costa, PM; Decaestecker, C; Gordover, L; Harper, L; Kiss, R; Lavergne, O; Lesueur-Ginot, L; Malonne, H; Philippart, P | 1 |
| Declerck, PJ; Kwaan, HC; Svoboda, K; Wang, J | 1 |
| Arimoto, J; Bessho, T; Furukawa, T; Hirai, I; Maebeya, S; Matsuyama, K; Naito, Y; Oura, S; Sakurai, T; Suzuma, T; Tanino, H; Yano, T; Yoshimasu, T | 1 |
| Barret, JM; Etiévant, C; Hill, BT | 1 |
| Enomoto, T; Katada, T; Masuko, T; Narita, Y; Seki, M; Sonoda, E; Takeda, S; Wang, W; Yamada, K | 1 |
| Bryant, PE; Johnson, MA; Jones, NJ | 1 |
| Jeng, J; Wang, TT | 1 |
| Masuda, N; Negoro, S | 1 |
| Fukuoka, M; Kudoh, S; Masuda, N; Negoro, S | 1 |
| Koshiishi, H; Takahashi, E; Tamamoto, F; Utsumi, K | 1 |
| Barret, JM; Hill, BT; Olive, PL | 1 |
| Bukowski, RM; Ganapathi, MK; Ganapathi, R; Grabowski, DR; Tabata, M; Tabata, R | 1 |
| Hareyama, M; Imai, K; Itoh, F; Kakiuchi, H; Kobayashi, T; Sasaki, Y; Suzuki, H | 1 |
| Bowman, KJ; Calvert, AH; Curtin, NJ; Newell, DR | 1 |
| Kobayashi, A; Yamaguchi, M | 1 |
| Fujishiro, M; Fukuda, H; Fukuda, M; Kunitoh, H; Nishiwaki, Y; Ohe, Y; Saijo, N; Sekine, I; Shinkai, T; Tamura, T | 1 |
| Arnaudeau, C; Cazaux, C; Defais, M; Helleday, T; Jenssen, D; Rozier, L | 1 |
| Bigg, D; Camara, J; Coulomb, H; Demarquay, D; Huchet, M; Lavergne, O; Lesueur-Ginot, L | 1 |
| Tamura, T | 1 |
| Bonomi, P; Shirazi, W | 1 |
| Belani, CP; Calvo, AR | 1 |
| Bondada, S; Culmsee, C; Mattson, MP | 1 |
| Ogino, T; Okada, S; Omori, M; Than, TA | 1 |
| Furuichi, Y; Goto, M; Heo, SJ; Nishikawa, K; Sakamoto, S; Shimamoto, A | 1 |
| Ganesh, A; Meuth, M; Phillips, E; Thacker, J | 1 |
| Mashima, T; Tsuruo, T; Udagawa, S | 1 |
| Bastow, KF; Cheng, HH; Ito, J; Lee, KH; Luo, TY; Nakanishi, Y; Tachibana, Y; Wang, HK; Xu, Z | 1 |
| Fukuoka, M | 1 |
| Inoue, A; Saijo, N | 1 |
| Akiyama, S; Chen, ZS; Ise, T; Izumi, H; Kohno, K; Matsuo , K; Murakami, T; Nakagawa, M; Nakamura, T; Shibuya, I; Yamada, Y | 1 |
| Aguado, M; Fallik, D; Jacob, S; Praz, F | 1 |
| Kimura, T | 1 |
| Bell, B; Scheer, E; Tora, L | 1 |
| Kherfellah, D; Montaudon, D; Pavillard, V; Richard, S; Robert, J | 1 |
| Aller, P; de Blas, E; Fernández, C; Sancho, P; Troyano, A | 1 |
| Kumazaki, T; Nishiyama, M; Okamoto, R; Sekikawa, T; Takano, H; Tanaka, T; Tanimoto, K; Toyada, M; Ukon, K | 1 |
| Fu, W; Lu, C; Mattson, MP | 1 |
| Heldebrant, MP; Kaufmann, SH; Meng, XW | 1 |
| Chen, Y; Di, C; Han, W; Ma, D; Song, Q; Sun, R; Zhang, Y | 1 |
| Boccieri, MG; Bruschi, G; Lo Re, G; Saracchini, S; Toffoli, G; Tumolo, S | 1 |
| Wen, Z; Xiong, X; Zhu, Z | 1 |
| Fukuoka, M; Kawahara, M; Mori, K; Negoro, S; Nishiwaki, Y; Noda, K; Saijo, N; Sugiura, T; Tamura, T; Watanabe, K; Yamamoto, S; Yokoyama, A | 1 |
| Carney, DN | 1 |
| Baptiste, N; Chen, X; Friedlander, P; Prives, C | 1 |
| Agata, H; Fujimoto, T; Hirota, T; Hori, T; Kawai, N; Kitagawa, S; Konno, K; Sawada, K; Tsurusawa, M | 1 |
| Cronk, M; Dunstan, HM; Evans, DR; Goehle, S; Lamb, JR; Ludlow, C; Simon, JA; Szankasi, P | 1 |
| Cheng, YC; Lam, W; Park, SY | 1 |
| Castell, JV; Gómez-Lechón, MJ; Jover, R; O'Connor, E | 1 |
| Budd, RC; Ito, M; Kataoka, T; Nagai, K; Tschopp, J | 1 |
| Amorino, GP; Cao, Q; Choy, H; Kim, JS; Pyo, H | 1 |
| Bieszczad, CK; Cleaveland, ES; Craig, RW; Ma, Y; Mohandas, TK; Park, JP; Vrana, JA | 1 |
| Fujita, K; Furuichi, Y; Imamura, O; Itoh, C; Matsumoto, T; Takeda, S | 1 |
| Aiba, K; Akaza, H; Blackledge, G; Boku, N; Ikeda, T; Isonishi, S; Kato, M; Kawai, K; Mikami, O; Ohashi, Y; Saeki, T; Saijo, N; Sone, S; Stribling, D; Tsukagoshi, S; Tsuruo, T | 1 |
| Ashkenazi, A; Fong, S; Lawrence, D; LeBlanc, H; Morlan, J; Schow, P; Schwall, R; Sinicropi, D; Totpal, K; Varfolomeev, E | 1 |
| Cummings, J; Jardine, L; Joel, SP; Okorokov, AL; te Poele, RH | 1 |
| Brill, S; Halpern, Z; Khaikin, M; Kouniavsky, G; Papa, M; Zippel, D; Zvibel, I | 1 |
| Acquaviva, AM; Apicella, A; Di Matola, T; di Palma, A; Pensabene, M; Pignata, S; Ricchi, P; Ruggiero, G; Zanzi, D; Zarrilli, R | 1 |
| Berg, S; Bernstein, M; Blaney, SM; Cherrick, I; Kuttesch, N; Murry, DJ; Salama, V | 1 |
| Sandler, A | 1 |
| Alvarez, AM; Boscá, L; Castrillo, A; Hortelano, S; Zeini, M | 1 |
| Akeshima, R; Iba, T; Itamochi, H; Kamazawa, S; Kanamori, Y; Kigawa, J; Sultana, H; Terakawa, N | 1 |
| Yokoyama, A | 1 |
| Nokihara, H; Ohe, Y | 1 |
| Bozko, P; Larsen, AK; Raymond, E; Skladanowski, A | 1 |
| Hara, O; Ikegami, S; Iwamatsu, T; Shibata, Y; Yamashita, M | 1 |
| Arnt, CR; Chiorean, MV; Gores, GJ; Heldebrant, MP; Kaufmann, SH | 1 |
| Furuichi, Y; Goto, M; Hayashi, M; Honma, M; Sakamoto, H; Satoh, T; Sofuni, T; Sugimoto, M; Tadokoro, S; Tanabe, H | 1 |
| Deslandes, E; Gauduchon, P; Godard, T; Poul, JM; Sichel, F | 1 |
| Suzuki, K; Uyeda, M | 1 |
| Deguchi, N; Murai, M; Nonaka, S; Ueno, M; Yamazaki, R | 1 |
| Adams, R; Albritton, K; Coffin, C; Goldsby, R; Pulsipher, M; Wagner, L | 1 |
| Friberg, LE; Henningsson, A; Karlsson, MO; Maas, H; Nguyen, L | 1 |
| Cen, XN; Ma, MX; Ren, YL; Shi, YJ; Yu, JR; Zhu, P | 1 |
| Cavarec, L; de Saint-Vincent, BR; Decesse, J; Delaporte, C; Dubart, A; Frey, S; Gros, L; Gudkov, AV; Jacquemin-Sablon, A | 1 |
| Turrisi, AT | 1 |
| Eguchi, K; Goto, K; Hojo, F; Kakinuma, R; Kodama, T; Kubota, K; Kunitoh, H; Matsumoto, T; Nishiwaki, Y; Ohe, Y; Ohmatsu, H; Saijo, N; Sekine, I; Shinkai, T; Tamura, T; Yoshimura, K | 1 |
| Austin, RC; Baumeister, P; Kaufman, RJ; Lee, AS; Mao, C; Reddy, RK | 1 |
| Fedier, A; Fink, D; Haller, U; Lenherr, L; Schwarz, VA; Steiner, RA | 1 |
| Fukuoka, M; Kudoh, S; Matsui, K; Mori, K; Nakano, T; Negoro, S; Nishiwaki, Y; Noda, K; Ohsaki, Y; Saijo, N; Sekine, I; Yokoyama, A | 1 |
| Chen, LM; Ding, Y; Fu, LW; Liang, YJ; Pan, QC; Xiong, HY; Yang, XP | 1 |
| Aisner, J; Beers, S; Gounder, M; Licitra, EJ; Lin, Y; Musanti, R; Nelson, K; Poplin, E; Rajendra, R; Rubin, EH; Saleem, A; Schaaf, LJ; Smith, S; Thomas, C; Toppmeyer, D; Vyas, V | 1 |
| Bey, SJ; Chang, JY; Chen, LT; Hsieh, HP; Liou, JP; Liu, JF; Pan, WY; Song, JS | 1 |
| Blumenschein, GR; Fossella, FV; Glisson, BS; Johnson, FM; Komaki, R; Kurie, JM; Papadimitrakopoulou, VA; Peeples, BO; Pisters, KM | 1 |
| Langer, CJ | 2 |
| Dhar, SK; Jonsson, Z; Kannapiran, M; Mondal, N; Parvin, JD; Zhang, Y | 1 |
| Asim, M; Chen, X; Shankar, S; Singh, TR; Srivastava, RK | 1 |
| Hao, C; Herlyn, M; Petruk, KC; Song, DK; Song, JH | 1 |
| Daikoku, T; Goshima, F; Nishiyama, Y; Yamauchi, Y | 1 |
| Blumenschein, GR; Feng, L; Fossella, FV; Glisson, BS; Johnson, FM; Komaki, R; Kurie, JM; Lee, JJ; Papadimitrakopoulou, VA; Peeples, BO; Pisters, KM | 1 |
| El-Deiry, WS; Wang, S | 1 |
| Saijo, N | 1 |
| Akaike, T; Fang, J; Greish, K; Maeda, H; Sawa, T | 1 |
| Aibe, H; Asayama, Y; Honda, H; Irie, H; Kakihara, D; Matake, K; Nakamura, K; Nakayama, T; Nishie, A; Ohga, S; Tajima, T; Yamamoto, N; Yoshimitsu, K | 1 |
| Malik, M; Nitiss, JL | 1 |
| Block, WD; Lees-Miller, SP; Yu, Y | 1 |
| Kim, M; Lee, HS; Lee, M; Seo, J; Shin, CG | 1 |
| Funato, T; Imoto, I; Inazawa, J; Mihara, S; Naito, S; Okamoto, H; Saito-Ohara, F; Tomida, A; Tsuruo, T; Yasui, K; Yokomizo, A; Zhao, C | 1 |
| Arlander, SJ; Hackbarth, J; Hopkins, KM; Karnitz, LM; Kaufmann, SH; Lieberman, HB; Loegering, D; Roos-Mattjus, P; Vroman, BT | 1 |
| Doi, S; Suzuki, K; Uyeda, M; Yahara, S | 1 |
| Choi, SH; Hong, SY; Hyung, WJ; Jung, HC; Kim, KS; Lee, MH; Noh, SH; Roh, JK | 1 |
| Cheong, K; Chrystal, K; Harper, P | 1 |
| Conticello, C; De Maria, R; Messina, A; Patti, M; Pedini, F; Peschle, C; Stassi, G; Zerilli, M; Zeuner, A | 1 |
| Andoh, T; Takahashi, N; Umemura, K; Yanase, K | 1 |
| Dhakshinamoorthy, S; Hentze, H; Künstle, G; Latta, M; Ng, PY; Porter, AG; Wendel, A | 1 |
| Cejka, P; Jiricny, J; Papouli, E | 1 |
| Gillenwater, HH; Wolf, T | 1 |
| Nakanishi, Y; Uchino, J | 1 |
| Liu, WM; Propper, DJ; Scott, KA; Shahin, S | 1 |
| Dwarakanath, BS; Khaitan, D; Ravindranath, T | 1 |
| Kishida, T; Komiyama, M; Mori, T; Noguchi, M; Noguchi, Y; Ohnishi, M; Sawaguchi, K; Yabushita, H | 1 |
| Horiike, A; Saijo, N | 2 |
| Goto, K; Kakinuma, R; Kodama, T; Kubota, K; Kunitoh, H; Matsui, K; Matsumoto, T; Niho, S; Nishiwaki, Y; Nokihara, H; Ohe, Y; Ohmatsu, H; Saijo, N; Sekine, I; Shinkai, T; Sugiura, T; Tamura, T; Yamamoto, N; Yoshida, K | 1 |
| Hanazono, Y; Ichimura, K; Kanazawa, T; Kitamura, K; Kume, A; Mizukami, H; Nishino, H; Okada, T; Ozawa, K | 1 |
| Feuer, G; Ma, JW; Sieburg, M; Tripp, A | 1 |
| Gräslund, A; Jarvet, J; Kogner, P; Lindskog, M; Spenger, C | 1 |
| Beurel, E; Blivet-Van Eggelpoël, MJ; Cadoret, A; Capeau, J; Desbois-Mouthon, C; Kornprobst, M; Ruiz-Ruiz, C | 1 |
| Barthelmes, HU; Boege, F; Christensen, MO; Habermeyer, M; Interthal, H; Marko, D; Mielke, C; Pouliot, JJ | 1 |
| Hatae, M; Nakamura, T; Onishi, Y | 1 |
| Agner, J; Bartek, J; Falck, J; Lukas, J | 1 |
| Burris, HA; Erland, JB; Greco, FA; Hainsworth, JD; Hermann, R; Litchy, S; Morrissey, LH; Rodriguez, GI; Shaffer, DW; Yardley, DA | 1 |
| Adachi, M; Horichi, N; Ichikawa, I; Imai, T; Kashiwabara, Y; Kiuchi, Y; Kogo, M; Koichi, K; Murayama, J; Saito, Y | 1 |
| Beauchemin, M; Bergeron, S; Bertrand, R | 1 |
| Bissler, JJ; Dixon, K; Lu, L; Robison, JG | 1 |
| Sugiyama, T | 1 |
| André, A; Braekman, JC; Bruyneel, F; Darro, F; Decaestecker, C; Dewelle, J; El Yazidi, M; Guissou, P; Kiss, R; Nacoulma, O; Simon, G; Tuti, J; Van Quaquebeke, E | 1 |
| Hu, H; Ip, C; Jiang, C; Lü, J; Rustum, YM | 1 |
| Hoshiai, H; Nakai, H; Watanabe, Y | 1 |
| Bushman, F; Groschel, B | 1 |
| Jurgensen, S; Nair, AR; Ramabhadran, R; Schliekelman, M; Thomas, MB; Wakefield, J | 1 |
| Choi, VW; McCarty, DM; Samulski, RJ | 1 |
| Cho, KH; Han, JY; Kim, EA; Kim, HY; Lee, DH; Lee, JS; Lee, SY | 1 |
| Eimermacher, A; Flieger, D; Galle, PR; Geer, T; Gracien, E; Heike, M; Höhler, T; Junginger, T; Menges, M; Moehler, M; Siebler, J; Wein, A | 1 |
| Beurel, E; Blivet-Van Eggelpoël, MJ; Cadoret, A; Capeau, J; Desbois-Mouthon, C; Kornprobst, M | 1 |
| Bamias, A; Briasoulis, E; Christodoulou, C; Dimopoulos, MA; Fountzilas, G; Kalofonos, H; Kosmidis, P; Makatsoris, T; Pavlidis, N; Samantas, E; Skarlos, D | 1 |
| Farmakis, D; Pectasides, D; Pectasides, M | 1 |
| Berchtold, C; Chang, PY; Miyamoto, S; Wuerzberger-Davis, SM | 1 |
| Ariyoshi, Y; Fukuda, Y; Fukuoka, M; Isobe, T; Katakami, N; Komuta, K; Kudoh, S; Nakamura, S; Nakano, T; Takada, M; Takada, Y | 1 |
| Imamura, F; Kawahara, M; Kubota, K; Mori, K; Negoro, S; Nishiwaki, Y; Noda, K; Saijo, N; Sugiura, T; Tamura, T; Watanabe, K | 1 |
| Cervinka, M; Rudolf, E | 1 |
| de Léséleuc, L; Denis, F | 2 |
| Brodsky, I; Rosenbluth, JZ; Styler, MJ; Zak, D | 1 |
| Kaneda, T; Narita, Y; Suzuki, A; Takahashi, N; Tsunematsu, K | 1 |
| Earnshaw, WC; Kaufmann, SH; Loegering, DA; Ruchaud, S | 1 |
| Fischer von Weikersthal, L; Hortig, P; Keilholz, U; Martus, P; Reeb, M; Schmittel, A; Schulze, K; Sebastian, M; Thiel, E | 1 |
| Akiyama, S; Furukawa, T; Gotanda, T; Haraguchi, M; Jueng, HC; Sakata, R; Shimamoto, Y; Sumizawa, T | 1 |
| Kawauchi, A; Miki, T; Mizutani, Y; Nakamura, T; Nomoto, T | 1 |
| Bai, T; Tanaka, T; Umesaki, N; Yukawa, K | 1 |
| Rodríguez-Arnaiz, R; Sortibrán, AN; Téllez, MG | 1 |
| Fukuoka, Y; Hasegawa, Y; Hitsuda, Y; Igishi, T; Kodani, M; Kurai, J; Miyata, M; Shimizu, E; Suyama, H; Touge, H; Yasuda, K | 1 |
| Iwashige, A; Kagami, S; Tsukada, J; Uramoto, H | 1 |
| Barrett, LE; Eberwine, JH; Haydon, PG; Sul, JY; Takano, H; Van Bockstaele, EJ | 1 |
| Cloughesy, TF; Lai, A; Mischel, P; Nghiemphu, P; Pope, WB | 1 |
| Büchler, P; Ganten, TM; Haas, TL; Koschny, R; Schader, MB; Schulze-Bergkamen, H; Stremmel, W; Sykora, J; Untergasser, A; Walczak, H | 1 |
| Gandara, DR; Lara, PN; Natale, RB | 1 |
| Ansari, R; Beck, T; Bunn, PA; Byrne, M; Einhorn, L; Ellis, P; Guthrie, T; Hanna, N; Hariharan, S; Langer, C; Morrison, M; Sandler, A; Wang, B | 1 |
| Hasegawa, H; Miyagi, T; Nagasaki, A; Nakachi, S; Shinzato, O; Taira, N; Takasu, N; Tomoyose, T | 1 |
| Fournel, P | 1 |
| Inoue, H; Miyashita, T; Takemura, H; Ueda, T; Yoshida, A | 1 |
| Kawashima, O; Morishita, Y; Nagashima, T; Sugano, M | 1 |
| Cho, HJ; Jin, SM; Jung, MW; Mook-Jung, I | 1 |
| Danks, MK; Hatfield, MJ; Lee, RE; Potter, PM; Qi, J; Remack, JS; Virga, KG; Yoon, KJ | 1 |
| Anai, H; Anegawa, G; Honda, M; Kai, T; Kaneko, S; Masuda, T; Nakamura, Y; Ohta, R; Saeki, H; Yokoyama, S | 1 |
| Anderson, JR; Breitfeld, PP; Lager, JJ; Lyden, ER; Meyer, WH; Pappo, AS | 1 |
| Bell, CW; Jiang, W; Pisetsky, DS; Reich, CF | 1 |
| Brunetto, AL; Castro, CG; Cruz, LB; Rech, A; Ribeiro, AS; Rosa, LG | 1 |
| Akutsu, M; Furukawa, Y; Izumi, T; Kano, Y; Kobayashi, H; Mano, H; Tsunoda, S | 1 |
| Katakami, N | 1 |
| Antonia, S; Cantor, A; Fishman, M; Garrett, C; Gump, J; Lush, RM; Munster, PN; Rocha-Lima, C; Simon, GR; Sullivan, DM; Tetteh, L; Williams, C | 1 |
| Butler, RN; Davidson, GP; Howarth, GS; Tooley, KL | 1 |
| Kamoto, T; Kawahara, T; Nishiyama, H; Ogawa, O; Yamamoto, S | 1 |
| Hasty, P; Kim, TM; Marple, T | 1 |
| Abiri, SO; Apostolov, EO; Basnakian, AG; Shah, SV; Singh, AB; Stewart, AG; Yin, X | 1 |
| Feun, LG; Heros, D; Herrera, C; Landy, H; Marini, A; Markoe, A; Robles, C; Savaraj, N | 1 |
| Berchtold, CM; Huang, TT; Miyamoto, S; Wu, ZH | 1 |
| Ando, M; Eguchi, K; Fukuoka, M; Ichinose, Y; Kudoh, S; Matsui, K; Nakagawa, K; Negoro, S; Saito, H; Tada, T; Takada, M; Takada, Y; Tamura, K | 1 |
| Charlton, PA; Coley, HM; Lewis, LJ; Mistry, P; Thomas, H | 1 |
| Holme, AL; Pervaiz, S; Yadav, SK | 1 |
| Hashimoto, T; Izumi, Y; Kato, T; Kawada, K; Miura, A; Momma, K; Oota, M | 1 |
| Aoyama, C; Hosoya, R; Kamiya, T; Kato, I; Manabe, A; Ogawa, C; Ozawa, M; Takahashi, H; Takusagawa, A; Yokoyama, K | 1 |
| Al Harbi, T; Al-Faris, N; Doyle, J; Gassas, A; Goia, C; Pappo, A | 1 |
| Becherel, OJ; Chen, P; de Murcia, G; de Murcia, JM; Epe, B; Fusser, M; Grattan-Smith, P; Gueven, N; Haince, JF; Howe, O; Lavin, MF; McGowan, CH; Mothersill, C; Ouellet, ME; Parton, R; Poirier, GG; Waterhouse, N | 1 |
| Ono, A; Yamamoto, N | 1 |
| Harita, S; Hotta, K; Kiura, K; Kuyama, S; Okimoto, N; Segawa, Y; Shinkai, T; Tabata, M; Tanimoto, M; Ueoka, H; Yonei, T | 1 |
| Yoneda, S | 1 |
| Chijiiwa, K; Igarashi, T; Izumi, H; Kohno, K; Miyamoto, N; Niina, I; Okayasu, R; Onitsuka, T; Shiota, M; Torigoe, T; Uchiumi, T; Wakasugi, T | 1 |
| Kamura, T; Kitagawa, R; Nishio, S; Shouji, T; Sugiyama, T; Ushijima, K; Yoshizaki, A | 1 |
| Allen, WL; Galligan, L; Johnston, PG; Longley, DB; Rogers, KM; Sakai, H; Thomas, M; Wilson, TR | 1 |
| Fujimoto, K; Hirao, Y; Matsushita, C; Miyake, M; Tanaka, M; Tanaka, N | 1 |
| Hotta, K; Ichimura, K; Kiura, K; Matsuoka, J; Osawa, M; Tabata, M; Takigawa, N; Tanimoto, M | 1 |
| Chang, J; Cheon, SH; Cho, BC; Choi, HJ; Jung, JY; Kim, JH; Kim, SK; Shin, SJ; Sohn, JH | 1 |
| Fujiwara, Y; Kunitoh, H; Nokihara, H; Ohe, Y; Sekine, I; Tamura, T; Tsuta, K; Yamada, K; Yamamoto, N | 1 |
| Albotiano, S; Breietman, M; Har-Vardi, I; Levitas, E; Mali, R; Potashnik, G; Priel, E; Sonin, Y | 1 |
| Afanasyeva, EA; Bahram, F; Guzhova, IV; Komarova, EY; Larsson, LG; Margulis, BA | 1 |
| Briasoulis, E; Dimopoulos, MA; Economopoulos, T; Fountzilas, G; Kalofonos, HP; Kosmidis, P; Pectasides, D; Samantas, E; Skarlos, D; Syrigos, K | 1 |
| Seto, T | 1 |
| Bai, ZG; Jiang, L; Liu, YL; Ma, B; Mi, DH; Tan, JY; Tian, JH; Yang, KH | 1 |
| Arimura, K; Armstrong, DL; Bhattacharjee, MB; Boerkoel, CF; Champoux, JJ; Choi, K; Deguchi, K; Hirano, R; Huang, C; Inoue, K; Interthal, H; Izumo, S; Nakamura, T; Northrop, JL; Salih, MA; Takashima, H; Umehara, F | 1 |
| Cohen, RB; Dahlberg, S; Hidalgo, M; Johnson, DH; Lee, MW; Pandya, KJ; Schiller, JH | 1 |
| Alexeyev, M; Pastukh, V; Shokolenko, I; Wang, B; Wilson, G | 1 |
| Begg, AC; Bertocci, B; Vens, C; Vermeulen, C | 1 |
| Isobe, H; Matsui, K; Mori, K; Nakagawa, K; Nishiwaki, Y; Nokihara, H; Saijo, N; Sekine, I; Takeda, K; Tamura, T | 1 |
| Chinen, T; Hirayasu, T; Ishikawa, K; Kawabata, T; Kawasaki, H; Kuniyoshi, M; Ogawa, K; Ohta, M; Oshiro, Y; Samura, H; Teruya, J; Teruya, T; Uehara, T; Yohena, T | 1 |
| Duh, MS; Lefebvre, P; Neary, M; Reynolds Weiner, J; Skarin, AT | 1 |
| Burt, HM; Higo, T; Hunter, WL; Jackson, JK | 1 |
| Cho, HJ; Jin, SM; Jung, ES; Mook-Jung, I; Shim, MY | 1 |
| Hirose, S; Hojo, T; Ikeuchi, S; Isobe, Y; Kinoshita, T; Kubochi, K; Matsumoto, S; Sadako, AT; Shien, T; Terada, K | 1 |
| Matsunaga, T; Matsuura, K; Wakasugi, M; Yamashita, K | 1 |
| Ito, N; Kamba, T; Kamoto, T; Kanematsu, A; Masui, K; Nakamura, E; Nishiyama, H; Ogawa, O; Soda, T; Watanabe, J; Yoshimura, K | 1 |
| Bleibel, WK; Cook, E; Eileen Dolan, M; Hennessy, K; Innocenti, F; Liu, W; Mirkov, S; Nagasubramanian, R; Ramírez, J; Ratain, MJ; Rosner, GL; Shukla, SJ | 1 |
| Betta, PG; Catalano, A; Lazzarini, R; Moretti, S; Orecchia, S; Procopio, A | 1 |
| Aasebø, U; Bergman, B; Bremnes, R; Ek, L; Fluge, S; Hermes, A; Sederholm, C; Sörenson, S; Sundstrøm, S; Thaning, L; Vilsvik, J | 1 |
| Jahng, Y; Jung, MJ; Kwon, Y; Lee, SH; Liang, JL; Motiur Rahman, AF; Son, JK | 1 |
| Carr, AM; Hartsuiker, E; Neale, MJ | 1 |
| Chung, JH; Jin, HS; Kim, DH; Lee, DH; Lee, SJ; Lee, TH | 1 |
| Chen, GQ; Duan, XF; Wen, DH; Zhao, M | 1 |
| Carleton, JE; Chansky, K; Crowley, J; Dakhil, SR; Gandara, DR; Jett, J; Kuebler, JP; Langer, CJ; Lara, PN; Lenz, HJ; Natale, R; Redman, MW | 1 |
| Chen, GQ; Huang, Y; Wang, LS; Yu, Y; Yuan, TT; Zhou, CX; Zhuang, HY | 1 |
| Andresen, L; Hansen, KA; Jensen, H; Skov, S | 1 |
| Pappo, A; Paulino, AC | 1 |
| Darroudi, F; de Groot, J; de Winter, JP; Godthelp, BC; Joenje, H; Oostra, AB; Scheper, RJ; Steltenpool, J; van der Lelij, P; van Gosliga, D; van Zon, W; Waisfisz, Q; Wolthuis, RM | 1 |
| Falaschi, A | 1 |
| Chiang, PC; Guh, JH; Hsu, JL | 1 |
| Chelis, L; Christophyllakis, Ch; Georgoulias, V; Giassas, S; Kakolyris, S; Kalykaki, A; Kentepozidis, N; Kotsakis, A; Polyzos, A; Vamvakas, L; Vardakis, N; Xenidis, N | 1 |
| Glisson, BS; Johnson, FM | 1 |
| Caldecott, KW; Cortes Ledesma, F; El Khamisy, SF; Osborn, K; Zuma, MC | 1 |
| Brodie, KM; Henderson, BR | 1 |
| Adachi, M; Hirose, T; Nakamura, A; Ohnishi, T; Okuda, K; Yamaoka, T; Yashiki, C | 1 |
| Dianov, GL; Fanta, M; Freschauf, GK; Grassot, JM; Hall, DG; Mani, RS; Mereniuk, TR; Virgen, CA; Weinfeld, M | 1 |
| Adachi, M; Hirose, T; Kusumoto, S; Nakamura, A; Ohmori, T; Shirai, T; Sugiyama, T; Yashiki, C | 1 |
| Blumenschein, GR; Feng, L; Fossella, FV; Glisson, BS; Johnson, FM; Karp, DD; Peeples, BO; Stewart, DJ; Uyeki, J; William, WN | 1 |
| Cardenal, F; Cisar, L; Domine, M; Gorbunova, V; Moiseyenko, V; Soria, JC; Szczesna, A; Thomas, M; Zatloukal, P; Zhang, X | 1 |
| Charpidou, A; Gkiozos, I; Makrilia, N; Stratakos, G; Syrigos, K; Tsagouli, S; Tsimpoukis, S; Vassias, A | 1 |
| Cervinka, M; Rudolf, E; Rudolf, K | 1 |
| Bushell, M; Chew, EH; Chua, YL; Gao, J; Hagen, T; Lou, JJ | 1 |
| Chu, Z; Huang, L; Huang, R; Jiang, J; Liang, X; Zhan, Q; Zhou, X | 1 |
| Leo, E; Marchand, C; Pommier, Y; Zhang, H | 1 |
| Bodiagin, DA; Pokrovskiĭ, VS; Treshchalin, MI; Treshchalina, EM | 1 |
| Araki, M; Hasegawa, H; Itoh, M; Kodama, Y; Kuzushita, N; Mano, M; Mita, E; Morita, K; Nakazuru, S; Ohta, M; Ohta, T; Suemura, S; Sueyoshi, Y; Toyama, T; Yoshio, T; Yoshioka, C | 1 |
| Chansky, K; Crowley, J; Fukuda, H; Gandara, DR; Lara, PN; Natale, R; Redman, MW; Saijo, N; Shibata, T; Tamura, T | 1 |
| Chen, Z; Miyamoto, S; Niu, J; Shi, Y; Tergaonkar, V; Wong, ET; Wu, ZH | 1 |
| Cantor, A; Miley, D; Reddy, V; Robert, F; Rossman, J | 1 |
| dos Santos, LV; Lima, CS; Lima, JP; Sasse, AD; Sasse, EC | 1 |
| Agelaki, S; Androulakis, N; Bozionelou, V; Georgoulias, V; Hatzidaki, D; Kalbakis, K; Kalykaki, A; Kotsakis, A; Saridaki, Z; Vamvakas, L; Vardakis, N | 1 |
| Chen, L; Feng, XC; Guo, XY; Li, QY; Lu, F; Xu, XL; Zhou, GH | 1 |
| Kumabe, T; Niizuma, H; Osawa, S; Saito, R; Sonoda, Y; Tominaga, T; Watanabe, M | 1 |
| Guo, S; Liang, Y; Zhou, Q | 1 |
| Binder, D; Caca, K; Eberhardt, WE; Fischer von Weikersthal, L; Fischer, B; Fischer, JR; Gauler, TC; Hortig, P; Kaufmann, C; Keilholz, U; Link, H; Martus, P; Schmittel, A; Sebastian, M | 1 |
| Kopacek, J; Krizanova, O; Labudova, M; Lencesova, L; Ondrias, K; Pastorekova, S; Sirova, M | 1 |
| Fujimoto, T; Kumagai, S; Kurachi, H; Mizunuma, H; Nakahara, K; Nishiyama, H; Omi, H; Shoji, T; Sugiyama, T; Takano, T; Takatori, E; Tase, T; Yaegashi, N; Yokoyama, Y; Yoshizaki, A | 1 |
| Pham, XH; Tran, NQ; Tuteja, N; Tuteja, R | 1 |
| Hirao, N; Nose, Y; Saeki, K; Takasawa, R; Tanuma, S | 1 |
| Asanuma, H; Hasegawa, T; Hirata, K; Hirohashi, Y; Inoda, S; Ishitani, K; Kondo, T; Morita, R; Nakatsugawa, M; Nishizawa, S; Sato, N; Takahashi, A; Tamura, Y; Terui, T; Torigoe, T; Tsuruma, T | 1 |
| Hirakawa, K; Miwa, A; Qiu, H; Yashiro, M; Zhang, X | 1 |
| Amin, NP; Camidge, DR; Gaspar, LE; Kavanagh, B; Miften, M; Raben, D; Rochford, N; Thornton, D | 1 |
| Bonnabry, P; Fleury-Souverain, S; Geiser, L; Hochstrasser, D; Nussbaumer, S; Sadeghipour, F; Veuthey, JL | 1 |
| Abdulghani, J; Allen, JE; Dicker, DT; Dolloff, NG; El-Deiry, WS; Gallant, JN; Hong, B; Katz, SI; Navaraj, A; Smith, CD; Wang, W | 1 |
| Bae, H; Guan, JL | 1 |
| Allen, PJ; Brady, MS; Busam, KJ; Chou, JF; Coit, DG; Fields, RC; Kraus, DH; Panageas, KS; Pulitzer, MP | 1 |
| Heo, JI; Kang, HJ; Kho, YJ; Kim, HS; Kim, J; Kim, JH; Kim, MJ; Kim, SC; Lee, JY; Park, JB; Park, SH | 1 |
| Cheema, TA; Kanai, R; Kim, GW; Martuza, RL; Passer, B; Rabkin, SD; Wakimoto, H | 1 |
| Bhattacharyya, J; Hoshi, M; Kimura, A; Mihara, K; Ohtsubo, M; Sakai, A; Takei, Y; Takihara, Y; Yanagihara, K; Yasunaga, S | 1 |
| Desjardins, A; Sampson, JH | 1 |
| Allmaier, G; Cheung, HY; Cheung, MT; Dong, H; Kin-Chung Au, O; Lam, YW; Liang, Y; Shen, W | 1 |
| Darzynkiewicz, Z; Dobrucki, J; Rybak, P; Traganos, F; Zhao, H | 1 |
| Hwang, JH; Kang, S; Lim, MC; Park, SY; Seo, SS; Yoo, HJ | 1 |
| Bellot, GL; Koh, D; Tan, WH; Tay, LL; Wang, X | 1 |
| Fadlalla, K; Katkoori, V; Manne, U; Mosley, L; Samuel, T; Turner, T | 1 |
| Jin, S; Shao, N; Zhu, W | 1 |
| Cho, YJ; Duk Lee, J; Go, SI; Hwang, YS; Jeong, YY; Kim, DC; Kim, HC; Ko, GH; Lee, GW; Lee, JH; Lee, JS; Oh, S; Yang, JW | 1 |
| Fukuda, H; Kamura, T; Katsumata, N; Konishi, I; Matsumoto, K; Saito, I; Shibata, T | 1 |
| Iyoda, A; Jiang, SX; Kageyama, T; Masuda, N; Matsumoto, T; Nagashio, R; Ryuge, S; Saegusa, M; Sato, Y; Satoh, Y | 1 |
| Jeong, KC; Jeong, YS; Jun, DW; Kim, HJ; Kim, S; Lee, CH | 1 |
| Ai, R; Jin, H; Li, X; Lu, J; Sha, S; Yang, J | 1 |
| Guan, QL; Jiang, L; Mi, DH; Wang, J; Yang, KH | 1 |
| Boisvert, RA; Cavallo, F; Esashi, F; Howlett, NG; Jasin, M; Mauro, M; Rego, MA | 1 |
| Li, Y; Xiong, H; Yang, DQ | 1 |
| Furuya, K; Goto, T; Kato, M; Kita, T; Kudoh, K; Miyamoto, M; Sasaki, N; Takano, M; Watanabe, A; Yoshikawa, T | 1 |
| Forment, JV; Jackson, SP; Walker, RV | 1 |
| Couvelard, A; Gillet, A; Goujon, G; Hammel, P; Hentic, O; Lévy, P; Maire, F; Palazzo, M; Rebours, V; Ruszniewski, P; Zappa, M | 1 |
| Ando, M; Gemma, A; Hino, M; Kobayashi, K; Kosaihira, S; Minegishi, Y; Miyanaga, A; Mizutani, H; Nomura, K; Noro, R; Okano, T; Seike, M; Yoshimura, A | 1 |
| Harada, D; Ichihara, E; Kiura, K; Kubo, T; Ninomiya, T; Ochi, N; Osawa, M; Takigawa, N; Tanimoto, M; Yamane, H | 1 |
| Mackenzie, IC; Navsaria, H; Storey, A; Wray, H | 1 |
| Basu, EM; Cheung, NK; Kramer, K; Kushner, BH; Modak, S; Roberts, SS | 1 |
| Ngok-Ngam, P; Satayavivad, J; Thiantanawat, A; Watcharasit, P | 1 |
| Ansari, RH; Atkins, JN; Bogart, JA; Green, MR; Hodgson, LD; Kelley, MJ; Pang, H; Vokes, EE | 1 |
| Fragoulis, EG; Korbakis, D; Scorilas, A | 1 |
| Herbst, RS; Isobe, T; Itasaka, S; Jacoby, JJ; Koo, PJ; Morgensztern, D; O'Reilly, MS; Onn, A; Shibuya, K; Shintani, T; Wu, W | 1 |
| Ahn, JS; Asami, Y; Erikson, RL; Jang, JH; Kim, BY; Kim, SO; Kim, YS; Kwon, YT; Lee, KS; N R, T; Sakchaisri, K; Soung, NK; Thimmegowda, NR | 1 |
| Akamatsu, H; Endo, M; Kenmotsu, H; Murakami, H; Naito, T; Nakajima, T; Nakamura, Y; Ono, A; Shukuya, T; Takahashi, T; Tsuya, A; Wakuda, K; Yamamoto, N | 1 |
| Barros, EM; Burn, PM; Gorski, JJ; Harkin, DP; Harte, MT; Kennedy, RD; McFarlane, C; Mullan, PB; Perkins, ND; Purcell, JW; Savage, KI | 1 |
| Batey, MA; Curtin, NJ; Kyle, S; Lau, A; Martin, NM; Newell, DR; Richardson, C; Slade, A; Zhao, Y | 1 |
| Bauer, D; Biassoni, V; Casanova, M; Catania, S; De Pava, MV; Gandola, L; Indini, A; Massimino, M; Modena, P; Pecori, E; Podda, M; Polastri, D; Rampini, P; Schiavello, E | 1 |
| Caot, JT; Li, JX; Wu, ZQ; Zhao, L; Zhu, JJ | 1 |
| Jett, JR; Kalemkerian, GP; Kesler, KA; Schild, SE | 1 |
| Chao, H; Huang, H; Ji, L; Qiao, L; Wang, J; Zhang, P | 1 |
| Ahn, HS; Kang, HJ; Kim, H; Lee, JW; Park, JD; Park, KD; Shin, HY | 1 |
| Blanch, A; Cheng, LS; Irwin, MS; Robinson, F; Watson, IR | 1 |
| Levy, B; Saxena, A; Schneider, BJ | 1 |
| Elsing, C; Hannig, CV; Herrmann, C; Herrmann, T; Jäger, D; Stremmel, W | 1 |
| Aisner, J; Axelrod, RS; Dahlberg, SE; Gounder, M; Owonikoko, TK; Ramalingam, SS; Rausch, PG; Rubin, EH; Schiller, JH; Wang, XV | 1 |
| Harada, M; Hida, T; Imamura, F; Ishikura, S; Kawahara, M; Kubota, K; Matsui, K; Mizusawa, J; Nakagawa, K; Negoro, S; Nishio, M; Okamoto, H; Saijo, N; Sakai, H; Shibata, T; Shinkai, T; Takeda, K; Tamura, T; Yamamoto, N; Yokoyama, A | 1 |
| Boren, J; Brindle, KM; Mahajan, S; Patel, II; Reichelt, S; Schreiner, A; Steuwe, C; Ul-Hasan, M | 1 |
| Chohnabayashi, N; Ishikawa, G; Jinta, T; Kitamura, A; Mochizuki, S; Nishimura, N; Suzuki, K; Tomishima, Y; Yamano, Y | 1 |
| Erbaykent-Tepedelen, B; Gonen-Korkmaz, C; Karamil, S; Korkmaz, KS | 1 |
| Asamura, H; Eba, J; Katayama, H; Kenmotsu, H; Niho, S; Shibata, T; Tamura, T; Tsuboi, M; Watanabe, S; Yamamoto, N | 1 |
| Arce-Lara, C; Kelley, MJ; Santana-Davila, R; Szabo, A; Whittle, J; Williams, CD | 1 |
| Yano, S | 1 |
| Altieri, DC; Bosari, S; Faversani, A; Lopergolo, A; Moro, GP; Rivadeneira, D; Schultz, DC; Tosi, D; Vaira, V | 1 |
| Boku, N; Furuse, J; Ishido, K; Kasuga, A; Machida, N; Morizane, C; Nishina, T; Okusaka, T; Sudo, K; Takahashi, H; Tobimatsu, K; Yamaguchi, T | 1 |
| Kadowaki, M; Kohno, K; Kondo, S; Kubota, A; Okamura, S; Takase, K; Takeshita, M; Tanimoto, K; Yamasaki, S | 1 |
| Hetman, M; Vashishta, A | 1 |
| Asamura, H; Fujiwara, Y; Horinouchi, H; Kanda, S; Kitazono, S; Mizugaki, H; Nokihara, H; Tamura, T; Tanaka, A; Tsuta, K; Yagishita, S; Yamamoto, N | 1 |
| Eba, J; Misumi, Y; Nakamura, K; Ohe, Y; Okamoto, H; Shibata, T; Shimokawa, T; Yamamoto, N | 1 |
| Kamura, T; Katsumata, N; Konishi, I; Matsumoto, K; Nakamura, K; Saitou, M; Satoh, T; Shibata, T; Takano, T; Yunokawa, M | 1 |
| Apte, RN; Kogan-Zviagin, I; Peleg, R; Priel, E; Romzova, M | 1 |
| Fox, JL; Storey, A | 1 |
| Komune, S; Nakashima, T; Toh, S; Yamauchi, M; Yasumatsu, R | 1 |
| Ikeda, M; Kondo, S; Mitsunaga, S; Morizane, C; Ohno, I; Okusaka, T; Okuyama, H; Shimizu, S; Takahashi, H; Ueno, H | 1 |
| Au-Yeung, TT; Fleisig, HB; Hukezalie, KR; Ludlow, AT; Thompson, CA; Wong, JM; Zhao, CR | 1 |
| Harada, M; Inoue, A; Ishida, T; Kinoshita, I; Maemondo, M; Mori, Y; Morikawa, N; Nakagawa, T; Nukiwa, T; Oizumi, S; Saito, R; Sugawara, S; Suzuki, T; Taima, K; Watanabe, H | 1 |
| Liang, G; Xu, T; Yang, L; Zhang, F | 1 |
| Barriuso, J; Borbath, I; Chougnet, CN; Crespo, G; Heetfeld, M; O'Toole, D; Olsen, IH; Pavel, M; Rinke, A; Walter, T | 1 |
| Fujisawa, M; Miyake, H; Nishikawa, M | 1 |
| Cacciola, NA; De Stefano, A; Federico, A; Forzati, F; Fusco, A; Malapelle, U; Pallante, P; Pellecchia, S; Rocco, D; Sepe, R | 1 |
| Kadayat, TM; Kwon, Y; Lee, ES; Song, C | 1 |
| Chang, GJ; Crane, CH; Das, P; Feig, BW; Krishnan, S; Minsky, BD; Rashid, A; Skibber, JM; Voong, KR; Wolff, RA; Yao, JC | 1 |
| Allendorf, DJ; Bordoni, RE; Dixon, PM; Grant, SC; Jerome, ML; Miley, DK; Reddy, VB; Robert, F; Saleh, MN; Singh, KP | 1 |
| Anderson, JR; Arndt, CA; Hawkins, DS; Lyden, E; Meyer, WH; Michalski, JM; Parham, DM; Rodeberg, DA; Weigel, BJ | 1 |
| Hur, GY; Kang, EJ; Kang, KH; Kim, JS; Lee, SY; Min, KH; Oh, SC; Seo, JH; Shim, JJ | 1 |
| Bortner, CD; Ehrenshaft, M; Kumar, A; Kumari, A; Mason, RP; Sharma, NK; Sinha, BK; Tokar, EJ; Waalkes, MP; Williams, J | 1 |
| Debus, J; Ho, AD; Huber, PE; Nicolay, NH; Perez, RL; Rühle, A; Saffrich, R; Schmezer, P; Sisombath, S; Trinh, T; Weber, KJ | 1 |
| Agama, K; Brünner, N; Doroshow, JH; Jensen, NF; Knudsen, BR; Pfister, TD; Pommier, Y; Roy, A; Rømer, MU; Smith, DH; Stenvang, J; Zhang, HL | 1 |
| Chen, L; Chen, Y; Feng, X; Peng, L; Wang, J; Zhong, D | 1 |
| Bernstein, KA; Godin, SK; Herken, BW; Lee, AG; Mihalevic, MJ; Resnick, MA; Sobol, RW; Westmoreland, JW; Yu, Z; Zhang, Z | 1 |
| Goto, K; Hida, T; Imamura, F; Kiura, K; Kozuki, T; Mori, K; Nakagawa, K; Nishio, M; Ohe, Y; Okamoto, H; Satouchi, M; Sawa, T; Seto, T; Shibata, T; Takahashi, T; Takeda, K; Tamura, T; Tanaka, H; Yoshimura, N | 1 |
| Bernas, T; Berniak, K; Bujnowicz, L; Darzynkiewicz, Z; Dobrucki, J; Hoang, A; Rybak, P; Zarębski, M | 1 |
| Jang, TW; Jeong, JH; Kim, KS; Kim, SY; Kim, YC; Lee, HK; Lee, JE; Lee, KH; Lee, KY; Lee, SY; Oh, IJ; Park, CK; Shin, KC | 1 |
| Asao, T; Fujiwara, Y; Goto, Y; Horinouchi, H; Kanda, S; Kitahara, S; Nokihara, H; Ohe, Y; Okuma, HS; Sunami, K; Yamamoto, N | 1 |
| Gress, TM; Rinke, A | 1 |
| Guha, M; Haljasorg, U; Kisand, K; Liiv, I; Maslovskaja, J; Metspalu, A; Milani, L; Peterson, P; Saare, M; Tasa, T | 1 |
| Chen, L; Chen, Y; Zhong, D | 1 |
| Han, D; Li, S; Ren, X; Shang, W; Sun, L; Wang, G; Xu, L | 1 |
| DeLuca, JG; Herman, JA; Lee, E; Paddison, P; Pain, M; Toledo, CM; Wang, H; Yong, RL; Zhu, J | 1 |
| Bang, SM; Chang, H; Kim, JH; Kim, JW; Kim, MJ; Kim, SH; Kim, YJ; Lee, JO; Lee, JS; Lee, KW | 1 |
| Li, Q; Sun, L; Wen, F; Zhang, P; Zheng, H; Zhou, J; Zhou, K | 1 |
| Fukuda, M; Hosokawa, M; Iwakawa, S; Masuda, A; Tanaka, S; Ueda, K | 1 |
| Fukui, T; Igawa, S; Katagiri, M; Kubota, M; Kurahayashi, S; Mitsufuji, H; Naoki, K; Nishinarita, N; Okuma, Y; Ono, T; Ozawa, T; Sasaki, J; Shirasawa, M; Sone, H; Sugimoto, A; Sugita, K | 1 |
| Dong, Q; Gao, H; Huang, A; Jiang, T; Liu, H; Shi, L; Sun, X; Sun, Y; Wang, X; Wu, X | 1 |
| Furuta, K; Hirata, Y; Ito, Y; Kiuchi, K; Nagase, H; Oh-Hashi, K; Sawada, M; Suzuki, H; Yamada, C; Yamamoto, S | 1 |
| Azuma, K; Hoshino, T; Imamura, Y; Ishii, H; Kinoshita, T; Matsuo, N; Naito, Y; Tokito, T; Yamada, K | 1 |
| Li, G; Tong, T; Xu, C; Yuan, F | 1 |
| Brandetti, E; Cifaldi, L; Ognibene, M; Pezzolo, A; Pistoia, V; Veneziani, I | 1 |
| Buscemi, G; Chan, SY; Delia, D; Magni, M; Maita, L; Montecucco, A; Peng, L; Zannini, L | 1 |
| Chen, Y; Li, Q; Li, R; Ren, X; Xia, S; Xu, F | 1 |
| Gao, Y; Kardos, J; Kim, WY; Major, MB; Mutter-Rottmayer, E; Tamir, TY; Vaziri, C; Weissman, B; Yang, Y | 1 |
| Fan, L; Jiang, T; Qiu, X; Yin, Y; Zhu, Q | 1 |
| Auerbach, C; Cheron, R; Natarajan, E; Pashankar, F | 1 |
| Chen, J; Hu, Q; Kim, H; Klages-Mundt, N; Kuma Saha, L; Li, L; Lynn, E; Paull, T; Shen, X; Srivastava, M; Takeda, S; Tian, Y; Wang, R; Ye, Y; Zhang, H | 1 |
| Bekiranov, S; Dinda, M; Manukyan, A; Raimer, HM; Singh, S; Szlachta, K; Wang, YH | 1 |
| Alam, MB; Chandrasekharan, A; Chauhan, M; Das, S; Gandhi, S; Ghosh, D; Kaushik, S; Ma, S; Parmar, AS; Santhoshkumar, TR; Sharma, A; Suhag, D | 1 |
| Li, J; Lu, M; Peng, Z; Shen, L; Wang, X; Zhang, P; Zhang, X; Zhou, J | 1 |
| Difilippantonio, S; Huang, SN; James, A; Marzi, L; Pommier, Y; Sun, Y | 1 |
| Franěk, R; Gazo, I; Lebeda, I; Pšenička, M; Shivaramu, S; Šindelka, R; Steinbach, C | 1 |
| Hamada, M; Ichikawa, D; Imaya, M; Kawashima, N; Kojima, S; Miwata, S; Muramatsu, H; Narita, A; Narita, K; Nishikawa, E; Nishio, N; Takahashi, Y; Wakamatsu, M; Yamamori, A; Yoshida, T | 1 |
| Akagi, K; Dotsu, Y; Fukuda, M; Gyotoku, H; Hayashi, F; Hisamatsu, Y; Ikeda, T; Kinoshita, A; Morinaga, R; Mukae, H; Nagashima, S; Nakatomi, K; Ogata, R; Ono, S; Senju, H; Shimada, M; Soda, H; Sugasaki, N; Tagawa, R; Takemoto, S; Taniguchi, H; Tomono, H; Umeyama, Y | 1 |
59 review(s) available for etoposide and camptothecin
| Article | Year |
|---|---|
A comprehensive review of topoisomerase inhibitors as anticancer agents in the past decade.
Topics: Coumarins; Diterpenes; DNA Topoisomerases; Fatty Acids; Flavonoids; Heterocyclic Compounds; Humans; Lignans; Organometallic Compounds; Polyphenols; Quinones; Topoisomerase Inhibitors | 2019 |
1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
Topics: Antineoplastic Agents; Humans; Molecular Structure; Neoplasms; Structure-Activity Relationship; Triazoles | 2019 |
Cascade synthetic strategies opening access to medicinal-relevant aliphatic 3- and 4-membered N-heterocyclic scaffolds.
Topics: Bridged Bicyclo Compounds; Nitrogen | 2022 |
Pharmacology of antitumor agents from higher plants.
Topics: Animals; Antineoplastic Agents, Phytogenic; Aporphines; Camptothecin; Carcinoma, Squamous Cell; Chemical Phenomena; Chemistry; Etoposide; Humans; Leukemia L1210; Leukemia, Experimental; Leukemia, Lymphoid; Maytansine; Melanoma; Naphthoquinones; Nasopharyngeal Neoplasms; Neoplasms; Neoplasms, Experimental; Phenanthrenes; Structure-Activity Relationship; Teniposide; Vinblastine; Vincristine | 1976 |
DNA topoisomerase-targeting antitumor agents and drug resistance.
Topics: Antineoplastic Agents; Camptothecin; DNA Topoisomerases, Type I; Drug Resistance; Etoposide; Humans; Teniposide; Tumor Cells, Cultured | 1992 |
Mechanisms of resistance to drugs that inhibit DNA topoisomerases.
Topics: Amsacrine; Animals; Antineoplastic Agents; Camptothecin; Cricetinae; Daunorubicin; DNA Replication; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Doxorubicin; Drug Resistance; Etoposide; Humans; Mice; Teniposide; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 1991 |
DNA topoisomerase inhibitors.
Topics: Animals; Camptothecin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Interactions; Drug Resistance; Etoposide; Humans; Irinotecan; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan | 1994 |
Chemotherapy administration: doses, infusions and choice of schedule.
Topics: Antineoplastic Agents; Camptothecin; Drug Administration Schedule; Etoposide; Fluorouracil; Humans; Infusions, Intravenous; Neoplasms | 1994 |
7-Ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy camptothecin: mechanism of resistance and clinical trials.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Survival; CHO Cells; Clinical Trials, Phase I as Topic; Cricetinae; DNA Topoisomerases, Type I; Drug Resistance; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Molecular Sequence Data; Neoplasms; Ovarian Neoplasms; Point Mutation; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 1994 |
[On the novel differentiation-apoptosis inducers in tumor cells].
Topics: Animals; Antineoplastic Agents; Apoptosis; Bufanolides; Camptothecin; Cell Differentiation; Etoposide; Humans; Neoplasms; Sodium-Potassium-Exchanging ATPase; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 1996 |
DNA topoisomerase inhibitors as antifungal agents.
Topics: Antifungal Agents; Aspergillus niger; Camptothecin; Candida albicans; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Etoposide; HeLa Cells; Humans; Saccharomyces cerevisiae; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 1994 |
[DNA topoisomerases targeting anticancer agents and mechanism for acquirement of drug resistance].
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Resistance, Neoplasm; Etoposide; Humans; Irinotecan; Mutation; Neoplasms; Teniposide; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1997 |
["State-of-the-art" chemotherapy for small-cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Drug Administration Schedule; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topotecan; Vincristine | 1997 |
[Treatment of recurrent gastric cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Doxorubicin; Drug Administration Schedule; Epirubicin; Etoposide; Fluorouracil; Humans; Immunologic Factors; Irinotecan; Liver Neoplasms; Lymphatic Metastasis; Methotrexate; Mitomycin; Neoplastic Cells, Circulating; Peritoneal Neoplasms; Stomach Neoplasms | 1998 |
[Chemotherapy of gastric cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Doxorubicin; Etoposide; Fluorouracil; Humans; Immunologic Factors; Irinotecan; Methotrexate; Stomach Neoplasms | 1998 |
Chemotherapy for gastric carcinoma: new and old options.
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Capecitabine; Deoxycytidine; Docetaxel; Drug Combinations; Enzyme Inhibitors; Etoposide; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Oxonic Acid; Paclitaxel; Pyridines; Randomized Controlled Trials as Topic; Stomach Neoplasms; Taxoids; Tegafur; Uracil | 1998 |
[Irinotecan-containing combinations in solid tumors, except colonic carcinomas].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Diarrhea; Docetaxel; Enzyme Inhibitors; Etoposide; Female; Genital Neoplasms, Female; Humans; Irinotecan; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Neoplasm Proteins; Neoplasms; Neutropenia; Paclitaxel; Stomach Neoplasms; Taxoids; Topoisomerase I Inhibitors; Treatment Outcome | 1998 |
[Pharmacokinetic monitoring].
Topics: Antineoplastic Agents; Body Mass Index; Camptothecin; Colorectal Neoplasms; Drug Interactions; Drug Monitoring; Etoposide; Fluorouracil; Humans; Irinotecan; Liver; Paclitaxel; Topotecan | 2000 |
Irinotecan in small-cell lung cancer--Japanese trials.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Etoposide; Humans; Irinotecan; Japan; Lung Neoplasms; Radiation-Sensitizing Agents | 2000 |
New state of the art in small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Etoposide; Humans; Irinotecan; Lung Neoplasms; Prognosis; Survival Rate | 2001 |
Chemoradiation in locally advanced non-small cell lung cancer.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Administration Schedule; Etoposide; Forecasting; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Multicenter Studies as Topic; Paclitaxel; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
Lung cancer: therapeutic options for stage IV and recurrent NSCLC.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Risk Factors; Survival Rate; Taxoids; Teniposide; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
Role of topoisomerase I inhibitors in small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Enzyme Inhibitors; Etoposide; Humans; Irinotecan; Lung Neoplasms; Survival Analysis; Topoisomerase I Inhibitors | 2001 |
Recent advances in the chemotherapy of non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Randomized Controlled Trials as Topic; Survival Rate; Tirapazamine; Triazines; Vinblastine; Vinorelbine | 2001 |
Topoisomerase I inhibitors combination chemotherapy in non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Doxorubicin; Enzyme Inhibitors; Etoposide; Gemcitabine; Humans; Ifosfamide; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topoisomerase I Inhibitors; Topotecan; Vinblastine; Vinorelbine | 2001 |
Irinotecan therapy for small-cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Enzyme Inhibitors; Etoposide; Humans; Irinotecan; Japan; Lung Neoplasms; Survival Analysis; Topoisomerase I Inhibitors; United States | 2002 |
[Irinotecan].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Etoposide; Humans; Irinotecan; Lung Neoplasms | 2002 |
[Recent progress in the treatment of ED small cell lung cancer].
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Imatinib Mesylate; Irinotecan; Lung Neoplasms; Piperazines; Pyrimidines; Vincristine | 2002 |
Limited stage small cell lung cancer: treatment and therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Etoposide; Humans; Irinotecan; Lung Neoplasms; Prognosis; Treatment Outcome | 2003 |
The global role of irinotecan in the treatment of lung cancer: 2003 update.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Administration Schedule; Etoposide; Gemcitabine; Humans; Irinotecan; Japan; Lung Neoplasms; Multicenter Studies as Topic; Neoplasm Staging; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome; United States; Vindesine | 2003 |
Progress in treatment of small-cell lung cancer: role of CPT-11.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Topoisomerase I Inhibitors | 2003 |
Chemotherapy of small cell lung cancer: state of the art.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Etoposide; Humans; Ifosfamide; Irinotecan; Lung Neoplasms; Quality of Life; Survival Rate; Treatment Outcome | 2004 |
Treatment options for small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Camptothecin; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Imatinib Mesylate; Irinotecan; Lung Neoplasms; Male; Neoplasm Staging; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Radiotherapy, Adjuvant; Risk Factors; Sex Distribution; Smoking; Survival Rate; Treatment Outcome; United States | 2004 |
[Treatment of platinum-resistant ovarian cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials as Topic; DNA Damage; Docetaxel; Drug Resistance, Neoplasm; Etoposide; Female; Gynecologic Surgical Procedures; Humans; Irinotecan; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 2004 |
[Second-line chemotherapy for recurrent ovarian cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Irinotecan; Ovarian Neoplasms; Paclitaxel; Platinum; Taxoids | 2005 |
Small-cell lung cancer: current therapy and novel agents.
Topics: Adult; Age Factors; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Etoposide; Humans; Irinotecan; Lung Neoplasms; Middle Aged; Neoplasm Staging; Prognosis | 2005 |
Recent advances in conventional-dose salvage chemotherapy in patients with cisplatin-resistant or refractory testicular germ cell tumors.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Etoposide; Gemcitabine; Humans; Ifosfamide; Irinotecan; Male; Neoplasms, Germ Cell and Embryonal; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Salvage Therapy; Testicular Neoplasms; Vinblastine | 2005 |
[Treatment of small cell lung cancer].
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Dose Fractionation, Radiation; Drug Administration Schedule; Etoposide; Humans; Irinotecan; Lung Neoplasms; Survival Analysis | 2005 |
Combination of gemcitabine and irinotecan for recurrent metastatic osteogenic sarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Cisplatin; Combined Modality Therapy; Deoxycytidine; Doxorubicin; Etoposide; Femoral Neoplasms; Gemcitabine; Head and Neck Neoplasms; Humans; Ifosfamide; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Methotrexate; Middle Aged; Neoadjuvant Therapy; Osteosarcoma; Palliative Care; Salvage Therapy; Scalp; Skin Neoplasms; Thoracotomy | 2005 |
[Progress in therapy for testicular tumors].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Camptothecin; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Administration Schedule; Etoposide; Gemcitabine; Humans; Irinotecan; Lymph Node Excision; Male; Paclitaxel; Taxoids; Testicular Neoplasms | 2006 |
[Chemotherapy for lung cancer patients].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Erlotinib Hydrochloride; Etoposide; Evidence-Based Medicine; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Taxoids | 2006 |
Pooled analysis of phase II window studies in children with contemporary high-risk metastatic rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Clinical Trials, Phase II as Topic; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Enzyme Inhibitors; Etoposide; Female; Humans; Ifosfamide; Irinotecan; Lymphatic Metastasis; Male; Rhabdomyosarcoma; Survival Analysis; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Treatment Outcome | 2006 |
[Lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Drug Administration Schedule; Etoposide; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Pemetrexed; Taxoids | 2007 |
[Chemotherapy in lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Survival Rate | 2007 |
Safety of irinotecan/cisplatin versus etoposide/cisplatin for patients with extensive-stage small-cell lung cancer: a metaanalysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Diarrhea; Etoposide; Female; Hematologic Diseases; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Randomized Controlled Trials as Topic; Vomiting | 2007 |
A meta-analysis of randomized controlled trials comparing irinotecan/platinum with etoposide/platinum in patients with previously untreated extensive-stage small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Cisplatin; Disease-Free Survival; Etoposide; Humans; Irinotecan; Lung Neoplasms; Randomized Controlled Trials as Topic | 2010 |
DNA topoisomerases and their poisoning by anticancer and antibacterial drugs.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Camptothecin; DNA Topoisomerases; Doxorubicin; Enzyme Inhibitors; Etoposide; Humans; Mitoxantrone; Quinolones; Topoisomerase Inhibitors | 2010 |
Camptothecins compared with etoposide in combination with platinum analog in extensive stage small cell lung cancer: systematic review with meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease-Free Survival; Etoposide; Humans; Lung Neoplasms; Neoplasm Staging; Small Cell Lung Carcinoma | 2010 |
Complement and correction for meta-analysis of patients with extensive-stage small cell lung cancer managed with irinotecan/cisplatin versus etoposide/cisplatin as first-line chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Etoposide; Humans; Irinotecan; Lung Neoplasms; Neoplasm Staging; Small Cell Lung Carcinoma; Survival Rate; Treatment Outcome | 2011 |
An updated meta-analysis of randomized controlled trials comparing irinotecan/platinum with etoposide/platinum in patients with previously untreated extensive-stage small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Etoposide; Humans; Irinotecan; Lung Neoplasms; Prognosis; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Survival Rate | 2012 |
Cisplatin plus etoposide versus other platin-based regimens for patients with extensive small-cell lung cancer: a systematic review and meta-analysis of randomised, controlled trials.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cisplatin; Cost-Benefit Analysis; Cyclophosphamide; Drug Therapy, Combination; Epirubicin; Etoposide; Humans; Irinotecan; Lung Neoplasms; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Treatment Outcome | 2012 |
Systemic therapy for small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance, Neoplasm; Etoposide; Humans; Irinotecan; Lung Neoplasms; Platinum; Recurrence; Small Cell Lung Carcinoma | 2013 |
[Programs for continuing medical education: B session; 4. Progress in lung cancer therapy].
Topics: Anaplastic Lymphoma Kinase; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cisplatin; Crizotinib; Drug Discovery; Education, Medical, Continuing; Erlotinib Hydrochloride; Etoposide; Gefitinib; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Molecular Targeted Therapy; Pemetrexed; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Small Cell Lung Carcinoma | 2014 |
Chemotherapy for advanced poorly differentiated pancreatic neuroendocrine carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Neuroendocrine; Cisplatin; Drug Administration Schedule; Etoposide; Everolimus; Humans; Irinotecan; Pancreatic Neoplasms | 2015 |
[First-line Chemotherapy for Extensive-disease Small Cell Lung Cancer:
A Network Meta-analysis].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Network Meta-Analysis; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma | 2016 |
Neuroendocrine Cancer, Therapeutic Strategies in G3 Cancers.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Neuroendocrine; Cisplatin; Etoposide; Gastrointestinal Neoplasms; Humans; Irinotecan; Ki-67 Antigen; Neoplasm Grading; Neuroendocrine Tumors; Practice Guidelines as Topic; Prognosis; Treatment Outcome | 2017 |
Comparing the adverse effects of platinum in combination with etoposide or irinotecan in previously untreated small-cell lung cancer patients with extensive disease: A network meta-analyses.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug-Related Side Effects and Adverse Reactions; Etoposide; Humans; Irinotecan; Network Meta-Analysis; Platinum; Small Cell Lung Carcinoma | 2017 |
Comparison of irinotecan/platinum versus etoposide/platinum chemotherapy for extensive-stage small cell lung cancer: A meta-analysis.
Topics: Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chemotherapy-Induced Febrile Neutropenia; Cisplatin; Diarrhea; Etoposide; Fatigue; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Nausea; Neoplasm Staging; Neutropenia; Odds Ratio; Proportional Hazards Models; Small Cell Lung Carcinoma; Thrombocytopenia; Vomiting | 2017 |
Irinotecan-platinum combination therapy for previously untreated extensive-stage small cell lung cancer patients: a meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Etoposide; Female; Humans; Irinotecan; Male; Platinum; Proportional Hazards Models; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma | 2018 |
68 trial(s) available for etoposide and camptothecin
| Article | Year |
|---|---|
Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Diarrhea; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Half-Life; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Recombinant Proteins; Remission Induction; Thrombocytopenia | 1994 |
Phase I study of CPT-11 and etoposide in patients with refractory solid tumors.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Treatment Outcome | 1993 |
CPT-11: population pharmacokinetic model and estimation of pharmacokinetics using the Bayesian method in patients with lung cancer.
Topics: Bayes Theorem; Camptothecin; Etoposide; Humans; Irinotecan; Lung Neoplasms; Metabolic Clearance Rate | 1994 |
Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Remission Induction; Salvage Therapy; Survival Rate; Topotecan; United States | 1996 |
Phase II study of irinotecan and etoposide in patients with metastatic non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged | 1997 |
Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Enzyme Inhibitors; Etoposide; Female; Hematologic Diseases; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 1997 |
Unexpected hepatotoxicities in patients with non-Hodgkin's lymphoma treated with irinotecan (CPT-11) and etoposide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Drug Interactions; Etoposide; Humans; Irinotecan; Liver; Lymphoma, Non-Hodgkin; Middle Aged; Topoisomerase I Inhibitors | 1998 |
Limited sampling model for the area under the concentration versus time curve of irinotecan and its application to a multicentric phase II trial.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Metabolic Clearance Rate; Middle Aged; Nausea; Recombinant Proteins; Reproducibility of Results; Vomiting | 1997 |
Induction of gamma-glutamylcysteine synthetase gene expression by platinum drugs in peripheral mononuclear cells of lung cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Blotting, Northern; Camptothecin; Carboplatin; Cisplatin; Drug Resistance, Neoplasm; Etoposide; Female; Gene Expression; Glutamate-Cysteine Ligase; Humans; Irinotecan; Leukocytes, Mononuclear; Lung Neoplasms; Male; Middle Aged; Molecular Sequence Data; Polymerase Chain Reaction; RNA, Messenger; Statistics, Nonparametric; Tumor Cells, Cultured | 1999 |
[Combination of irinotecan hydrochloride and etoposide for treatment of refractory or relapsed small-cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local | 2000 |
[Evaluation of bronchial arterial infusion (BAI) for high risk lung cancer].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bronchial Arteries; Camptothecin; Carcinoma, Large Cell; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intra-Arterial; Irinotecan; Lung Neoplasms; Male; Middle Aged | 2000 |
Phase I study of a weekly infusion of irinotecan hydrochloride (CPT-11) and a 14-day continuous infusion of etoposide in patients with lung cancer: JCOG trial 9408.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged | 2000 |
[Preliminary clinical comparison of HLF and ELF regimen in the treatment of advanced gastric carcinoma in middle-aged and elderly patients].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Etoposide; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Staging; Stomach Neoplasms | 2000 |
Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Disease-Free Survival; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Survival Analysis | 2002 |
[Phase I study with irinotecan hydrochloride (CPT-11) for advanced neuroblastoma].
Topics: Adrenal Gland Neoplasms; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child, Preschool; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Infant; Irinotecan; Neuroblastoma | 2001 |
Radiation enhancement by the combined use of topoisomerase I inhibitors, RFS-2000 or CPT-11, and topoisomerase II inhibitor etoposide in human lung cancer cells.
Topics: Antineoplastic Agents; Camptothecin; Cell Survival; Colony-Forming Units Assay; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Combinations; Enzyme Inhibitors; Etoposide; Humans; Irinotecan; Lung Neoplasms; Radiation-Sensitizing Agents; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 2002 |
Phase I/II trial of weekly cisplatin, etoposide, and irinotecan chemotherapy for metastatic lung cancer: JCOG 9507.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Diarrhea; Dose-Response Relationship, Drug; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Irinotecan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Survival; Thrombocytopenia | 2003 |
Randomized phase II study of cisplatin, irinotecan and etoposide combinations administered weekly or every 4 weeks for extensive small-cell lung cancer (JCOG9902-DI).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Irinotecan; Male; Middle Aged; Prospective Studies; Survival Rate | 2003 |
Phase I evaluation of sequential topoisomerase targeting with irinotecan/cisplatin followed by etoposide in patients with advanced malignancy.
Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Cisplatin; Cohort Studies; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Etoposide; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2003 |
Dose-dense therapy with a novel irinotecan regimen for small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Treatment Outcome | 2003 |
Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Injections, Subcutaneous; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Prognosis; Survival Analysis; Treatment Outcome | 2003 |
Topoisomerase I inhibitors in small-cell lung cancer. The Japanese experience.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Enzyme Inhibitors; Etoposide; Female; Humans; Irinotecan; Japan; Lung Neoplasms; Male; Middle Aged; Remission Induction; Survival Rate; Topoisomerase I Inhibitors | 2004 |
Irinotecan in advanced lung cancer: focus on North American trials.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Deoxycytidine; Enzyme Inhibitors; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; North America; Radiotherapy, Adjuvant; Ribonucleotide Reductases; Survival Rate; Taxoids; Topoisomerase I Inhibitors; Vindesine | 2004 |
Multi-institutional phase II trial of irinotecan, cisplatin, and etoposide for sensitive relapsed small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Salvage Therapy; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2004 |
Carcinoma of unknown primary site: sequential treatment with paclitaxel/carboplatin/etoposide and gemcitabine/irinotecan: a Minnie Pearl Cancer Research Network phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Treatment Outcome | 2004 |
Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Dose-Response Relationship, Radiation; Etoposide; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Radiotherapy Dosage; Radiotherapy, Adjuvant; Remission Induction; Risk Assessment; Survival Analysis; Treatment Outcome | 2005 |
Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Esophagogastric Junction; Etoposide; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Levoleucovorin; Male; Middle Aged; Neoplasm Staging; Peritoneal Neoplasms; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2005 |
Phase I study of etoposide, cisplatin and irinotecan triplet in patients with advanced-stage small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Camptothecin; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Survival Analysis | 2005 |
Irinotecan and etoposide for previously untreated extensive-disease small cell lung cancer: a phase II trial of West Japan Thoracic Oncology Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Etoposide; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Survival Rate; Treatment Outcome | 2005 |
Pilot study of concurrent etoposide and cisplatin plus accelerated hyperfractionated thoracic radiotherapy followed by irinotecan and cisplatin for limited-stage small cell lung cancer: Japan Clinical Oncology Group 9903.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Dose Fractionation, Radiation; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Pilot Projects; Time Factors; Treatment Outcome | 2005 |
A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged | 2006 |
Randomized phase III trial of cisplatin/irinotecan versus cisplatin/etoposide in patients with extensive-stage small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Etoposide; Humans; Irinotecan; Lung Neoplasms; Survival Rate | 2006 |
Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging | 2006 |
Influence of low-energy laser in the prevention of oral mucositis in children with cancer receiving chemotherapy.
Topics: Adolescent; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Child; Child, Preschool; Cohort Studies; Etoposide; Female; Humans; Ifosfamide; Irinotecan; Low-Level Light Therapy; Male; Methotrexate; Mouth Mucosa; Neoplasms; Nutritional Status; Oral Hygiene; Severity of Illness Index; Stomatitis; Treatment Outcome | 2007 |
Sequential oral 9-nitrocamptothecin and etoposide: a pharmacodynamic- and pharmacokinetic-based phase I trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Treatment Outcome | 2006 |
Clinical trial of CPT-11 and VM-26/VP-16 for patients with recurrent malignant brain tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Etoposide; Female; Glioma; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Teniposide; Tomography, X-Ray Computed | 2007 |
Phase II study of etoposide and cisplatin with concurrent twice-daily thoracic radiotherapy followed by irinotecan and cisplatin in patients with limited-disease small-cell lung cancer: West Japan Thoracic Oncology Group 9902.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Diarrhea; Disease-Free Survival; Etoposide; Female; Fever; Humans; Infections; Irinotecan; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Radiotherapy Dosage; Radiotherapy, Adjuvant; Severity of Illness Index; Survival Analysis; Treatment Outcome | 2006 |
A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Diarrhea; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Injections, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Prospective Studies; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2007 |
Pilot study evaluating the efficacy and toxicity of irinotecan plus oral etoposide for platinum- and taxane-resistant epithelial ovarian cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Irinotecan; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Pilot Projects; Taxoids | 2007 |
Combination chemotherapy with cisplatin, etoposide and irinotecan in patients with extensive small-cell lung cancer: A phase II study of the Hellenic Co-operative Oncology Group.
Topics: Adult; Aged; Camptothecin; Carcinoma, Small Cell; Cisplatin; Disease Progression; Dose-Response Relationship, Drug; Drug Therapy, Combination; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Survival Rate | 2007 |
A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500)
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Remission Induction; Sirolimus; Survival Rate; Treatment Outcome | 2007 |
Randomised phase II trial of irinotecan plus cisplatin vs irinotecan, cisplatin plus etoposide repeated every 3 weeks in patients with extensive-disease small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Survival Rate | 2008 |
Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Prognosis; Survival Analysis | 2008 |
Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Cisplatin; Diarrhea; Etoposide; Female; Glucuronosyltransferase; Humans; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neutropenia; Pharmacogenetics; Polymorphism, Single Nucleotide; Risk Factors; Small Cell Lung Carcinoma | 2009 |
Etoposide plus cisplatin followed by concurrent chemo-radiotherapy and irinotecan plus cisplatin for patients with limited-stage small cell lung cancer: A multicenter phase II study.
Topics: Aged; Camptothecin; Cisplatin; Drug Therapy, Combination; Etoposide; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Radiotherapy, Adjuvant; Small Cell Lung Carcinoma | 2010 |
Weekly alternating therapy with irinotecan plus cisplatin and etoposide plus cisplatin in the treatment of patients with extensive small cell lung carcinoma.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Small Cell Lung Carcinoma | 2010 |
A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Etoposide; Female; Humans; International Agencies; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Small Cell Lung Carcinoma; Survival Rate; Young Adult | 2010 |
Triplet combination of carboplatin, irinotecan, and etoposide in the first-line treatment of extensive small-cell lung cancer: a single-institution phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Small Cell Lung Carcinoma; Treatment Outcome | 2010 |
A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Disease-Free Survival; Etoposide; Female; Germany; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Small Cell Lung Carcinoma | 2011 |
Phase II clinical study of the combination chemotherapy regimen of irinotecan plus oral etoposide for the treatment of recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 101 Group Study).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Disease-Free Survival; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2011 |
Phase I clinical trial of alternating belotecan and oral etoposide in patients with platinum-resistant or heavily treated ovarian cancer.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance, Neoplasm; Etoposide; Fallopian Tube Neoplasms; Female; Humans; Maximum Tolerated Dose; Middle Aged; Neutropenia; Ovarian Neoplasms; Peritoneal Neoplasms; Thrombocytopenia; Treatment Outcome | 2012 |
Phase II study of oral etoposide and intravenous irinotecan for patients with platinum-resistant and taxane-pretreated ovarian cancer: Japan Clinical Oncology Group Study 0503.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Infusions, Intravenous; Irinotecan; Ovarian Neoplasms; Research Design; Taxoids | 2012 |
Combination chemotherapy of alternating etoposide and carboplatin with weekly administration of irinotecan and cisplatin in extensive-stage small-cell lung cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Severity of Illness Index; Small Cell Lung Carcinoma; Thrombocytopenia; Treatment Outcome | 2012 |
Phase II study of induction cisplatin and irinotecan followed by concurrent carboplatin, etoposide, and thoracic radiotherapy for limited-stage small-cell lung cancer, CALGB 30206.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chemoradiotherapy; Cisplatin; Confidence Intervals; Dehydration; Disease-Free Survival; Dose Fractionation, Radiation; Esophagitis; Etoposide; Female; Humans; Induction Chemotherapy; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Small Cell Lung Carcinoma | 2013 |
E5501: phase II study of topotecan sequenced with etoposide/cisplatin, and irinotecan/cisplatin sequenced with etoposide for extensive-stage small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Small Cell Lung Carcinoma; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan | 2014 |
Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Chemoradiotherapy; Cisplatin; Dose Fractionation, Radiation; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging | 2014 |
A Phase III trial comparing irinotecan and cisplatin with etoposide and cisplatin in adjuvant chemotherapy for completely resected pulmonary high-grade neuroendocrine carcinoma (JCOG1205/1206).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Chemotherapy, Adjuvant; Cisplatin; Clinical Protocols; Disease-Free Survival; Etoposide; Female; Humans; Incidence; Irinotecan; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Second Primary; Patient Selection; Survival Analysis; Treatment Outcome | 2014 |
Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Neuroendocrine; Cisplatin; Deoxycytidine; Disease-Free Survival; Etoposide; Female; Fluorouracil; Gastrointestinal Neoplasms; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Organoplatinum Compounds; Oxaliplatin; Prognosis; Proportional Hazards Models; Retrospective Studies; Treatment Outcome | 2014 |
A Phase II/III study comparing carboplatin and irinotecan with carboplatin and etoposide for the treatment of elderly patients with extensive-disease small-cell lung cancer (JCOG1201).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Humans; Irinotecan; Japan; Lung Neoplasms; Male; Middle Aged; Patient Selection; Small Cell Lung Carcinoma; Survival Analysis; Treatment Outcome | 2015 |
Phase II trial of oral etoposide plus intravenous irinotecan in patients with platinum-resistant and taxane-pretreated ovarian cancer (JCOG0503).
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Irinotecan; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Taxoids; Young Adult | 2015 |
Randomized phase II trial comparing amrubicin with re-challenge of platinum doublet in patients with sensitive-relapsed small-cell lung cancer: North Japan Lung Cancer Study Group trial 0702.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chemotherapy-Induced Febrile Neutropenia; Cisplatin; Disease-Free Survival; Etoposide; Female; Humans; Irinotecan; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Retreatment; Small Cell Lung Carcinoma; Survival Rate | 2015 |
Phase I/IIa study of sequential chemotherapy regimen of bendamustine/irinotecan followed by etoposide/carboplatin in untreated patients with extensive disease small cell lung cancer (EDSCLC).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Biomarkers, Tumor; Brain Diseases, Metabolic; Camptothecin; Carboplatin; Carcinoma, Small Cell; Disease-Free Survival; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Administration Schedule; Endonucleases; Etoposide; Fatigue; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mitosis; Multiple Organ Failure; Pneumonia; Treatment Outcome; Weight Loss | 2015 |
Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Child; Child, Preschool; Cyclophosphamide; Disease Progression; Doxorubicin; Drug Administration Schedule; Etoposide; Feasibility Studies; Female; Follow-Up Studies; Humans; Ifosfamide; Infant; Irinotecan; Lymphatic Metastasis; Male; Middle Aged; Patient Selection; Radiotherapy, Adjuvant; Rhabdomyosarcoma; Risk Assessment; Risk Factors; Severity of Illness Index; Treatment Outcome; Vincristine | 2016 |
Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Etoposide; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Salvage Therapy; Small Cell Lung Carcinoma; Survival Rate; Topotecan | 2016 |
Belotecan/cisplatin versus etoposide/cisplatin in previously untreated patients with extensive-stage small cell lung carcinoma: a multi-center randomized phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Disease-Free Survival; Etoposide; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged | 2016 |
Cost-effectiveness analysis of sensitive relapsed small-cell lung cancer based on JCOG0605 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Cost-Benefit Analysis; Etoposide; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Neoplasm Recurrence, Local; Prognosis; Quality-Adjusted Life Years; Small Cell Lung Carcinoma; Survival Rate; Topotecan | 2018 |
Etoposide and cisplatin versus irinotecan and cisplatin as the first-line therapy for patients with advanced, poorly differentiated gastroenteropancreatic neuroendocrine carcinoma: A randomized phase 2 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Cisplatin; Etoposide; Humans; Irinotecan; Lung Neoplasms | 2020 |
Phase II study of IRInotecan treatment after COmbined chemo-immunotherapy for extensive-stage small cell lung cancer: Protocol of IRICO study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase II as Topic; Disease Progression; Etoposide; Humans; Immunotherapy; Irinotecan; Lung Neoplasms; Neoplasm Recurrence, Local; Platinum; Small Cell Lung Carcinoma | 2023 |
532 other study(ies) available for etoposide and camptothecin
| Article | Year |
|---|---|
Synthesis and evaluation of new 6-amino-substituted benzo[c]phenanthridine derivatives.
Topics: Adenocarcinoma; Alkaloids; Animals; Antineoplastic Agents; Benzophenanthridines; Breast Neoplasms; Humans; Leukemia L1210; Leukemia P388; Mice; Molecular Structure; Phenanthridines; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1993 |
Synthesis and antitumor properties of N-[2-(dimethylamino)ethyl]carboxamide derivatives of fused tetracyclic quinolines and quinoxalines: a new class of putative topoisomerase inhibitors.
Topics: Acridines; Animals; Antineoplastic Agents; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Mice; Mice, Inbred C57BL; Models, Chemical; Phenazines; Quinolines; Quinoxalines; Structure-Activity Relationship; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 1997 |
Geometrically and conformationally restrained cinnamoyl compounds as inhibitors of HIV-1 integrase: synthesis, biological evaluation, and molecular modeling.
Topics: Anti-HIV Agents; Antineoplastic Agents; Cell Division; Cinnamates; Crystallography, X-Ray; HIV Integrase Inhibitors; HIV-1; Humans; Models, Molecular; Structure-Activity Relationship; Tumor Cells, Cultured; Virus Replication | 1998 |
Homocamptothecins: synthesis and antitumor activity of novel E-ring-modified camptothecin analogues.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzoxepins; Camptothecin; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Female; Humans; Inhibitory Concentration 50; Male; Mice; Mice, Nude; Neoplasm Transplantation; Stereoisomerism; Structure-Activity Relationship; Topoisomerase I Inhibitors; Transplantation, Heterologous; Tumor Cells, Cultured | 1998 |
Derivatives of the new ring system indolo[1,2-c]benzo[1,2,3]triazine with potent antitumor and antimicrobial activity.
Topics: Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Antifungal Agents; Antineoplastic Agents; Bacteria; Drug Evaluation, Preclinical; Drug Resistance, Multiple; Drug Resistance, Neoplasm; HIV-1; Humans; Microbial Sensitivity Tests; Structure-Activity Relationship; Triazines; Tumor Cells, Cultured | 1999 |
Design, synthesis, and biological evaluation of analogues of the antitumor agent, 2-(4-[(7-chloro-2-quinoxalinyl)oxy]phenoxy)propionic acid (XK469).
Topics: Animals; Antineoplastic Agents; Drug Design; Drug Screening Assays, Antitumor; Humans; Mice; Quinoxalines; Stereoisomerism; Structure-Activity Relationship; Transplantation, Heterologous; Tumor Cells, Cultured | 2001 |
Catalytic inhibition of topoisomerase IIalpha by demethylzeylasterone, a 6-oxophenolic triterpenoid from Kokoona zeylanica.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Catalysis; DNA; DNA Topoisomerases, Type II; DNA-Binding Proteins; Electrophoresis, Agar Gel; Electrophoretic Mobility Shift Assay; Enzyme Inhibitors; Female; Glioma; Humans; Inhibitory Concentration 50; Lung Neoplasms; Methyl Green; Molecular Structure; Plants, Medicinal; Saccharomyces cerevisiae; Structure-Activity Relationship; Topoisomerase II Inhibitors; Triterpenes; Tumor Cells, Cultured | 2001 |
Cheminformatic models to predict binding affinities to human serum albumin.
Topics: Adrenergic beta-Antagonists; Antidepressive Agents, Tricyclic; Chromatography, Affinity; Cyclooxygenase Inhibitors; Databases, Factual; Humans; Hydrophobic and Hydrophilic Interactions; Penicillins; Pharmaceutical Preparations; Protein Binding; Quantitative Structure-Activity Relationship; Reproducibility of Results; Serum Albumin; Steroids | 2001 |
Synthesis and cytotoxic activity of carboxamide derivatives of benzo[b][1,6]naphthyridines.
Topics: Animals; Antineoplastic Agents; Cell Division; Drug Screening Assays, Antitumor; Humans; Mice; Naphthyridines; Neoplasm Transplantation; Neoplasms, Experimental; Structure-Activity Relationship; Transplantation, Heterologous; Tumor Cells, Cultured | 2003 |
Inhibitory activities against topoisomerase I and II by polyhydroxybenzoyl amide derivatives and their structure-activity relationship.
Topics: Cell Cycle; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Enzyme Inhibitors; Growth Inhibitors; HeLa Cells; Humans; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2004 |
6-Arylamino-7-chloro-quinazoline-5,8-diones as novel cytotoxic and DNA topoisomerase inhibitory agents.
Topics: Antineoplastic Agents; Cell Line, Tumor; DNA Topoisomerases; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Quinazolines; Structure-Activity Relationship; Topoisomerase Inhibitors | 2004 |
Indole alkaloids and other constituents of Rauwolfia serpentina.
Topics: Antineoplastic Agents, Phytogenic; Drug Screening Assays, Antitumor; HL-60 Cells; Humans; Indole Alkaloids; Molecular Structure; Nuclear Magnetic Resonance, Biomolecular; Plant Roots; Plants, Medicinal; Rauwolfia; Thailand | 2005 |
Synthesis and antitumor characterization of pyrazolic analogues of the marine pyrroloquinoline alkaloids: wakayin and tsitsikammamines.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Indole Alkaloids; Pyrazoles; Pyrroles; Quinolines; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2006 |
Synthesis of 6-chloroisoquinoline-5,8-diones and pyrido[3,4-b]phenazine-5,12-diones and evaluation of their cytotoxicity and DNA topoisomerase II inhibitory activity.
Topics: Caco-2 Cells; Cell Line, Tumor; Cell Proliferation; DNA; Drug Screening Assays, Antitumor; Drug Stability; Enzyme Inhibitors; Humans; Isoquinolines; Molecular Structure; Permeability; Phenazines; Stereoisomerism; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2007 |
Synthesis, cytotoxicity, and DNA topoisomerase II inhibitory activity of benzofuroquinolinediones.
Topics: Cell Death; Cell Line, Tumor; Doxorubicin; Humans; Inhibitory Concentration 50; Quinolones; Topoisomerase II Inhibitors | 2007 |
Cells lacking DNA topoisomerase II beta are resistant to genistein.
Topics: Animals; DNA; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Resistance, Neoplasm; Genistein; Luteolin; Mice; Molecular Structure | 2007 |
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Synthesis, DNA binding, and cytotoxicity of 1,4-bis(2-amino-ethylamino)anthraquinone-amino acid conjugates.
Topics: Amino Acid Sequence; Amino Acids; Anthraquinones; Antineoplastic Agents; Combinatorial Chemistry Techniques; DNA; Drug Screening Assays, Antitumor; Humans; Molecular Structure; Stereoisomerism; Structure-Activity Relationship | 2008 |
Curcumin induces high levels of topoisomerase I- and II-DNA complexes in K562 leukemia cells.
Topics: Acetylcysteine; Antineoplastic Agents, Phytogenic; Antioxidants; Curcumin; DNA; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Screening Assays, Antitumor; Humans; K562 Cells; Microscopy, Fluorescence; Molecular Structure; Reactive Oxygen Species; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 2007 |
New insight for fluoroquinophenoxazine derivatives as possibly new potent topoisomerase I inhibitor.
Topics: Antineoplastic Agents; Enzyme Inhibitors; Fluoroquinolones; HCT116 Cells; HeLa Cells; HL-60 Cells; Humans; Oxazines; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2008 |
Photochemical electrocyclisation of 3-vinylindoles to pyrido[2,3-a]-, pyrido[4,3-a]- and thieno[2,3-a]-carbazoles: design, synthesis, DNA binding and antitumor cell cytotoxicity.
Topics: Animals; Antineoplastic Agents; Binding Sites; Carbazoles; Cattle; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Circular Dichroism; Cyclization; DNA; Drug Design; Fluorescence; Humans; Indoles; Nucleic Acid Denaturation; Photochemical Processes; Spectrophotometry, Ultraviolet; Stereoisomerism; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Transition Temperature | 2009 |
Rational design and semisynthesis of betulinic acid analogues as potent topoisomerase inhibitors.
Topics: Betulinic Acid; DNA; Humans; Models, Chemical; Molecular Structure; Pentacyclic Triterpenes; Topoisomerase I Inhibitors; Triterpenes | 2009 |
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
Topics: Animals; Antimalarials; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromosome Mapping; Crosses, Genetic; Dihydroergotamine; Drug Design; Drug Resistance; Humans; Inhibitory Concentration 50; Mutation; Plasmodium falciparum; Quantitative Trait Loci; Transfection | 2009 |
Synthesis of isoquinolinone-based tetracycles as poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors.
Topics: Antineoplastic Agents; Cell Line, Tumor; DNA Damage; Enzyme Inhibitors; Heterocyclic Compounds, 4 or More Rings; Humans; Isoquinolines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Quinolones | 2009 |
Oxiranylmethyloxy or thiiranylmethyloxy-azaxanthones and -acridone analogues as potential topoisomerase I inhibitors.
Topics: Acridines; Antineoplastic Agents; Aza Compounds; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Molecular Structure; Stereoisomerism; Structure-Activity Relationship; Topoisomerase I Inhibitors; Xanthones | 2009 |
2-Thienyl-4-furyl-6-aryl pyridine derivatives: synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Screening Assays, Antitumor; Humans; Inhibitory Concentration 50; Neoplasms; Pyrimidines; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2010 |
2,6-Dithienyl-4-furyl pyridines: Synthesis, topoisomerase I and II inhibition, cytotoxicity, structure-activity relationship, and docking study.
Topics: Antineoplastic Agents; Binding Sites; Cell Line, Tumor; Computer Simulation; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Screening Assays, Antitumor; Humans; Pyridines; Structure-Activity Relationship; Thiophenes; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2010 |
A diazirine-based photoaffinity etoposide probe for labeling topoisomerase II.
Topics: Antineoplastic Agents; Binding Sites; Cell Proliferation; Chromatography, Liquid; Diazomethane; DNA; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Etoposide; Humans; Kinetics; Molecular Structure; Photoaffinity Labels; Photochemistry; Solvents; Structure-Activity Relationship; Tandem Mass Spectrometry; Topoisomerase II Inhibitors; Tumor Cells, Cultured; Ultraviolet Rays | 2010 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
New benzoxanthone derivatives as topoisomerase inhibitors and DNA cross-linkers.
Topics: Antineoplastic Agents; Benzene Derivatives; Cell Line, Tumor; Cell Proliferation; DNA; DNA Topoisomerases; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Screening Assays, Antitumor; Humans; Molecular Structure; Neoplasms; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topoisomerase Inhibitors; Xanthones | 2010 |
Synthesis of 2-(thienyl-2-yl or -3-yl)-4-furyl-6-aryl pyridine derivatives and evaluation of their topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship.
Topics: Antineoplastic Agents; Cell Proliferation; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Design; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Molecular Structure; Pyridines; Stereoisomerism; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 2010 |
New diterpenoids from Caesalpinia species and their cytotoxic activity.
Topics: Antineoplastic Agents, Phytogenic; Caesalpinia; Diterpenes; HeLa Cells; HL-60 Cells; Humans; Magnetic Resonance Spectroscopy; Molecular Conformation | 2010 |
Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study of hydroxylated 2,4-diphenyl-6-aryl pyridines.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cytotoxins; Drug Screening Assays, Antitumor; Humans; Inhibitory Concentration 50; Molecular Structure; Pyridines; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2010 |
Synthesis and pharmacological evaluation of new methyloxiranylmethoxyxanthone analogues.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cross-Linking Reagents; DNA; DNA Topoisomerases, Type II; Humans; Topoisomerase II Inhibitors; Xanthones | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Synthesis of 4β-N-polyaromatic substituted podophyllotoxins: DNA topoisomerase inhibition, anticancer and apoptosis-inducing activities.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; DNA Topoisomerases, Type II; Drug Screening Assays, Antitumor; Humans; Podophyllotoxin; Topoisomerase II Inhibitors | 2010 |
Synthesis and antiproliferative activity of novel symmetrical alkylthio- and alkylseleno-imidocarbamates.
Topics: Antineoplastic Agents; Apoptosis; Carbamates; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Humans; Inhibitory Concentration 50 | 2011 |
Synthesis and topoisomerase II inhibitory and cytotoxic activity of oxiranylmethoxy- and thiiranylmethoxy-chalcone derivatives.
Topics: Antineoplastic Agents; Cell Line, Tumor; Chalcone; Chalcones; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Screening Assays, Antitumor; Humans; Sulfides; Topoisomerase II Inhibitors | 2011 |
The selectivity of austocystin D arises from cell-line-specific drug activation by cytochrome P450 enzymes.
Topics: Aflatoxin B1; Aflatoxins; Antineoplastic Agents; Aspergillus; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Cytochrome P-450 Enzyme System; DNA Damage; Drug Resistance, Multiple; Drug Screening Assays, Antitumor; Humans; Molecular Structure | 2011 |
Synthesis, biological evaluation, and molecular docking study of 3-(3'-heteroatom substituted-2'-hydroxy-1'-propyloxy) xanthone analogues as novel topoisomerase IIα catalytic inhibitor.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Biocatalysis; Cell Line, Tumor; Cell Survival; DNA Topoisomerases, Type II; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; HeLa Cells; HL-60 Cells; Humans; Models, Molecular; Molecular Structure; Stereoisomerism; Structure-Activity Relationship; Topoisomerase II Inhibitors; Xanthones | 2011 |
Synthesis and biological evaluation of N-substituted benzo[c]phenanthrolines and benzo[c]phenanthrolinones as antiproliferative agents.
Topics: Animals; Antineoplastic Agents; Cattle; Cell Cycle; Cell Proliferation; DNA; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; HT29 Cells; Humans; Molecular Structure; Phenanthrolines; Stereoisomerism; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2011 |
Synthesis and evaluation of mansonone F derivatives as topoisomerase inhibitors.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antigens, Neoplasm; Antineoplastic Agents; Carcinoma; Cell Line, Tumor; Cell Survival; DNA; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Screening Assays, Antitumor; Etoposide; Humans; Inhibitory Concentration 50; Lung Neoplasms; Naphthoquinones; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Plasmids; Pyrans; Quinones; Sesquiterpenes; Structure-Activity Relationship; Telomerase; Topoisomerase Inhibitors | 2011 |
Synthesis of 2,4-diaryl chromenopyridines and evaluation of their topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Benzopyrans; Cell Line, Tumor; Cell Proliferation; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Screening Assays, Antitumor; Female; Humans; Male; Neoplasms; Pyridines; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2011 |
Synthesis of polyfunctionalized piperidone oxime ethers and their cytotoxicity on HeLa cells.
Topics: Antineoplastic Agents; Cell Survival; Ethers; Female; HeLa Cells; Humans; Oximes; Piperidones; Structure-Activity Relationship; Uterine Cervical Neoplasms | 2011 |
Sulfur and selenium derivatives of quinazoline and pyrido[2,3-d]pyrimidine: synthesis and study of their potential cytotoxic activity in vitro.
Topics: Absorption; Antineoplastic Agents; Cell Cycle; Cell Death; Cell Line, Tumor; Humans; Pyrimidines; Quinazolines; Selenium; Sulfur | 2012 |
Cytotoxic phloroglucinols from the leaves of Myrtus communis.
Topics: Anti-Bacterial Agents; Antineoplastic Agents, Phytogenic; Drug Screening Assays, Antitumor; Hep G2 Cells; Humans; Italy; Microbial Sensitivity Tests; Molecular Structure; Myrtus; Phloroglucinol; Plant Leaves; Staphylococcus aureus | 2012 |
Dihydroxylated 2,4,6-triphenyl pyridines: synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Humans; Neoplasms; Pyridines; Topoisomerase Inhibitors | 2012 |
Hybrids of privileged structures benzothiazoles and pyrrolo[2,1-c] [1,4]benzodiazepin-5-one, and diversity-oriented synthesis of benzothiazoles.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Benzodiazepines; Benzothiazoles; Etoposide; Humans; Molecular Structure; Neoplasms; Structure-Activity Relationship; Tumor Cells, Cultured | 2012 |
Synthesis and biological evaluation of 4β-sulphonamido and 4β-[(4'-sulphonamido)benzamide]podophyllotoxins as DNA topoisomerase-IIα and apoptosis inducing agents.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Apoptosis; Benzamides; Cell Cycle; Cell Line, Tumor; Comet Assay; DNA Breaks; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Screening Assays, Antitumor; Etoposide; Humans; Neoplasms; Podophyllotoxin; Podophyllum | 2012 |
Design, synthesis, and antitumor evaluation of 2,4,6-triaryl pyridines containing chlorophenyl and phenolic moiety.
Topics: Antineoplastic Agents; Cell Line, Tumor; Chemistry Techniques, Synthetic; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Design; Humans; Models, Molecular; Phenols; Protein Conformation; Pyridines | 2012 |
Antitumor agents 294. Novel E-ring-modified camptothecin-4β-anilino-4'-O-demethyl-epipodophyllotoxin conjugates as DNA topoisomerase I inhibitors and cytotoxic agents.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Proliferation; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Humans; Podophyllotoxin; Stereoisomerism; Topoisomerase I Inhibitors | 2012 |
Synthesis of benzo-annulated tryptanthrins and their biological properties.
Topics: Animals; Cattle; DNA; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Molecular Structure; Quinazolines; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2012 |
New tricks for an old natural product: discovery of highly potent evodiamine derivatives as novel antitumor agents by systemic structure-activity relationship analysis and biological evaluations.
Topics: Antineoplastic Agents, Phytogenic; Biological Products; Cell Line, Tumor; Drug Screening Assays, Antitumor; Evodia; Humans; Quinazolines; Structure-Activity Relationship | 2012 |
Inhibition of human topoisomerases I and II by simocyclinone D8.
Topics: Coumarins; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Glycosides; Humans; Molecular Structure; Streptomyces antibioticus; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2012 |
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
Topics: Acetylcholinesterase; Amyloid beta-Peptides; Benzophenanthridines; Binding Sites; Butyrylcholinesterase; Catalytic Domain; Cholinesterase Inhibitors; Humans; Isoquinolines; Kinetics; Molecular Docking Simulation; Structure-Activity Relationship | 2012 |
Indenoindolone derivatives as topoisomerase II-inhibiting anticancer agents.
Topics: Antineoplastic Agents; DNA Topoisomerases, Type II; Humans; Indoles; Models, Molecular; Neoplasms; Topoisomerase II Inhibitors | 2013 |
Oxo-heterocyclic fused naphthalimides as antitumor agents: synthesis and biological evaluation.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Heterocyclic Compounds; Humans; Mice; Molecular Structure; Naphthalimides; Structure-Activity Relationship | 2013 |
Cytotoxicity and topoisomerase I/II inhibition activity of novel 4-aryl/alkyl-1-(piperidin-4-yl)-carbonylthiosemicarbazides and 4-benzoylthiosemicarbazides.
Topics: Antineoplastic Agents; Cell Culture Techniques; Cell Survival; DNA, Superhelical; Fibroblasts; Humans; Inhibitory Concentration 50; MCF-7 Cells; Molecular Structure; Semicarbazides; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2014 |
Chalcones, inhibitors for topoisomerase I and cathepsin B and L, as potential anti-cancer agents.
Topics: Antineoplastic Agents; Cathepsin B; Cathepsin L; Cell Line, Tumor; Cell Survival; Chalcones; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Enzyme Inhibitors; Humans; Structure-Activity Relationship; Topoisomerase I Inhibitors | 2013 |
Structural variations on antitumour agents derived from bisacylimidoselenocarbamate. A proposal for structure-activity relationships based on the analysis of conformational behaviour.
Topics: Antineoplastic Agents; Carbamates; HT29 Cells; Humans; MCF-7 Cells; Models, Molecular; Molecular Conformation; Organoselenium Compounds; Structure-Activity Relationship | 2013 |
4β-[4'-(1-(Aryl)ureido)benzamide]podophyllotoxins as DNA topoisomerase I and IIα inhibitors and apoptosis inducing agents.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Binding Sites; Cell Line, Tumor; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Screening Assays, Antitumor; G1 Phase Cell Cycle Checkpoints; Humans; Hydrogen Bonding; Molecular Docking Simulation; Podophyllotoxin; Protein Structure, Tertiary; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2013 |
Synthesis of imine-pyrazolopyrimidinones and their mechanistic interventions on anticancer activity.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Binding Sites; Cell Line, Tumor; Cell Proliferation; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Design; Drug Screening Assays, Antitumor; G2 Phase Cell Cycle Checkpoints; HeLa Cells; Humans; Imines; M Phase Cell Cycle Checkpoints; MCF-7 Cells; Molecular Docking Simulation; Protein Structure, Tertiary; Pyrazoles; Pyridines; Structure-Activity Relationship | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
3-(3-Butylamino-2-hydroxy-propoxy)-1-hydroxy-xanthen-9-one acts as a topoisomerase IIα catalytic inhibitor with low DNA damage.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Biocatalysis; Cell Line, Tumor; Cell Proliferation; DNA Damage; DNA Topoisomerases, Type II; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Structure-Activity Relationship; Topoisomerase II Inhibitors; Xanthones | 2013 |
Novel N-4-piperazinyl-ciprofloxacin-chalcone hybrids: synthesis, physicochemical properties, anticancer and topoisomerase I and II inhibitory activity.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Chalcone; Ciprofloxacin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Molecular Structure; Piperazines; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2013 |
Extending the record of bis-γ-pyrone polypropionates from marine pulmonate mollusks.
Topics: Animals; Drug Screening Assays, Antitumor; Humans; Marine Biology; Molecular Structure; Mollusca; Nuclear Magnetic Resonance, Biomolecular; Propionates; Pyrones | 2013 |
Rational design and synthesis of topoisomerase I and II inhibitors based on oleanolic acid moiety for new anti-cancer drugs.
Topics: Antineoplastic Agents; Humans; Models, Molecular; Oleanolic Acid; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2014 |
Design, synthesis and systematic evaluation of cytotoxic 3-heteroarylisoquinolinamines as topoisomerases inhibitors.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Crystallography, X-Ray; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Heterocyclic Compounds; Humans; Isoquinolines; Models, Molecular; Molecular Structure; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2014 |
Design, synthesis, mechanisms of action, and toxicity of novel 20(s)-sulfonylamidine derivatives of camptothecin as potent antitumor agents.
Topics: Amidines; Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Proliferation; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Female; HCT116 Cells; Humans; KB Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Conformation; Neoplasms, Experimental; Structure-Activity Relationship; Sulfonamides; Topoisomerase I Inhibitors | 2014 |
Synthesis, antitumor activity, and structure-activity relationship study of trihydroxylated 2,4,6-triphenyl pyridines as potent and selective topoisomerase II inhibitors.
Topics: Cell Line, Tumor; Cell Proliferation; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; HEK293 Cells; Humans; Molecular Docking Simulation; Molecular Structure; Neoplasms; Phenols; Pyridines; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2014 |
Design and synthesis of 2-phenylnaphthalenoids as inhibitors of DNA topoisomeraseIIα and antitumor agents.
Topics: Animals; Antigens, Neoplasm; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Proliferation; DNA Topoisomerases, Type II; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; HeLa Cells; Humans; Mice; Mice, Nude; Molecular Structure; Naphthalenes; Neoplasms, Experimental; Quantitative Structure-Activity Relationship; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 2014 |
Design and synthesis of novel 2,4-diaryl-5H-indeno[1,2-b]pyridine derivatives, and their evaluation of topoisomerase inhibitory activity and cytotoxicity.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Design; Humans; Pyridines; Structure-Activity Relationship; Topoisomerase I Inhibitors | 2015 |
Design, synthesis and biological evaluation of novel 7-alkylamino substituted benzo[a]phenazin derivatives as dual topoisomerase I/II inhibitors.
Topics: Amines; Cell Line, Tumor; Cell Proliferation; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; HeLa Cells; HL-60 Cells; Humans; K562 Cells; Molecular Structure; Phenazines; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2015 |
Structure-based hybridization, synthesis and biological evaluation of novel tetracyclic heterocyclic azathioxanthone analogues as potential antitumor agents.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Heterocyclic Compounds; Humans; Molecular Structure; Quinolines; Structure-Activity Relationship; Thioxanthenes; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2015 |
Discovery of Novel Multiacting Topoisomerase I/II and Histone Deacetylase Inhibitors.
Topics: | 2015 |
Topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study of dihydroxylated 2,6-diphenyl-4-aryl pyridines.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Humans; Pyridines; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2015 |
Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study of 2-phenyl- or hydroxylated 2-phenyl-4-aryl-5H-indeno[1,2-b]pyridines.
Topics: Antineoplastic Agents; Binding Sites; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Screening Assays, Antitumor; Humans; Hydroxylation; Inhibitory Concentration 50; Molecular Structure; Protein Binding; Pyridines; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2015 |
Imine/amide-imidazole conjugates derived from 5-amino-4-cyano-N1-substituted benzyl imidazole: Microwave-assisted synthesis and anticancer activity via selective topoisomerase-II-α inhibition.
Topics: Antigens, Neoplasm; Apoptosis; Cell Proliferation; DNA Topoisomerases, Type II; DNA-Binding Proteins; Humans; Imidazoles; Microwaves; Molecular Structure; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2015 |
Substituted 2-arylquinazolinones: Design, synthesis, and evaluation of cytotoxicity and inhibition of topoisomerases.
Topics: Cell Line, Tumor; Cell Proliferation; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; HeLa Cells; Humans; Molecular Structure; Quinazolinones; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2015 |
Design and synthesis of conformationally constrained hydroxylated 4-phenyl-2-aryl chromenopyridines as novel and selective topoisomerase II-targeted antiproliferative agents.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Design; Drug Screening Assays, Antitumor; Humans; Hydroxylation; Pyridines; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2015 |
Synthesis and evaluation of antibacterial and antitumor activities of new galactopyranosylated amino alcohols.
Topics: Amino Alcohols; Anti-Bacterial Agents; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Molecular Structure; Structure-Activity Relationship | 2016 |
Discovery of antitumor anthra[2,3-b]furan-3-carboxamides: Optimization of synthesis and evaluation of antitumor properties.
Topics: Animals; Anthracenes; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Furans; Humans; Leukemia; Mice; Neoplasms; Protein Kinase Inhibitors; Structure-Activity Relationship; Topoisomerase Inhibitors | 2016 |
Effect of chlorine substituent on cytotoxic activities: Design and synthesis of systematically modified 2,4-diphenyl-5H-indeno[1,2-b]pyridines.
Topics: Antineoplastic Agents; Biphenyl Compounds; Breast; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Design; Female; Halogenation; HeLa Cells; Humans; Indenes; Pyridines; Structure-Activity Relationship; Topoisomerase Inhibitors | 2016 |
A new series of 2-phenol-4-aryl-6-chlorophenyl pyridine derivatives as dual topoisomerase I/II inhibitors: Synthesis, biological evaluation and 3D-QSAR study.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Molecular Structure; Pyridines; Quantitative Structure-Activity Relationship; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2016 |
Design, synthesis, topoisomerase I & II inhibitory activity, antiproliferative activity, and structure-activity relationship study of pyrazoline derivatives: An ATP-competitive human topoisomerase IIα catalytic inhibitor.
Topics: Adenosine Triphosphate; Antigens, Neoplasm; Antineoplastic Agents; Binding, Competitive; Biocatalysis; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Humans; Molecular Docking Simulation; Molecular Structure; Pyrazoles; Structure-Activity Relationship; Topoisomerase Inhibitors | 2016 |
Synthesis and Antiproliferative and Metabolic Evaluations of Novel Securinine Derivatives.
Topics: | 2016 |
Scaffold-hopping of bioactive flavonoids: Discovery of aryl-pyridopyrimidinones as potent anticancer agents that inhibit catalytic role of topoisomerase IIα.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Design; Flavonoids; Humans; Neoplasm Invasiveness; Pyrimidinones; Topoisomerase II Inhibitors | 2016 |
Synthesis and biological evaluation of C1-O-substituted-3-(3-butylamino-2-hydroxy-propoxy)-xanthen-9-one as topoisomerase IIα catalytic inhibitors.
Topics: Adenosine Triphosphate; Antigens, Neoplasm; Antineoplastic Agents; Binding Sites; Biocatalysis; DNA Damage; DNA Topoisomerases, Type II; DNA-Binding Proteins; Humans; Topoisomerase II Inhibitors; Xanthones | 2016 |
Novel 2-aryl-4-(4'-hydroxyphenyl)-5H-indeno[1,2-b]pyridines as potent DNA non-intercalative topoisomerase catalytic inhibitors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; DNA; DNA Topoisomerases, Type II; DNA-Binding Proteins; Humans; Molecular Docking Simulation; Pyridines; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2017 |
Fluorescein hydrazones: A series of novel non-intercalative topoisomerase IIα catalytic inhibitors induce G1 arrest and apoptosis in breast and colon cancer cells.
Topics: Animals; Antigens, Neoplasm; Apoptosis; Apoptosis Regulatory Proteins; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Dose-Response Relationship, Drug; Female; Fluorescein; G1 Phase Cell Cycle Checkpoints; Humans; Hydrazones; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2017 |
Synthesis and topoisomerases inhibitory activity of heteroaromatic chalcones.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Chalcones; DNA Topoisomerases; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Molecular Structure; Structure-Activity Relationship; Topoisomerase Inhibitors | 2016 |
Scaffold-Hopping of Aurones: 2-Arylideneimidazo[1,2-
Topics: | 2016 |
Rational design, synthesis, and evaluation of novel 2,4-Chloro- and Hydroxy-Substituted diphenyl Benzofuro[3,2-b]Pyridines: Non-intercalative catalytic topoisomerase I and II dual inhibitor.
Topics: Antineoplastic Agents; Apoptosis; Benzofurans; Biocatalysis; Cell Line, Tumor; Cell Proliferation; Chemistry Techniques, Synthetic; DNA; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Design; Humans; Pyridines; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2017 |
Dihydroxylated 2,6-diphenyl-4-chlorophenylpyridines: Topoisomerase I and IIα dual inhibitors with DNA non-intercalative catalytic activity.
Topics: Antineoplastic Agents; Biphenyl Compounds; Cell Line, Tumor; Cell Proliferation; DNA Topoisomerases, Type I; Halogenation; Humans; Neoplasms; Pyridines; Topoisomerase II Inhibitors | 2017 |
Synthesis and biological evaluation of N-(carbobenzyloxy)-l-phenylalanine and N-(carbobenzyloxy)-l-aspartic acid-β-benzyl ester derivatives as potent topoisomerase IIα inhibitors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Aspartic Acid; Cell Line, Tumor; DNA Topoisomerases, Type II; DNA-Binding Proteins; HeLa Cells; Humans; Molecular Docking Simulation; Neoplasms; Phenylalanine; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2017 |
2-Chlorophenyl-substituted benzofuro[3,2-b]pyridines with enhanced topoisomerase inhibitory activity: The role of the chlorine substituent.
Topics: Antineoplastic Agents; Benzofurans; Cell Line, Tumor; Cell Proliferation; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Halogenation; Humans; Neoplasms; Pyridines; Topoisomerase Inhibitors | 2017 |
Design, synthesis, and biological evaluation of 1,3-diarylisoquinolines as novel topoisomerase I catalytic inhibitors.
Topics: Antineoplastic Agents; Biocatalysis; Cell Line, Tumor; Cell Proliferation; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Humans; Isoquinolines; Molecular Structure; Polymerization; Structure-Activity Relationship; Topoisomerase I Inhibitors; Tubulin | 2018 |
Neutral Porphyrin Derivative Exerts Anticancer Activity by Targeting Cellular Topoisomerase I (Top1) and Promotes Apoptotic Cell Death without Stabilizing Top1-DNA Cleavage Complexes.
Topics: Antineoplastic Agents; Apoptosis; Biocatalysis; DNA Breaks; DNA Cleavage; DNA Topoisomerases, Type I; Humans; MCF-7 Cells; Porphyrins; Reactive Oxygen Species; Topoisomerase I Inhibitors | 2018 |
Synthesis of carbazole derivatives containing chalcone analogs as non-intercalative topoisomerase II catalytic inhibitors and apoptosis inducers.
Topics: Antineoplastic Agents; Apoptosis; Biocatalysis; Carbazoles; Cell Cycle Checkpoints; Cell Proliferation; Chalcone; DNA Cleavage; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; HL-60 Cells; Humans; Molecular Structure; Plasmids; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2018 |
Design, synthesis, and structure-activity relationships of new benzofuro[3,2-b]pyridin-7-ols as DNA topoisomerase II inhibitors.
Topics: Antineoplastic Agents; Benzofurans; Cell Line, Tumor; Cell Proliferation; DNA Topoisomerases, Type I; Drug Design; Drug Screening Assays, Antitumor; Etoposide; Humans; Molecular Structure; Pyridines; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2018 |
Synthesis and SAR study of new hydroxy and chloro-substituted 2,4-diphenyl 5H-chromeno[4,3-b]pyridines as selective topoisomerase IIα-targeting anticancer agents.
Topics: Antineoplastic Agents; Benzopyrans; Cell Line, Tumor; Cell Proliferation; DNA Topoisomerases, Type II; HeLa Cells; Humans; Protein Binding; Pyridines; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2018 |
Synthesis, antitumor activity and DNA binding features of benzothiazolyl and benzimidazolyl substituted isoindolines.
Topics: Antineoplastic Agents; Apoptosis; Benzimidazoles; Benzothiazoles; Cell Line, Tumor; Cell Proliferation; Circular Dichroism; DNA; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Screening Assays, Antitumor; Humans; Isoindoles; MCF-7 Cells; Microscopy, Fluorescence; Structure-Activity Relationship | 2018 |
Synthesis and biological evaluation of novel carbazole-rhodanine conjugates as topoisomerase II inhibitors.
Topics: Antineoplastic Agents; Carbazoles; Cell Line, Tumor; DNA Topoisomerases, Type II; Drug Screening Assays, Antitumor; Etoposide; Humans; Intercalating Agents; Rhodanine; Topoisomerase II Inhibitors | 2018 |
Design, synthesis and biological evaluation of benzimidazole-rhodanine conjugates as potent topoisomerase II inhibitors.
Topics: | 2018 |
Development of 13H-benzo[f]chromeno[4,3-b][1,7]naphthyridines and their salts as potent cytotoxic agents and topoisomerase I/IIα inhibitors.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Humans; Molecular Structure; Naphthyridines; Salts; Structure-Activity Relationship; Topoisomerase Inhibitors | 2018 |
A new phenolic series of indenopyridinone as topoisomerase inhibitors: Design, synthesis, and structure-activity relationships.
Topics: Antineoplastic Agents; Cell Line; Cell Proliferation; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; HeLa Cells; Humans; Indenes; Molecular Structure; Phenols; Pyridones; Structure-Activity Relationship; Topoisomerase Inhibitors | 2018 |
Eucalypglobulusals A-J, Formyl-Phloroglucinol-Terpene Meroterpenoids from Eucalyptus globulus Fruits.
Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; DNA Topoisomerases, Type I; Drug Screening Assays, Antitumor; Eucalyptus; Fruit; Humans; Molecular Structure; Terpenes; Topoisomerase I Inhibitors | 2018 |
Discovery and Mechanistic Study of Tailor-Made Quinoline Derivatives as Topoisomerase 1 Poison with Potent Anticancer Activity.
Topics: Antineoplastic Agents; Cell Line, Tumor; DNA Breaks, Double-Stranded; DNA Topoisomerases, Type I; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Point Mutation; Topoisomerase I Inhibitors | 2019 |
Design, synthesis and evaluation of antiproliferative activity of fluorinated betulinic acid.
Topics: Betulinic Acid; Cell Proliferation; Humans; Molecular Structure; Pentacyclic Triterpenes; Triterpenes | 2019 |
Discovery and Biological Evaluations of Halogenated 2,4-Diphenyl Indeno[1,2-
Topics: Animals; Antineoplastic Agents; Biphenyl Compounds; Breast Neoplasms; Cell Proliferation; Cell Survival; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Female; Humans; Male; Mammary Neoplasms, Experimental; Mice; Mice, Inbred ICR; Microwaves; Molecular Structure; Pyridines; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 2019 |
Design, synthesis and biological research of novel N-phenylbenzamide-4-methylamine acridine derivatives as potential topoisomerase I/II and apoptosis-inducing agents.
Topics: Apoptosis; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Humans; Methylamines; Molecular Docking Simulation; Molecular Structure; Structure-Activity Relationship | 2019 |
Natural Product Evodiamine with Borate Trigger Unit: Discovery of Potent Antitumor Agents against Colon Cancer.
Topics: | 2020 |
Total Synthesis of Natural Lembehyne C and Investigation of Its Cytotoxic Properties.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Stereoisomerism | 2020 |
Structural simplification of evodiamine: Discovery of novel tetrahydro-β-carboline derivatives as potent antitumor agents.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carbolines; Cell Proliferation; Drug Screening Assays, Antitumor; G2 Phase Cell Cycle Checkpoints; HCT116 Cells; Humans; Male; Mice, Nude; Molecular Structure; Neoplasms; Proof of Concept Study; Quinazolines; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Xenograft Model Antitumor Assays | 2021 |
Identification of new halogen-containing 2,4-diphenyl indenopyridin-5-one derivative as a boosting agent for the anticancer responses of clinically available topoisomerase inhibitors.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Cell Survival; DNA; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Halogens; Humans; Indenes; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Structure; Neoplasms, Experimental; Poly-ADP-Ribose Binding Proteins; Pyridones; Structure-Activity Relationship; Topoisomerase Inhibitors; Tumor Cells, Cultured | 2022 |
Design, synthesis and biological evaluation of 3-arylisoquinoline derivatives as topoisomerase I and II dual inhibitors for the therapy of liver cancer.
Topics: Alkaloids; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; DNA; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Design; Humans; Isoquinolines; Liver Neoplasms; Molecular Docking Simulation; Phosphatidylinositol 3-Kinases; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2022 |
Overview of early and investigational chemotherapeutic agents in solid tumors.
Topics: Alkylating Agents; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Aziridines; Azo Compounds; Camptothecin; Cycloleucine; Etoposide; Floxuridine; Humans; Neoplasms; Nitrogen Mustard Compounds; Picolinic Acids; Platinum; Porfiromycin; Streptonigrin; Teniposide; Thiotepa; Tubercidin | 1976 |
Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression.
Topics: Adenocarcinoma; Antineoplastic Agents; Blotting, Northern; Blotting, Southern; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cell Line; Cell Survival; Cisplatin; DNA Topoisomerases, Type II; DNA, Neoplasm; Doxorubicin; Drug Screening Assays, Antitumor; Etoposide; Fluorouracil; Humans; Lung Neoplasms; Phenotype; Restriction Mapping; RNA, Neoplasm; Teniposide | 1992 |
Characterization of camptothecin-resistant Chinese hamster lung cells.
Topics: Animals; Base Sequence; Camptothecin; Cell Line; Cricetinae; Cricetulus; DNA; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Drug Resistance; Etoposide; Lung; Molecular Sequence Data; Podophyllotoxin; RNA, Messenger; Vincristine | 1992 |
Effect of ICRF-193, a novel DNA topoisomerase II inhibitor, on simian virus 40 DNA and chromosome replication in vitro.
Topics: Camptothecin; Cell Line; Chromosomes; Diketopiperazines; DNA Replication; DNA, Viral; Electrophoresis, Gel, Two-Dimensional; Etoposide; HeLa Cells; Humans; Neutralization Tests; Piperazines; Simian virus 40; Topoisomerase II Inhibitors | 1992 |
Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Division; Colonic Neoplasms; DNA Damage; DNA, Neoplasm; DNA, Single-Stranded; Drug Administration Schedule; Drug Interactions; Etoposide; Humans; Kinetics; RNA, Neoplasm; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1992 |
Inhibitors of topoisomerases do not block the passage of human lymphocyte chromosomes through mitosis.
Topics: Amsacrine; Camptothecin; Chromosome Aberrations; Chromosomes, Human; Daunorubicin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Ellipticines; Ethidium; Etoposide; Humans; In Vitro Techniques; Lymphocytes; Mitosis; Mitoxantrone; Nalidixic Acid; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 1992 |
Potentiation of topoisomerase I and II inhibitors cell killing by tumor necrosis factor: relationship to DNA strand breakage formation.
Topics: Camptothecin; Cell Death; Cisplatin; DNA Damage; DNA, Neoplasm; Drug Synergism; Epirubicin; Etoposide; Female; Humans; Mitomycin; Ovarian Neoplasms; Recombinant Proteins; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 1992 |
Pre-treatment of a human T-lymphoblastoid cell line with L-asparaginase reduces etoposide-induced DNA strand breakage and cytotoxicity.
Topics: Asparaginase; Camptothecin; Cell Cycle; Cross-Linking Reagents; DNA; DNA Damage; Etoposide; Humans; In Vitro Techniques; Tumor Cells, Cultured | 1992 |
Lack of interference of DNA single-strand breaks with the measurement of double-strand breaks in mammalian cells using the neutral filter elution assay.
Topics: Animals; Camptothecin; Cell Line; Cricetinae; Deoxyribonucleases, Type II Site-Specific; DNA; DNA Damage; DNA Topoisomerases, Type II; DNA, Single-Stranded; Etoposide; Filtration; Hydrogen-Ion Concentration | 1991 |
Etoposide sensitivity and topoisomerase II activity in Chinese hamster V79 monolayers and small spheroids.
Topics: Animals; Camptothecin; Cell Aggregation; Cell Survival; Cells, Cultured; DNA Damage; DNA Topoisomerases, Type II; Etoposide; Fluorouracil; Topoisomerase II Inhibitors | 1991 |
Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons.
Topics: Amsacrine; Animals; Antibiotics, Antineoplastic; Aphidicolin; Camptothecin; Cell Survival; Cricetinae; Cricetulus; Cycloheximide; Deoxyadenosines; Dichlororibofuranosylbenzimidazole; Diterpenes; DNA; Etoposide; Mutagens; Nucleic Acids; RNA; Time Factors; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 1990 |
Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line.
Topics: Amsacrine; Aphidicolin; Blotting, Western; Camptothecin; Colony-Forming Units Assay; Cycloheximide; Daunorubicin; Deoxyadenosines; Dichlororibofuranosylbenzimidazole; Diterpenes; DNA Polymerase II; DNA Replication; Drug Synergism; Etoposide; Female; Humans; Leukemia, Promyelocytic, Acute; Mutagens; RNA; Topoisomerase II Inhibitors; Topotecan; Tumor Cells, Cultured | 1991 |
[Clinical pharmacology of anticancer agents (Part 3). Plant alkaloids].
Topics: Alkaloids; Antineoplastic Agents; Camptothecin; Etoposide; Humans; Plants, Medicinal; Podophyllin; Vinca Alkaloids | 1992 |
[Isolation of drug-resistant mutant cells].
Topics: Alkylating Agents; Amphotericin B; Anti-Bacterial Agents; Antifungal Agents; Aphidicolin; Camptothecin; Cell Separation; Drug Resistance; Etoposide; Humans; Hydroxamic Acids; Lovastatin; Monensin; Nucleic Acids; Teniposide; Toxins, Biological; Tunicamycin | 1991 |
Topoisomerase inhibitors have potent differentiation-inducing activity for human and mouse myeloid leukemia cells.
Topics: Animals; Biomarkers, Tumor; Camptothecin; Cell Differentiation; DNA; DNA Damage; Drug Synergism; Etoposide; Humans; In Vitro Techniques; Leukemia, Myeloid; Mice; Time Factors; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 1991 |
Rapid evaluation of topoisomerase inhibitors: caffeine inhibition of topoisomerases in vivo.
Topics: Animals; Caffeine; Camptothecin; Etoposide; Haplorhini; Teniposide; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 1990 |
Involvement of topoisomerases in replication, transcription, and packaging of the linear adenovirus genome.
Topics: Adenoviruses, Human; Alkaloids; Blotting, Southern; Camptothecin; Cell Nucleus; Deoxyribonucleoproteins; DNA Replication; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA, Viral; Electrophoresis, Gel, Two-Dimensional; Electrophoresis, Polyacrylamide Gel; Ellipticines; Etoposide; HeLa Cells; Humans; Microscopy, Electron; Templates, Genetic; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Transcription, Genetic | 1990 |
DNA topoisomerase I as a site of action for 10-hydroxycamptothecin in human promyelocytic leukemia cells.
Topics: Amsacrine; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Division; DNA Damage; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Resistance; Enzyme Inhibitors; Etoposide; Humans; Leukemia, Promyelocytic, Acute; Mutation; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1990 |
Effect of topoisomerase modulators on cisplatin cytotoxicity in human ovarian carcinoma cells.
Topics: Antibiotics, Antineoplastic; Camptothecin; Cell Line; Cisplatin; DNA Topoisomerases, Type I; Drug Interactions; Etoposide; Female; Humans; Naphthoquinones; Novobiocin; Ovarian Neoplasms; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1990 |
The inhibition of cellular recovery in human tumour cells by inhibitors of topoisomerase.
Topics: Camptothecin; Cell Survival; DNA; DNA Repair; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Drug Combinations; Etoposide; Humans; Radiation Tolerance; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Urinary Bladder Neoplasms | 1990 |
Patterns of strongly protein-associated simian virus 40 DNA replication intermediates resulting from exposures to specific topoisomerase poisons.
Topics: Animals; Camptothecin; Chlorocebus aethiops; Deoxyribonucleoproteins; DNA Replication; DNA, Viral; Ellipticines; Etoposide; Proflavine; Simian virus 40; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 1990 |
Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells.
Topics: Amsacrine; Animals; Aphidicolin; Camptothecin; Cell Line; Cell Survival; Cricetinae; Cricetulus; Diterpenes; DNA Replication; Etoposide; Hydroxyurea; Kinetics; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 1989 |
Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: a cautionary note.
Topics: Antineoplastic Agents; Camptothecin; Cell Line; Cell Nucleus; Dinitrophenols; DNA Damage; DNA, Neoplasm; Etoposide; Humans; Kinetics; Leukemia, Myeloid, Acute; Nuclear Proteins; Tumor Cells, Cultured | 1989 |
Sister chromatid exchanges, chromosomal aberrations, and cytotoxicity produced by antitumor topoisomerase II inhibitors in sensitive (DC3F) and resistant (DC3F/9-OHE) Chinese hamster cells.
Topics: Amsacrine; Animals; Camptothecin; Cell Line; Cell Survival; Chromosome Aberrations; Cricetinae; Drug Resistance; Ellipticines; Etoposide; Mitomycin; Mitomycins; Sister Chromatid Exchange; Topoisomerase II Inhibitors | 1988 |
Topoisomerase inhibitors induce irreversible fragmentation of replicated DNA in concanavalin A stimulated splenocytes.
Topics: Animals; Camptothecin; Concanavalin A; DNA; DNA Replication; DNA Topoisomerases, Type II; Etoposide; Lymphocyte Activation; Lymphocytes; Mice; Mice, Inbred C57BL; Novobiocin; Phenylmethylsulfonyl Fluoride; Spleen; Sulfones; Topoisomerase II Inhibitors | 1988 |
Swiveling and decatenation of replicating simian virus 40 genomes in vivo.
Topics: Animals; Camptothecin; Cell Line; DNA Replication; DNA, Viral; Etoposide; Genes, Viral; Intercalating Agents; Simian virus 40; Teniposide; Topoisomerase II Inhibitors; Virus Replication | 1988 |
Comparison of lesions induced by intra-articular injections of quinolones and compounds damaging cartilage components in rat femoral condyles.
Topics: Administration, Oral; Animals; Bleomycin; Camptothecin; Cartilage, Articular; Chondroitin Lyases; Ciprofloxacin; Collagenases; Cycloheximide; Ethylmaleimide; Etoposide; Fluorescent Dyes; Hydroxyurea; Injections, Intra-Articular; Iodoacetates; Iodoacetic Acid; Irinotecan; Levofloxacin; Male; Ofloxacin; Papain; Rats; Rats, Sprague-Dawley; Rhodamines; Topoisomerase I Inhibitors | 1994 |
Expression of a deletion mutant of the E2F1 transcription factor in fibroblasts lengthens S phase and increases sensitivity to S phase-specific toxins.
Topics: 3T3 Cells; Animals; Aphidicolin; Apoptosis; Bleomycin; Camptothecin; Carrier Proteins; Cell Cycle; Cell Cycle Proteins; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; DNA; DNA Topoisomerases, Type I; DNA-Binding Proteins; E2F Transcription Factors; E2F1 Transcription Factor; Etoposide; Mice; Retinoblastoma-Binding Protein 1; S Phase; Sequence Deletion; Transcription Factor DP1; Transcription Factors; Tumor Suppressor Protein p53 | 1995 |
The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leukemic cells to topoisomerase I and II inhibitors.
Topics: Apoptosis; Base Sequence; Camptothecin; Cell Cycle; Cell Line; Cell Survival; DNA Damage; DNA Primers; DNA, Neoplasm; Dose-Response Relationship, Drug; Etoposide; Humans; Leukemia; Microscopy, Electron; Molecular Sequence Data; Polymerase Chain Reaction; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1995 |
Aspartate-based inhibitor of interleukin-1 beta-converting enzyme prevents antitumor agent-induced apoptosis in human myeloid leukemia U937 cells.
Topics: Antineoplastic Agents; Apoptosis; Aspartic Acid; Camptothecin; Caspase 1; Cell Cycle; Cell Line; Cysteine Endopeptidases; Cytarabine; DNA, Neoplasm; Doxorubicin; Etoposide; Humans; Kinetics; Leukemia, Myeloid; Time Factors; Tumor Cells, Cultured | 1995 |
Establishment and characterization of acquired resistance to platinum anticancer drugs in human ovarian carcinoma cells.
Topics: Camptothecin; Carboplatin; Cisplatin; Cystadenocarcinoma, Serous; Drug Resistance; Drug Resistance, Multiple; Etoposide; Female; Glutathione; Glutathione Transferase; Humans; Ovarian Neoplasms; Tumor Cells, Cultured | 1995 |
Efficient induction of chromosome-type aberrations by topoisomerase II inhibitors closely associated with stabilization of the cleavable complex in cultured fibroblastic cells.
Topics: 2,4-Dinitrophenol; Aclarubicin; Adenosine Triphosphate; Animals; Camptothecin; Cells, Cultured; Chromosome Aberrations; Cricetinae; Dinitrophenols; DNA; DNA Damage; DNA Topoisomerases, Type II; Doxorubicin; Etoposide; Fibroblasts; Topoisomerase II Inhibitors | 1995 |
Altered topoisomerase I and II activities in suramin-resistant lung fibrosarcoma cells.
Topics: Amsacrine; Animals; Camptothecin; Cell Nucleus; Cricetinae; Cricetulus; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA, Neoplasm; Doxorubicin; Drug Resistance; Etoposide; Fibrosarcoma; Lung Neoplasms; Neoplasm Proteins; Suramin; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1995 |
SEQPWR and SEQOPR: computer programs for design of maximum information trials based on group sequential logrank tests.
Topics: Algorithms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Data Interpretation, Statistical; Etoposide; Feasibility Studies; Follow-Up Studies; Humans; Linear Models; Lung Neoplasms; Programming Languages; Research Design; Sensitivity and Specificity; Software; Survival Rate; Topotecan | 1995 |
Unscheduled activation of cyclin B1/Cdc2 kinase in human promyelocytic leukemia cell line HL60 cells undergoing apoptosis induced by DNA damage.
Topics: Aphidicolin; Apoptosis; Camptothecin; CDC2 Protein Kinase; Cyclins; DNA Damage; Enzyme Activation; Etoposide; Humans; Leukemia, Promyelocytic, Acute; Mechlorethamine; Phosphorylation; S Phase; Tumor Cells, Cultured | 1995 |
Schedule-dependent cytotoxicity of topotecan alone and in combination chemotherapy regimens.
Topics: Alkylating Agents; Animals; Antineoplastic Combined Chemotherapy Protocols; Aphidicolin; Camptothecin; Carmustine; Cell Cycle; Cell Death; Cell Line; Cisplatin; Cricetinae; Cricetulus; DNA Damage; DNA Repair; DNA, Neoplasm; Doxorubicin; Drug Synergism; Etoposide; Fibroblasts; Hydroxyurea; Lung; Melphalan; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan | 1994 |
Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Computer Simulation; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Antagonism; Drug Synergism; Etoposide; Humans; Paclitaxel; Teratocarcinoma; Topotecan; Tumor Cells, Cultured; Vincristine | 1994 |
Synergistic enhancement of cisplatin cytotoxicity by SN-38, an active metabolite of CPT-11, for cisplatin-resistant HeLa cells.
Topics: Camptothecin; Cisplatin; Drug Resistance; Etoposide; Glutathione; HeLa Cells; Humans; In Vitro Techniques; Irinotecan; Methionine | 1994 |
Quantification of topoisomerase-DNA complexes in leukemia cells from patients undergoing therapy with a topoisomerase-directed agent.
Topics: Amsacrine; Antineoplastic Agents; Camptothecin; DNA Probes; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA, Neoplasm; Drug Resistance; Etoposide; Humans; Immunoblotting; Leukemia; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Tumor Cells, Cultured | 1994 |
Inhibition of potentially lethal and sublethal damage repair by camptothecin and etoposide in human melanoma cell lines.
Topics: Camptothecin; Cell Death; DNA; DNA Repair; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Etoposide; Humans; Melanoma; Radiation Tolerance; Radiation-Sensitizing Agents; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1994 |
Selective inhibition of dexamethasone-induced apoptosis in rat thymocytes by herbimycin A.
Topics: Animals; Apoptosis; Benzoquinones; Camptothecin; Catechols; Cells, Cultured; Dexamethasone; DNA; DNA Damage; Dose-Response Relationship, Drug; Etoposide; Genistein; Isoflavones; Kinetics; L-Lactate Dehydrogenase; Lactams, Macrocyclic; Nitriles; Nucleosomes; Protein-Tyrosine Kinases; Quinones; Rats; Rifabutin; Thymus Gland; Topoisomerase I Inhibitors; Tyrphostins | 1994 |
Different modes of cell-killing action between DNA topoisomerase I and II inhibitors revealed by kinetic analysis.
Topics: Amsacrine; Antineoplastic Agents; Camptothecin; Carbazoles; Cell Cycle; Colonic Neoplasms; Diterpenes; DNA Replication; Dose-Response Relationship, Drug; Etoposide; Flow Cytometry; G2 Phase; Humans; Indoles; Mitosis; Quinones; S Phase; Teniposide; Time Factors; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1994 |
The effect of two topoisomerase inhibitors on low-dose hypersensitivity and increased radioresistance in Chinese hamster V79 cells.
Topics: Animals; Camptothecin; Cell Survival; Cells, Cultured; Cricetinae; Cricetulus; Dose-Response Relationship, Radiation; Etoposide; Radiation Tolerance; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 1994 |
Topoisomerase inhibitors potentiate the effect of retinoic acid on cell growth inhibition and induction of differentiation of leukemia HL-60 cells.
Topics: Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; Cell Cycle; Cell Differentiation; DNA, Neoplasm; Drug Synergism; Etoposide; Growth Inhibitors; Humans; In Vitro Techniques; Leukemia, Myeloid; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tretinoin; Tumor Cells, Cultured | 1994 |
Differential induction of chromosomal aberrations by topoisomerase inhibitors in cultured Chinese hamster cells.
Topics: Aclarubicin; Animals; Camptothecin; Cells, Cultured; Chromosome Aberrations; Cricetinae; Cricetulus; Doxorubicin; Etoposide; Fibroblasts; Lung; Mitoxantrone; Sister Chromatid Exchange; Topoisomerase I Inhibitors | 1994 |
Growth inhibition of human gastrointestinal cancer xenograft lines by treatment with CPT-11 and VP-16.
Topics: Adult; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Etoposide; Female; Gastrointestinal Neoplasms; Humans; Irinotecan; Male; Mice; Mice, Nude; Neoplasm Transplantation; Transplantation, Heterologous; Tumor Cells, Cultured | 1993 |
A temperature sensitive topoisomerase II allele confers temperature dependent drug resistance on amsacrine and etoposide: a genetic system for determining the targets of topoisomerase II inhibitors.
Topics: Alleles; Amsacrine; Camptothecin; Cell Division; DNA Damage; DNA Repair; DNA Topoisomerases, Type II; Drug Resistance; Etoposide; Models, Biological; Saccharomyces cerevisiae; Sensitivity and Specificity; Temperature; Topoisomerase II Inhibitors | 1993 |
Topoisomerase inhibitors induce apoptosis in thymocytes.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Aphidicolin; Apoptosis; Azides; Camptothecin; Cell Survival; DNA; Etoposide; Isoquinolines; L-Lactate Dehydrogenase; Male; Mice; Mice, Inbred BALB C; Phorbol 12,13-Dibutyrate; Piperazines; Quinazolines; Quinazolinones; Sodium Azide; Thymus Gland; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Zinc | 1993 |
Inhibition of DNA synthesis and DNA fragmentation in stimulated splenocytes by the concerted action of topoisomerase I and II poisons.
Topics: Animals; Aphidicolin; Camptothecin; DNA; DNA Replication; Etoposide; Mice; Mice, Inbred C57BL; Spleen; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 1993 |
Enhanced expression of the DNA topoisomerase II gene in response to heat shock stress in human epidermoid cancer KB cells.
Topics: Camptothecin; DNA Topoisomerases, Type II; Etoposide; Gene Expression; Hot Temperature; Humans; Irinotecan; KB Cells; Neoplasms; RNA, Messenger; Teniposide | 1993 |
Differential induction of apoptosis in undifferentiated and differentiated HL-60 cells by DNA topoisomerase I and II inhibitors.
Topics: Amsacrine; Apoptosis; Camptothecin; Cell Differentiation; DNA; DNA Damage; Etoposide; Humans; Leukemia, Promyelocytic, Acute; Tetradecanoylphorbol Acetate; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tretinoin; Tumor Cells, Cultured | 1993 |
Effect of topoisomerase inhibitors on the in vitro HIV DNA integration reaction.
Topics: Amsacrine; Antineoplastic Agents; Antiviral Agents; Base Sequence; Camptothecin; Carbazoles; DNA Nucleotidyltransferases; Ellipticines; Escherichia coli; Etoposide; HIV Long Terminal Repeat; HIV-1; Integrases; Kinetics; Molecular Sequence Data; Netropsin; Oligodeoxyribonucleotides; Plasmids; Recombinant Proteins; Substrate Specificity; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 1993 |
Suramin inhibits DNA damage in human prostate cancer cells treated with topoisomerase inhibitors in vitro.
Topics: Amsacrine; Camptothecin; Cell Survival; Chemical Precipitation; DNA Damage; Dose-Response Relationship, Drug; Drug Interactions; Etoposide; Humans; Male; Prostatic Neoplasms; Suramin; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1993 |
The sensitivity to DNA topoisomerase inhibitors in L5178Y lymphoma strains is not related to a primary defect of DNA topoisomerases.
Topics: Amsacrine; Animals; Camptothecin; DNA Damage; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA, Superhelical; Etoposide; Leukemia L5178; Mice; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1993 |
Modification of chemo-radiosensitivity of a human lung cancer cell line by introduction of the glutathione S-transferase pi gene.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cisplatin; Doxorubicin; Etoposide; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glutathione Transferase; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Radiation Tolerance; Tumor Cells, Cultured | 1996 |
BCR-ABL does not prevent apoptotic death induced by human natural killer or lymphokine-activated killer cells.
Topics: Apoptosis; Camptothecin; Cycloheximide; Cytotoxicity, Immunologic; Dactinomycin; DNA Damage; DNA, Neoplasm; Etoposide; Fusion Proteins, bcr-abl; Hematopoietic Stem Cells; Humans; Hydrogen Peroxide; Killer Cells, Lymphokine-Activated; Killer Cells, Natural; Leukemia, Megakaryoblastic, Acute; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Puromycin; Recombinant Fusion Proteins; Transfection; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 1996 |
Biomodulation by hyperthermia of topoisomerase II-targeting drugs in human colorectal cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Cycle; Colorectal Neoplasms; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Hot Temperature; Humans; Neoplasm Proteins; Teniposide; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured; Tumor Stem Cell Assay; Vincristine | 1995 |
Effects of DNA topoisomerase inhibitors on nonhomologous and homologous recombination in mammalian cells.
Topics: Adenine Phosphoribosyltransferase; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; CHO Cells; Chromosome Aberrations; Cricetinae; Diketopiperazines; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Enzyme Inhibitors; Etoposide; Mutagenesis; Mutagenicity Tests; Nucleic Acid Heteroduplexes; Piperazines; Recombination, Genetic; Teniposide; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Transfection | 1996 |
Selective inhibition of topoisomerase II by ICRF-193 does not support a role for topoisomerase II activity in the fragmentation of chromatin during apoptosis of human leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Diketopiperazines; DNA Damage; Enzyme Inhibitors; Etoposide; Formamides; HL-60 Cells; Humans; Piperazines; Topoisomerase II Inhibitors | 1996 |
Microtubule effects of welwistatin, a cyanobacterial indolinone that circumvents multiple drug resistance.
Topics: Alkaloids; Antineoplastic Agents; Camptothecin; Cell Cycle; Cell Division; Cell Line; Cell Survival; Colchicine; Cyanobacteria; Cytoskeleton; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA, Neoplasm; Drug Resistance, Multiple; Etoposide; Female; GTP Phosphohydrolases; Humans; Indole Alkaloids; Kinetics; Microtubules; Muscle, Smooth, Vascular; Ovarian Neoplasms; Tubulin | 1996 |
Heat shock proteins increase resistance to apoptosis.
Topics: Animals; Apoptosis; Camptothecin; Cell Line; Cell Survival; Dactinomycin; DNA Damage; Etoposide; Fibrosarcoma; Heat-Shock Proteins; Heat-Shock Response; Humans; Mice; Monocytes; Tumor Cells, Cultured | 1996 |
Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21.
Topics: Antineoplastic Agents; Apoptosis; Bisbenzimidazole; Camptothecin; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinases; Cyclins; DNA Damage; Doxorubicin; Enzyme Inhibitors; Etoposide; Fluorescent Dyes; Gamma Rays; Humans; Mitosis; S Phase; Tumor Cells, Cultured | 1996 |
Induction of somatic mutation and recombination by four inhibitors of eukaryotic topoisomerases assayed in the wing spot test of Drosophila melanogaster.
Topics: Animals; Camptothecin; Drosophila melanogaster; Ellipticines; Enzyme Inhibitors; Etoposide; Female; Male; Mutagenicity Tests; Mutation; Recombination, Genetic; Teniposide; Topoisomerase I Inhibitors | 1996 |
[The results of chemosensitivity test for clear cell adenocarcinoma of the ovary].
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Doxorubicin; Drug Screening Assays, Antitumor; Etoposide; Female; Humans; Irinotecan; Mitomycin; Ovarian Neoplasms | 1996 |
Sister-chromatid exchanges (SCE) induction by inhibitors of DNA topoisomerases in cultured human lymphocytes.
Topics: Amsacrine; Camptothecin; Cells, Cultured; Enzyme Inhibitors; Etoposide; Humans; Lymphocytes; Mitomycin; Nalidixic Acid; Sister Chromatid Exchange; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 1996 |
Expression of proliferation-associated nuclear autoantigens, p330d/CENP-F and PCNA, in differentiation and in drug-induced growth inhibition using two-parameter flow cytometry.
Topics: Aphidicolin; Autoantigens; Camptothecin; Cell Cycle; Cell Differentiation; Centromere; Chromosomal Proteins, Non-Histone; DNA Replication; Etoposide; Flow Cytometry; Fluorescent Antibody Technique, Indirect; Growth Inhibitors; HL-60 Cells; Humans; Microfilament Proteins; Proliferating Cell Nuclear Antigen; Tumor Cells, Cultured | 1996 |
[Apoptosis of human leukemic cells induced by topoisomerase I and II inhibitors].
Topics: Alkaloids; Apoptosis; Camptothecin; Cell Cycle; Cell Differentiation; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA, Neoplasm; Etoposide; Humans; Leukemia; Protein Kinase C; Signal Transduction; Staurosporine; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1996 |
Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line; Cisplatin; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Enzyme Inhibitors; Etoposide; Female; Humans; Irinotecan; Mice; Mice, Nude; Neuroblastoma; Neuroectodermal Tumors, Primitive; Neuroectodermal Tumors, Primitive, Peripheral; Paclitaxel; Thiotepa; Topoisomerase I Inhibitors; Transplantation, Heterologous | 1996 |
Inhibition of P-glycoprotein-dependent multidrug resistance by an isoquinolinesulfonamide compound H-87 in rat ascites hepatoma AH66 cells.
Topics: Affinity Labels; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Azides; Camptothecin; Dihydropyridines; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Female; Irinotecan; Isoquinolines; Protein Binding; Protein Kinase Inhibitors; Rats; Sulfonamides; Tritium; Tumor Cells, Cultured; Vinblastine | 1996 |
Brefeldin A is a potent inducer of apoptosis in human cancer cells independently of p53.
Topics: Alkaloids; Antineoplastic Agents, Phytogenic; Apoptosis; Brefeldin A; Camptothecin; Cell-Free System; Cyclin B; Cyclin B1; Cyclins; Cycloheximide; Cyclopentanes; DNA Fragmentation; DNA, Neoplasm; Dose-Response Relationship, Drug; Enzyme Inhibitors; Etoposide; HL-60 Cells; HT29 Cells; Humans; Mutation; Protein Synthesis Inhibitors; Staurosporine; Time Factors; Tumor Suppressor Protein p53 | 1996 |
Effect of v-rasH on sensitivity of NCI-H82 human small cell lung cancer cells to cisplatin, etoposide, and camptothecin.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Small Cell; Cell Survival; Cisplatin; Drug Resistance; Etoposide; Genes, ras; Humans; Lung Neoplasms; Metallothionein; Phenotype; RNA, Messenger; RNA, Transfer; Sulfhydryl Compounds; Transfection; Tumor Cells, Cultured | 1995 |
Inactivation of topoisomerase I or II may lead to recombination or to aberrant replication termination on both SV40 and yeast 2 micron DNA.
Topics: Camptothecin; DNA Replication; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA, Circular; DNA, Fungal; DNA, Viral; Electrophoresis, Gel, Two-Dimensional; Enzyme Activation; Enzyme Inhibitors; Etoposide; Hypertonic Solutions; Mutation; Plasmids; Recombination, Genetic; Simian virus 40; Teniposide; Thiobarbiturates; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Yeasts | 1996 |
Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan.
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Antineoplastic Agents; Camptothecin; Carcinoma, Small Cell; Cisplatin; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Thrombocytopenia; Topotecan | 1996 |
Delayed cyclin B1 expression during the G2 arrest following DNA damage.
Topics: Antineoplastic Agents; Camptothecin; Cyclin B; Cyclin B1; Cyclins; DNA Damage; Etoposide; G2 Phase; Gene Expression Regulation; HeLa Cells; Humans; Mechlorethamine; Promoter Regions, Genetic; RNA, Messenger | 1996 |
Molecular cloning of the genes suppressed in RVC lymphoma cells by topoisomerase inhibitors.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents, Phytogenic; Base Sequence; Camptothecin; Cloning, Molecular; DNA, Neoplasm; Down-Regulation; Etoposide; Gene Expression Regulation, Neoplastic; Heterogeneous Nuclear Ribonucleoprotein A1; Heterogeneous-Nuclear Ribonucleoprotein Group A-B; Heterogeneous-Nuclear Ribonucleoproteins; Lymphoma; Mice; Molecular Sequence Data; Neoplasm Proteins; Radiation Leukemia Virus; Ribonucleoproteins; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1996 |
Mechanisms of cell killing by drugs that trap covalent complexes between DNA topoisomerases and DNA.
Topics: Amsacrine; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Death; DNA; DNA Damage; DNA Replication; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Etoposide; G1 Phase; Mating Factor; Peptides; S Phase; Saccharomyces cerevisiae | 1996 |
Topoisomerase poisons activate the transcription factor NF-kappaB in ACH-2 and CEM cells.
Topics: Antioxidants; Camptothecin; Cell Line; Cycloheximide; Dactinomycin; Daunorubicin; DNA; DNA Damage; DNA Topoisomerases, Type I; Etoposide; HIV-1; NF-kappa B; Nucleic Acid Synthesis Inhibitors; Poly(ADP-ribose) Polymerase Inhibitors; Topoisomerase I Inhibitors; Transcriptional Activation; Virus Activation | 1996 |
A glass fiber/diethylaminoethyl double filter binding assay that measures apoptotic internucleosomal DNA fragmentation.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Chemistry Techniques, Analytical; DNA Fragmentation; Doxorubicin; Ethanolamines; Etoposide; Filtration; Glass; Humans; Microscopy, Fluorescence; Microscopy, Phase-Contrast; Nucleosomes; Thymidine; Tritium; Tumor Cells, Cultured | 1996 |
Selective induction of apoptosis in Hep 3B cells by topoisomerase I inhibitors: evidence for a protease-dependent pathway that does not activate cysteine protease P32.
Topics: Apoptosis; Camptothecin; Carcinoma, Hepatocellular; Caspase 1; Caspase 3; Caspases; Cell Line; Cysteine Endopeptidases; Endopeptidases; Enzyme Inhibitors; Etoposide; Humans; Kinetics; Liver Neoplasms; Protease Inhibitors; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1996 |
Induction of apoptosis in malignant and camptothecin-resistant human cells.
Topics: Androgens; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Camptothecin; Cell Cycle; Cell Cycle Proteins; DNA Topoisomerases, Type I; Drug Interactions; Drug Resistance; Enzyme Inhibitors; Etoposide; Humans; Male; Prostatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Suramin; Tumor Cells, Cultured | 1996 |
Cytotoxic efficacy with combinations of topoisomerase I and topoisomerase II inhibitors in sensitive and multidrug-resistant L1210 mouse leukemia cells.
Topics: Amsacrine; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance, Multiple; Drug Synergism; Enzyme Inhibitors; Etoposide; Leukemia L1210; Mice; Mitoxantrone; Topoisomerase I Inhibitors; Topotecan | 1996 |
The significance of the sequence of administration of topotecan and etoposide.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Survival; Cells, Cultured; Cricetinae; Drug Synergism; Enzyme Inhibitors; Etoposide; Fibroblasts; Lung; Topoisomerase I Inhibitors; Topotecan | 1996 |
c-Jun NH2-terminal kinase-mediated activation of interleukin-1beta converting enzyme/CED-3-like protease during anticancer drug-induced apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Caenorhabditis elegans Proteins; Calcium-Calmodulin-Dependent Protein Kinases; Camptothecin; Caspase 1; Caspases; Cysteine Endopeptidases; Enzyme Activation; Etoposide; Helminth Proteins; Humans; JNK Mitogen-Activated Protein Kinases; Mitogen-Activated Protein Kinases; Oligonucleotides, Antisense; Tumor Cells, Cultured | 1997 |
Antitumor effect of CPT-11, a camptothecin derivative, on human testicular tumor xenografts in nude mice.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Dose-Response Relationship, Drug; Etoposide; Humans; Irinotecan; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Organoplatinum Compounds; Teratocarcinoma; Testicular Neoplasms; Topoisomerase I Inhibitors; Transplantation, Heterologous; Vinblastine | 1997 |
Increased gadd153 messenger RNA level is associated with apoptosis in human leukemic cells treated with etoposide.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; CCAAT-Enhancer-Binding Proteins; Daunorubicin; DNA Fragmentation; DNA-Binding Proteins; Etoposide; HL-60 Cells; Humans; Leukemia; Nuclear Proteins; RNA, Messenger; Serine Proteinase Inhibitors; Transcription Factor CHOP; Transcription Factors; Tumor Cells, Cultured | 1997 |
The multidrug resistance-associated protein gene confers drug resistance in human gastric and colon cancers.
Topics: Antineoplastic Agents; Camptothecin; Cisplatin; Colonic Neoplasms; Doxorubicin; Etoposide; Genes, MDR; Humans; Irinotecan; Mitomycin; Polymerase Chain Reaction; RNA, Messenger; Stomach Neoplasms; Tumor Cells, Cultured; Verapamil; Vincristine | 1996 |
Actin cleavage by CPP-32/apopain during the development of apoptosis.
Topics: Actins; Apoptosis; Camptothecin; Caspase 1; Caspase 3; Caspases; Cysteine Endopeptidases; Etoposide; Humans; Leukemia, Myeloid; Oligopeptides; Protease Inhibitors; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 1997 |
Topotecan increases topoisomerase IIalpha levels and sensitivity to treatment with etoposide in schedule-dependent process.
Topics: Animals; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Screening Assays, Antitumor; Enzyme Induction; Etoposide; Female; Humans; Isoenzymes; Mice; Mice, Nude; Neoplasm Proteins; Topoisomerase II Inhibitors; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured; Up-Regulation | 1997 |
A lymphoma cell line resistant to 4-piperidinopiperidine was less sensitive to CPT-11.
Topics: Antineoplastic Agents; Camptothecin; Cell Division; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Resistance, Neoplasm; Etoposide; Humans; Irinotecan; Lymphoma, T-Cell; Piperidines; Tumor Cells, Cultured | 1997 |
Induction of glutathione synthetase by 1,10-phenanthroline.
Topics: Animals; Apoptosis; Blotting, Northern; Camptothecin; Cloning, Molecular; DNA Damage; DNA Fragmentation; DNA Primers; Doxorubicin; Enzyme Induction; Etoposide; Genes, p53; Glutathione Synthase; Mice; Phenanthrolines; Polymerase Chain Reaction; RNA, Messenger; Sequence Analysis; Transfection; Tumor Cells, Cultured | 1997 |
Induction of apoptosis within T lymphoblastoid cells by a topoisomerase I inhibitor.
Topics: Aphidicolin; Apoptosis; Camptothecin; DNA Fragmentation; DNA, Neoplasm; Enzyme Inhibitors; Etoposide; Humans; Jurkat Cells; Kinetics; RNA, Neoplasm; T-Lymphocytes; Time Factors; Topoisomerase I Inhibitors | 1997 |
Correlated flow cytometric analysis of terminal events in apoptosis reveals the absence of some changes in some model systems.
Topics: Animals; Annexin A5; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Separation; Dexamethasone; Ethidium; Etoposide; Flow Cytometry; Fluorescent Dyes; Humans; Hydrogen-Ion Concentration; Models, Biological; Neutrophils; Pyrimidinones; Rhodamines; Thymus Gland; Tumor Cells, Cultured | 1997 |
Comparison of apoptosis in wild-type and Fas-resistant cells: chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions.
Topics: Affinity Labels; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Biotin; Camptothecin; Caspase 3; Caspase 7; Caspases; Cisplatin; Cysteine Endopeptidases; Doxorubicin; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Fas Ligand Protein; fas Receptor; Flow Cytometry; Humans; Lamin Type B; Lamins; Leukemia-Lymphoma, Adult T-Cell; Membrane Glycoproteins; Methotrexate; Neoplasm Proteins; Nuclear Proteins; Oligopeptides; Poly(ADP-ribose) Polymerases; Staurosporine; Topoisomerase II Inhibitors; Topotecan; Tumor Cells, Cultured | 1997 |
Inhibition of DNA unwinding and ATPase activities of human DNA helicase II by chemotherapeutic agents.
Topics: Adenosine Triphosphatases; Amsacrine; Antineoplastic Agents; Aphidicolin; Camptothecin; Dactinomycin; Daunorubicin; DNA; DNA Helicases; Ellipticines; Enzyme Inhibitors; Ethidium; Etoposide; Genistein; Humans; Isoflavones; Nogalamycin; Novobiocin; Topoisomerase I Inhibitors | 1997 |
Effect of inhibitors of DNA replication on early zebrafish embryos: evidence for coordinate activation of multiple intrinsic cell-cycle checkpoints at the mid-blastula transition.
Topics: Animals; Aphidicolin; Blastocyst; Camptothecin; Cell Cycle; DNA Replication; Embryo, Nonmammalian; Etoposide; Gene Deletion; Mutagenesis; Time Factors; Zebrafish | 1997 |
Apoptosis-resistant phenotype selected by alternating exposure to camptothecin and etoposide.
Topics: Antineoplastic Agents; Apoptosis; Arabinofuranosylcytosine Triphosphate; ATP Binding Cassette Transporter, Subfamily B, Member 1; bcl-X Protein; Calcimycin; Camptothecin; Clone Cells; Cycloheximide; Cytarabine; DNA Fragmentation; Drug Resistance, Neoplasm; Etoposide; HL-60 Cells; Humans; Hydroxyurea; Kinetics; Nucleosomes; Phenotype; Proto-Oncogene Proteins c-bcl-2; Ultraviolet Rays | 1997 |
Down-regulation of topoisomerase II by camptothecin does not prevent additive activity of the topoisomerase II inhibitor etoposide in vitro.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Cell Cycle; Cell Survival; DNA Topoisomerases, Type II; Doxorubicin; Drug Interactions; Etoposide; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Kinetics; Lung Neoplasms; Paclitaxel; Polymerase Chain Reaction; Rhodamines; Stomach Neoplasms; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured; Vincristine | 1997 |
New drugs for small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Doxorubicin; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Vincristine | 1997 |
p53 is phosphorylated in vitro and in vivo by the delta and epsilon isoforms of casein kinase 1 and enhances the level of casein kinase 1 delta in response to topoisomerase-directed drugs.
Topics: Animals; Camptothecin; Casein Kinases; COS Cells; Enzyme Inhibitors; Etoposide; Gene Expression Regulation, Enzymologic; Isoenzymes; Mice; Phosphopeptides; Phosphorylation; Protein Kinases; Rats; RNA, Messenger; Topoisomerase II Inhibitors; Tumor Suppressor Protein p53 | 1997 |
Mechanisms of resistance in a human cell line exposed to sequential topoisomerase poisoning.
Topics: Antineoplastic Agents; Camptothecin; Cell Nucleus; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Resistance, Neoplasm; Etoposide; Humans; Leukemia; Phenotype; Point Mutation; RNA, Messenger; Tumor Cells, Cultured | 1997 |
NADH dehydrogenase deficiency in an apoptosis-resistant mutant isolated from a human HL-60 leukemia cell line.
Topics: Antineoplastic Agents; Apoptosis; Calcimycin; Camptothecin; Cell Division; Clone Cells; Cloning, Molecular; Cytarabine; Deoxyglucose; Etoposide; Glucose; HL-60 Cells; Humans; Hydroxyurea; Macromolecular Substances; Mitochondria; Mutagenesis; NADH Dehydrogenase; Transcription, Genetic; Ultraviolet Rays | 1997 |
Activation of PKCalpha downstream from caspases during apoptosis induced by 7-hydroxystaurosporine or the topoisomerase inhibitors, camptothecin and etoposide, in human myeloid leukemia HL60 cells.
Topics: Alkaloids; Amino Acid Chloromethyl Ketones; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; Enzyme Activation; Enzyme Inhibitors; Etoposide; HL-60 Cells; Humans; Isoenzymes; Protein Kinase C; Protein Kinase C-alpha; Staurosporine; Up-Regulation | 1997 |
Antitumor activity of a novel quinoline derivative, TAS-103, with inhibitory effects on topoisomerases I and II.
Topics: Adenocarcinoma; Aminoquinolines; Animals; Antineoplastic Agents; Camptothecin; Cisplatin; Colonic Neoplasms; DNA; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Etoposide; Humans; Indenes; Indoles; Irinotecan; Lung Neoplasms; Male; Melanoma; Mice; Mice, Inbred Strains; Neoplasm Transplantation; Neoplasms, Experimental; Pyridines; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1997 |
Apoptosis in the absence of cytochrome c accumulation in the cytosol.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Biotin; Bleomycin; Blotting, Western; Camptothecin; Cytochrome c Group; Cytosol; Enzyme Inhibitors; Etoposide; Humans; Hydroxamic Acids; Lymphoma; Microscopy, Fluorescence; Mitochondria; Phalloidine; Poly(ADP-ribose) Polymerases; Staurosporine; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Vinblastine | 1998 |
Contribution of gene-specific lesions, DNA-replication-associated damage, and subsequent transcriptional inhibition in topoisomerase inhibitor-mediated apoptosis in lymphoma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Transformation, Viral; Chickens; Dactinomycin; DNA Damage; DNA Replication; DNA, Ribosomal; Etoposide; Genes, myc; Kinetics; Lymphoma, B-Cell; Lymphoma, T-Cell; Topoisomerase I Inhibitors; Transcription, Genetic; Tumor Cells, Cultured | 1998 |
Enhanced topoisomerase I activity and increased topoisomerase II alpha content in cisplatin-resistant cancer cell lines.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cisplatin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Resistance, Neoplasm; Etoposide; HeLa Cells; Humans; Irinotecan; Isoenzymes; Neoplasm Proteins; Tumor Cells, Cultured | 1997 |
IFN-beta partially counteracts inhibition of natural killer activity induced by some antitumor agents.
Topics: Antineoplastic Agents; Camptothecin; Cisplatin; Cytotoxicity Tests, Immunologic; Distamycins; Doxorubicin; Etoposide; Immunosuppressive Agents; Interferon-beta; Killer Cells, Natural; Melphalan; Nitrogen Mustard Compounds; Recombinant Proteins | 1998 |
Altered sensitivities to anticancer and differentiation agents in etoposide-resistant human myeloid leukemia U-937 cells.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Cell Differentiation; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Humans; Leukemia, Myeloid; Lymphotoxin-alpha; Mice; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 1998 |
Inhibition of pea chloroplast DNA helicase unwinding and ATPase activities by DNA-interacting ligands.
Topics: Adenosine Triphosphatases; Adenosine Triphosphate; Amsacrine; Camptothecin; Chloroplasts; Dactinomycin; Daunorubicin; DNA Helicases; Ellipticines; Ethidium; Etoposide; Genistein; Hydrolysis; Intercalating Agents; Ligands; Nogalamycin; Novobiocin; Pisum sativum | 1998 |
Clonal analysis of cancer cells that survived anticancer drug treatment.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; Cell Survival; Doxorubicin; Enzyme Inhibitors; Etoposide; Female; Humans; Irinotecan; Tumor Cells, Cultured; Uterine Cervical Neoplasms | 1997 |
A risk-benefit assessment of irinotecan in solid tumours.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cisplatin; Colorectal Neoplasms; Diarrhea; Drug Therapy, Combination; Etoposide; Fluorouracil; Humans; Irinotecan; Lung Neoplasms; Neoplasms; Risk Assessment | 1998 |
Genotoxic activity of four inhibitors of DNA topoisomerases in larval cells of Drosophila melanogaster as measured in the wing spot assay.
Topics: Amsacrine; Animals; Camptothecin; Drosophila melanogaster; Etoposide; Larva; Mutagens; Nalidixic Acid; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 1998 |
Induction of apoptosis in human retinoblastoma cells by topoisomerase inhibitors.
Topics: Amsacrine; Apoptosis; bcl-2-Associated X Protein; Camptothecin; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Cycloheximide; Dactinomycin; DNA Damage; DNA Topoisomerases, Type I; DNA, Neoplasm; Enzyme Inhibitors; Etoposide; Humans; Insulin-Like Growth Factor Binding Protein 3; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Retinal Neoplasms; Retinoblastoma; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1998 |
Distinct apoptotic responses imparted by c-myc and max.
Topics: Animals; Antineoplastic Agents; Apoptosis; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Basic-Leucine Zipper Transcription Factors; Basophils; bcl-X Protein; Camptothecin; Cell Cycle; Cell Line; Culture Media, Serum-Free; Dimerization; DNA-Binding Proteins; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Genes, myc; Hematopoietic Stem Cells; Interleukin-3; Mast Cells; Mice; Protein Multimerization; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Recombinant Fusion Proteins; Transcription Factors; Transfection | 1998 |
Apoptotic effects of different drugs on cultured retinoblastoma Y79 cells.
Topics: Amsacrine; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Butyrates; Butyric Acid; Camptothecin; Carboplatin; Cisplatin; DNA Damage; Drug Screening Assays, Antitumor; Etoposide; Humans; Paclitaxel; Retinoblastoma; Suramin; Tumor Cells, Cultured | 1998 |
Sequence effect of irinotecan (CPT-11) and topoisomerase II inhibitors in vivo.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Death; DNA, Neoplasm; Doxorubicin; Drug Interactions; Etoposide; Female; Irinotecan; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; RNA, Messenger; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 1998 |
Role of E2F-1 in chemosensitivity.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carrier Proteins; Cell Cycle; Cell Cycle Proteins; Cell Division; Cell Survival; Cloning, Molecular; Culture Media, Serum-Free; DNA-Binding Proteins; Doxorubicin; E2F Transcription Factors; E2F1 Transcription Factor; Etoposide; Fibrosarcoma; Humans; Irinotecan; Paclitaxel; Recombinant Proteins; Retinoblastoma-Binding Protein 1; Tetrahydrofolate Dehydrogenase; Transcription Factor DP1; Transcription Factors; Transfection; Tumor Cells, Cultured | 1998 |
Yeast cells expressing differential levels of human or yeast DNA topoisomerase II: a potent tool for identification and characterization of topoisomerase II-targeting antitumour agents.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Membrane Permeability; Culture Media; DNA Topoisomerases, Type II; Enzyme Inhibitors; Etoposide; Humans; Plasmids; Saccharomyces cerevisiae; Structure-Activity Relationship; Topoisomerase II Inhibitors; Vinblastine; Vinorelbine | 1998 |
Synergistic cytotoxicity of topoisomerase I inhibitors with alkylating agents and etoposide in human brain tumor cell lines.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Cisplatin; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Synergism; Etoposide; Humans; In Vitro Techniques; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured | 1998 |
Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Analysis | 1998 |
Evidence against a direct role for the induction of c-jun expression in the mediation of drug-induced apoptosis in human acute leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cisplatin; Cytarabine; Etoposide; Gene Expression Regulation, Neoplastic; Genes, bcl-2; Genes, jun; HL-60 Cells; Humans; Leukemia, B-Cell; Mitoxantrone; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-jun; Recombinant Proteins; Transfection; Tumor Cells, Cultured | 1995 |
Evaluation of irinotecan in combination with 5-fluorouracil or etoposide in xenograft models of colon adenocarcinoma and rhabdomyosarcoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Etoposide; Female; Fluorouracil; Humans; Irinotecan; Mice; Mice, Inbred CBA; Neoplasm Transplantation; Rhabdomyosarcoma; Transplantation, Heterologous | 1996 |
Role of oxygen radicals generated by NADPH oxidase in apoptosis induced in human leukemia cells.
Topics: Alkaloids; Antineoplastic Agents, Phytogenic; Antioxidants; Apoptosis; Camptothecin; Catalase; Cell Differentiation; Cell Line; DNA Fragmentation; Enzyme Inhibitors; Etoposide; Flow Cytometry; Granulomatous Disease, Chronic; Humans; Hydrogen Peroxide; Leukemia; Membrane Glycoproteins; Monocytes; NADPH Oxidase 2; NADPH Oxidases; Neoplasm Proteins; Neutrophils; NF-kappa B; Pyrrolidines; Reactive Oxygen Species; Staurosporine; Thiocarbamates; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Ultraviolet Rays | 1998 |
Increased cyclin E level in retinoblastoma cells during programmed cell death.
Topics: Amsacrine; Apoptosis; Camptothecin; Cyclin A; Cyclin E; Enzyme Inhibitors; Etoposide; Humans; Interleukin-1; Retinoblastoma; Sphingosine; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 1998 |
Replication-mediated DNA damage by camptothecin induces phosphorylation of RPA by DNA-dependent protein kinase and dissociates RPA:DNA-PK complexes.
Topics: Alkaloids; Androstadienes; Antigens, Nuclear; Ataxia Telangiectasia; Camptothecin; Cell Cycle; DNA Damage; DNA Helicases; DNA Repair; DNA Replication; DNA Topoisomerases, Type I; DNA-Activated Protein Kinase; DNA-Binding Proteins; Etoposide; Humans; Ku Autoantigen; Nuclear Proteins; Phosphorylation; Protein Serine-Threonine Kinases; Replication Protein A; Staurosporine; Tumor Cells, Cultured; Wortmannin | 1999 |
Phthalascidin, a synthetic antitumor agent with potency and mode of action comparable to ecteinascidin 743.
Topics: Antineoplastic Agents, Alkylating; Bleomycin; Camptothecin; Cell Division; Cisplatin; Cross-Linking Reagents; Dioxoles; DNA Topoisomerases, Type I; DNA, Neoplasm; Doxorubicin; Etoposide; Female; Humans; Isoquinolines; Male; Mitomycin; Models, Molecular; Molecular Structure; Neoplasm Proteins; Paclitaxel; Phthalimides; Structure-Activity Relationship; Tetrahydroisoquinolines; Trabectedin; Tumor Cells, Cultured | 1999 |
Synergistic cytotoxicity, apoptosis and protein-linked DNA breakage by etoposide and camptothecin in human U87 glioma cells: dependence on tyrosine phosphorylation.
Topics: Brain Neoplasms; Camptothecin; Cell Survival; Colonic Neoplasms; DNA Damage; Drug Synergism; Etoposide; Glioblastoma; Glioma; Humans; Mitotic Index; Phosphotyrosine; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1999 |
Immortalization and characterization of Nijmegen Breakage syndrome fibroblasts.
Topics: Abnormalities, Multiple; Antineoplastic Agents; Bleomycin; Camptothecin; Cell Line; Cell Line, Transformed; Cell Survival; Cell Transformation, Viral; Child, Preschool; Chromosome Breakage; DNA; DNA Damage; DNA Repair; Etoposide; Fibroblasts; HeLa Cells; Humans; Mitomycin; Mutation; Syndrome; X-Rays | 1999 |
Inhibition of phosphatidylcholine biosynthesis following induction of apoptosis in HL-60 cells.
Topics: Alkaloids; Apoptosis; Benzophenanthridines; Camptothecin; Choline; Cytidine Diphosphate Choline; Diacylglycerol Cholinephosphotransferase; Enzyme Inhibitors; Etoposide; Farnesol; Flow Cytometry; HL-60 Cells; Humans; Hydrogen-Ion Concentration; Phenanthridines; Phosphatidylcholines; Phosphorylcholine | 1999 |
Permanent cell cycle arrest in asynchronously proliferating normal human fibroblasts treated with doxorubicin or etoposide but not camptothecin.
Topics: Antineoplastic Agents; Camptothecin; Cell Cycle; Cell Division; Cell Survival; Cells, Cultured; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Dactinomycin; DNA Damage; Doxorubicin; Etoposide; Fibroblasts; Humans; Tumor Suppressor Protein p53 | 1999 |
Differential effects of chemotherapeutic agents on the Bcl-2/Bax apoptosis pathway in human breast cancer cell line MCF-7.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Breast Neoplasms; Camptothecin; Doxorubicin; Etoposide; Female; Humans; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured | 1999 |
[Evaluation of antitumor activity of etoposide administered orally for 21 consecutive days against human uterine cancer subcutaneous and/or orthotopic xenografts in nude mice].
Topics: Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Etoposide; Female; Floxuridine; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Skin; Transplantation, Heterologous; Uterine Neoplasms | 1999 |
Early effects of protein kinase modulators on DNA synthesis in rat cerebral cortex.
Topics: Animals; Anti-Inflammatory Agents; Benzoquinones; Camptothecin; Cerebral Cortex; Dimethyl Sulfoxide; DNA Replication; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA, Superhelical; Dose-Response Relationship, Drug; Enzyme Inhibitors; Etoposide; Genistein; Lactams, Macrocyclic; Naphthalenes; Nucleic Acid Synthesis Inhibitors; Phosphorylation; Phosphotyrosine; Protein-Tyrosine Kinases; Quinones; Rats; Rats, Sprague-Dawley; Rifabutin; Staurosporine; Steroids; Vanadates | 1999 |
Bcl-2 expression correlates with apoptosis induction but not tumor growth delay in transplantable murine lymphomas treated with different chemotherapy drugs.
Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cisplatin; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Gene Expression Regulation, Neoplastic; Genes, bcl-2; Lymphoma; Male; Mice; Mice, Inbred C3H; Proto-Oncogene Proteins c-bcl-2 | 1999 |
Macrostatin, a novel macromolecular inhibitor of topoisomerases produced by Streptomyces avermitilis no. C-127.
Topics: Binding, Competitive; Camptothecin; DNA; Doxorubicin; Enzyme Inhibitors; Ethidium; Etoposide; Hydrogen-Ion Concentration; Intercalating Agents; Kinetics; Microbial Sensitivity Tests; Streptomyces; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 1998 |
Posttranscriptional gene silencing in Neurospora by a RecQ DNA helicase.
Topics: Adenosine Triphosphatases; Amino Acid Sequence; Bloom Syndrome; Camptothecin; DNA Helicases; DNA, Fungal; Enzyme Inhibitors; Etoposide; Fungal Proteins; Gene Silencing; Genes, Fungal; Genetic Complementation Test; Humans; Molecular Sequence Data; Molecular Weight; Mutagenesis, Insertional; Neurospora crassa; RecQ Helicases; Sequence Alignment; Transcription, Genetic; Transgenes; Werner Syndrome | 1999 |
The isolation and genetic analysis of V79-derived etoposide sensitive Chinese hamster cell mutants: two new complementation groups of etoposide sensitive mutants.
Topics: Animals; Camptothecin; Cell Separation; CHO Cells; Cricetinae; Doxorubicin; Etoposide; Genetic Complementation Test; Mitomycin; Mutation; Nucleic Acid Hybridization; Streptonigrin; Topoisomerase II Inhibitors | 1999 |
Proteolytic activation of protein kinase C delta and epsilon by caspase-3 in U937 cells during chemotherapeutic agent-induced apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Caspase 3; Caspase Inhibitors; Caspases; Cysteine Proteinase Inhibitors; Cytarabine; Enzyme Activation; Etoposide; fas Receptor; Humans; Isoenzymes; Oligopeptides; Protein Kinase C; Protein Kinase C-delta; Protein Kinase C-epsilon; Tetradecanoylphorbol Acetate; U937 Cells | 1999 |
Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines.
Topics: Antineoplastic Agents; Camptothecin; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Humans; Irinotecan; Neuroblastoma; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Tumor Cells, Cultured | 2000 |
Detection of apoptosis induced by topoisomerase inhibitors and serum deprivation in syrian hamster embryo cells.
Topics: Animals; Apoptosis; Camptothecin; Caspase 3; Caspases; Cells, Cultured; Chlorides; Cricetinae; Culture Media, Serum-Free; Enzyme Inhibitors; Etoposide; Gene Expression; HL-60 Cells; Humans; Mesocricetus; Nucleic Acid Synthesis Inhibitors; Proto-Oncogene Proteins c-myc; Time Factors; Topoisomerase I Inhibitors; Tumor Suppressor Protein p53; Zinc Compounds | 2000 |
Uncoupling of apoptosis and Jun/AP-1 activity in human promonocytic cells treated with DNA-damaging and stress-inducing agents.
Topics: Apoptosis; Cadmium Chloride; Camptothecin; Colforsin; Cyclic AMP; DNA Damage; Enzyme Inhibitors; Etoposide; Gene Expression; Heating; Humans; Monocytes; Proto-Oncogene Proteins c-jun; Theophylline; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Transcription Factor AP-1; Tretinoin; U937 Cells; Uncoupling Agents | 2000 |
The topoisomerase inhibitors camptothecin and etoposide induce a CD95-independent apoptosis of activated peripheral lymphocytes.
Topics: Apoptosis; Camptothecin; Cells, Cultured; DNA Topoisomerases, Type I; Enzyme Inhibitors; Etoposide; fas Receptor; Humans; Lymphocyte Activation; Lymphocytes; Nucleic Acid Synthesis Inhibitors; Signal Transduction; Topoisomerase I Inhibitors | 2000 |
F 11782, a novel epipodophylloid non-intercalating dual catalytic inhibitor of topoisomerases I and II with an original mechanism of action.
Topics: Adenosine Triphosphatases; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Catalysis; Cattle; Cell Nucleus; DNA; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Electrophoresis, Polyacrylamide Gel; Enzyme Inhibitors; Enzyme Stability; Etoposide; Evaluation Studies as Topic; Humans; Naphthalenes; Pyrans; Saccharomyces cerevisiae; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2000 |
Sensitisation of HL60 human leukaemic cells to cytotoxic drug-induced apoptosis by inhibition of PI3-kinase survival signals.
Topics: Androstadienes; Antineoplastic Agents; Apigenin; Apoptosis; bcl-Associated Death Protein; bcl-X Protein; Camptothecin; Carrier Proteins; Cell Survival; Chromones; Cycloheximide; Dactinomycin; Dimerization; Doxorubicin; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Flavonoids; Genes, bcl-2; HL-60 Cells; Humans; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Mitoxantrone; Morpholines; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Sirolimus; Wortmannin | 2000 |
Anthracyclines trigger apoptosis of both G0-G1 and cycling peripheral blood lymphocytes and induce massive deletion of mature T and B cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; B-Lymphocytes; Camptothecin; Cell Cycle; Cells, Cultured; Daunorubicin; Doxorubicin; Etoposide; Fluorouracil; G1 Phase; Humans; Lymph Nodes; Lymphocyte Depletion; Lymphocytes; Methotrexate; Mice; Mice, Inbred BALB C; Resting Phase, Cell Cycle; Spleen; T-Lymphocytes; Thymus Gland | 2000 |
Reactive oxygen species-specific mechanisms of drug resistance in paraquat-resistant acute myelogenous leukemia sublines.
Topics: Alkynes; Antineoplastic Agents; Camptothecin; Cell Survival; Cisplatin; Daunorubicin; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Glutathione Transferase; Glycine; Humans; Leukemia, Myeloid, Acute; Metallothionein; Paraquat; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Superoxide Dismutase; Tumor Cells, Cultured; Vincristine | 2000 |
Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Carrier Proteins; Cell Cycle; Cell Cycle Proteins; Cell Survival; Cisplatin; DNA; DNA Damage; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; DNA, Recombinant; DNA, Single-Stranded; E2F Transcription Factors; E2F1 Transcription Factor; Enzyme Inhibitors; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Luciferases; Promoter Regions, Genetic; Recombinant Fusion Proteins; Retinoblastoma-Binding Protein 1; S Phase; Thymidine; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Transcription Factor DP1; Transcription Factors; Tumor Cells, Cultured | 2000 |
Homocamptothecin, an E-ring-modified camptothecin, exerts more potent antiproliferative activity than other topoisomerase I inhibitors in human colon cancers obtained from surgery and maintained in vitro under histotypical culture conditions.
Topics: Antineoplastic Agents; Biopsy; Camptothecin; Cell Division; Colon; Colonic Neoplasms; Culture Techniques; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Doxorubicin; Enzyme Inhibitors; Etoposide; Humans; Irinotecan; Thymidine; Topoisomerase I Inhibitors; Topotecan; Tritium; Tumor Cells, Cultured | 2000 |
Plasminogen activator inhibitor 1 may promote tumour growth through inhibition of apoptosis.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Camptothecin; DNA Fragmentation; Etoposide; HL-60 Cells; Humans; Plasminogen Activator Inhibitor 1; Receptors, Cell Surface; Receptors, Urokinase Plasminogen Activator; Tumor Cells, Cultured | 2000 |
[Histoculture drug response assay on non-small cell lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Doxorubicin; Drug Screening Assays, Antitumor; Etoposide; Female; Fluorouracil; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Mitomycin; Tumor Cells, Cultured | 2000 |
In vitro synergistic effects of vinflunine, a novel fluorinated vinca alkaloid, in combination with other anticancer drugs.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Division; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Evaluation; Drug Synergism; Drug Therapy, Combination; Etoposide; Fluorouracil; Gemcitabine; Humans; Mitomycin; Models, Chemical; Paclitaxel; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 2000 |
Possible association of BLM in decreasing DNA double strand breaks during DNA replication.
Topics: Adenosine Triphosphatases; Amino Acid Sequence; Animals; Base Sequence; Bloom Syndrome; Camptothecin; Cell Cycle; Cells, Cultured; Chickens; Chromosome Aberrations; DNA Damage; DNA Helicases; DNA Primers; DNA Repair Enzymes; DNA Replication; Etoposide; Fungal Proteins; Methyl Methanesulfonate; Molecular Sequence Data; RecQ Helicases; Saccharomyces cerevisiae Proteins; Sequence Homology, Amino Acid | 2000 |
Isolation of camptothecin-sensitive chinese hamster cell mutants: phenotypic heterogeneity within the ataxia telangiectasia-like XRCC8 (irs2) complementation group.
Topics: Alkylating Agents; Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Ataxia Telangiectasia; Ataxia Telangiectasia Mutated Proteins; Bleomycin; Camptothecin; Cell Cycle; Cell Cycle Proteins; Cell Line; Cricetinae; DNA Repair; DNA-Binding Proteins; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Doxorubicin; Enzyme Inhibitors; Etoposide; Gamma Rays; Genes, Dominant; Genetic Complementation Test; Mitomycin; Mutation; Nucleic Acid Synthesis Inhibitors; Phenotype; Protein Serine-Threonine Kinases; Streptonigrin; Tumor Suppressor Proteins | 2000 |
Coordinated regulation of two TRAIL-R2/KILLER/DR5 mRNA isoforms by DNA damaging agents, serum and 17beta-estradiol in human breast cancer cells.
Topics: Antineoplastic Agents; Base Sequence; Breast Neoplasms; Camptothecin; DNA Damage; Doxorubicin; Estradiol; Etoposide; Female; Gene Expression Regulation, Neoplastic; Gene Library; Humans; Molecular Sequence Data; Protein Isoforms; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; RNA, Messenger; Serum Albumin, Bovine; Tumor Cells, Cultured | 2000 |
Characterization of DNA-strand breakage induced in V79 cells by F 11782, a catalytic inhibitor of topoisomerases.
Topics: Animals; Camptothecin; Cell Line; Comet Assay; DNA; DNA Damage; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Etoposide; Naphthalenes; Pyrans; Spheroids, Cellular; Time Factors; Topoisomerase I Inhibitors | 2000 |
Roles of NF-kappaB and 26 S proteasome in apoptotic cell death induced by topoisomerase I and II poisons in human nonsmall cell lung carcinoma.
Topics: Apoptosis; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; DNA; DNA Damage; DNA-Binding Proteins; Enzyme Inhibitors; Etoposide; Humans; I-kappa B Proteins; Irinotecan; Leupeptins; Lung Neoplasms; NF-kappa B; NF-KappaB Inhibitor alpha; Paclitaxel; Peptide Hydrolases; Proteasome Endopeptidase Complex; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2001 |
Identification of genes highly expressed in G2-arrested Chinese hamster ovary cells by differential display analysis.
Topics: Animals; Arylamine N-Acetyltransferase; Camptothecin; CHO Cells; Cloning, Molecular; Cricetinae; DNA; DNA Damage; DNA, Complementary; Enzyme Inhibitors; Etoposide; Eukaryotic Initiation Factor-4A; G2 Phase; Gene Expression; Irinotecan; Isoenzymes; Nucleic Acid Synthesis Inhibitors; Peptide Initiation Factors; Ribosomal Proteins; RNA, Messenger; Topoisomerase I Inhibitors; X-Rays | 2000 |
Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; DNA Damage; DNA, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Inhibitors; Etoposide; Leukemia L1210; Nucleic Acid Synthesis Inhibitors; Proteins; Quinazolines; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2001 |
[Three cases of liver metastasis of colon cancer responding to systemic combination chemotherapy utilizing CPT-11].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colonic Neoplasms; Doxorubicin; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Humans; Irinotecan; Liver Neoplasms; Male; Tegafur; Uracil | 2000 |
RAD51 supports spontaneous non-homologous recombination in mammalian cells, but not the corresponding process induced by topoisomerase inhibitors.
Topics: Animals; Camptothecin; Cell Line; Cricetinae; Cricetulus; DNA Topoisomerases, Type I; DNA-Binding Proteins; DNA, Recombinant; Dose-Response Relationship, Drug; Enzyme Inhibitors; Etoposide; Gene Expression; Hypoxanthine Phosphoribosyltransferase; Plasmids; Point Mutation; Rad51 Recombinase; Recombination, Genetic; Topoisomerase I Inhibitors; Transfection; Tumor Suppressor Protein p53 | 2001 |
The homocamptothecin, BN 80927, is a potent topoisomerase I poison and topoisomerase II catalytic inhibitor.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Catalysis; Enzyme Inhibitors; Etoposide; Humans; Irinotecan; Nucleic Acid Synthesis Inhibitors; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2000 |
Hippocampal neurons of mice deficient in DNA-dependent protein kinase exhibit increased vulnerability to DNA damage, oxidative stress and excitotoxicity.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Camptothecin; DNA Damage; DNA-Activated Protein Kinase; DNA-Binding Proteins; Enzyme Inhibitors; Epilepsy; Etoposide; Glutamic Acid; Hippocampus; Mice; Mice, SCID; Neurons; Neurotoxins; Nucleic Acid Synthesis Inhibitors; Oxidative Stress; Protein Serine-Threonine Kinases; Topoisomerase I Inhibitors | 2001 |
Monochloramine inhibits etoposide-induced apoptosis with an increase in DNA aberration.
Topics: Aneuploidy; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Caspases; Cell Cycle; Cell Division; Cell Size; Cell Survival; Chloramines; DNA; DNA Damage; Enzyme Activation; Etoposide; Humans; Jurkat Cells; Oxidants; Staurosporine | 2001 |
Werner helicase relocates into nuclear foci in response to DNA damaging agents and co-localizes with RPA and Rad51.
Topics: 4-Nitroquinoline-1-oxide; Aphidicolin; Bleomycin; Camptothecin; Cell Line; Cell Nucleus; DNA Damage; DNA Helicases; DNA Replication; DNA-Binding Proteins; Dose-Response Relationship, Drug; Etoposide; Humans; Immunoblotting; Immunohistochemistry; In Situ Hybridization, Fluorescence; Mutagens; Proteins; Rad51 Recombinase; Trans-Activators; Werner Syndrome | 2001 |
Suppression of the radiation-sensitive phenotype of hamster irs1 and irs2 strains selected for resistance to 3-aminobenzamide.
Topics: Animals; Apoptosis; Benzamides; Camptothecin; Cell Line; Cricetinae; Cricetulus; DNA; DNA Damage; DNA Replication; Dose-Response Relationship, Radiation; Drug Resistance; Enzyme Inhibitors; Etoposide; Humans; Phenotype; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Radiation Tolerance; Radiation-Sensitizing Agents | 2001 |
Involvement of transcriptional repressor ATF3 in acceleration of caspase protease activation during DNA damaging agent-induced apoptosis.
Topics: Activating Transcription Factor 3; Active Transport, Cell Nucleus; Amino Acid Chloromethyl Ketones; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Camptothecin; Caspase Inhibitors; Caspases; Enzyme Activation; Enzyme Inhibitors; Etoposide; Fibrosarcoma; Gene Expression Regulation; HeLa Cells; Humans; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Repressor Proteins; Topoisomerase I Inhibitors; Transcription Factors; Transfection; Tumor Cells, Cultured | 2001 |
Cytotoxic pheophorbide-related compounds from Clerodendrum calamitosum and C. cyrtophyllum.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Cell Survival; Chlorophyll; Dose-Response Relationship, Drug; Drug Resistance; Etoposide; Female; Humans; Ileal Neoplasms; KB Cells; Kidney Neoplasms; Lung Neoplasms; Magnetic Resonance Spectroscopy; Melanoma; Molecular Structure; Ovarian Neoplasms; Plant Leaves; Plant Stems; Plants, Medicinal; Stereoisomerism; Structure-Activity Relationship; Taiwan; Tumor Cells, Cultured; Vincristine | 2001 |
Elevated expression of vacuolar proton pump genes and cellular PH in cisplatin resistance.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Blotting, Northern; Camptothecin; Cisplatin; DNA, Complementary; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Gene Expression Profiling; Humans; Hydrogen-Ion Concentration; Macrolides; Proton Pumps; Protons; Time Factors; Tumor Cells, Cultured; Up-Regulation; Vacuoles | 2001 |
The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents, Phytogenic; Base Pair Mismatch; Camptothecin; Carrier Proteins; Cell Cycle; Colorectal Neoplasms; DNA Repair; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Resistance, Multiple; Enzyme Inhibitors; Etoposide; Humans; MutL Protein Homolog 1; MutS Homolog 2 Protein; Neoplasm Proteins; Nuclear Proteins; Proto-Oncogene Proteins; Retrospective Studies; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Transfection; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2001 |
In vitro schedule dependency in the treatment of topoisomerase I and II inhibitor.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Drug Synergism; Enzyme Inhibitors; Etoposide; Humans; Irinotecan; Lung Neoplasms; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 2001 |
Identification of hTAF(II)80 delta links apoptotic signaling pathways to transcription factor TFIID function.
Topics: Amino Acid Sequence; Apoptosis; Apoptosis Regulatory Proteins; Camptothecin; Caspase Inhibitors; Caspases; Cell Line; Cloning, Molecular; Enzyme Inhibitors; Etoposide; GADD45 Proteins; Humans; Immunoblotting; Intracellular Signaling Peptides and Proteins; Macromolecular Substances; Membrane Glycoproteins; Molecular Sequence Data; Nucleic Acid Synthesis Inhibitors; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Protein Isoforms; Proteins; Recombinant Fusion Proteins; rho GTP-Binding Proteins; Sequence Alignment; Signal Transduction; Staurosporine; TATA-Binding Protein Associated Factors; TNF-Related Apoptosis-Inducing Ligand; Transcription Factor TFIID; Transcription Factors; Transcription Factors, TFII; Transcription, Genetic; Tumor Necrosis Factor-alpha | 2001 |
Effects of the combination of camptothecin and doxorubicin or etoposide on rat glioma cells and camptothecin-resistant variants.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Doxorubicin; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Glioma; Rats; Rats, Wistar; Tumor Cells, Cultured | 2001 |
Effect of glutathione depletion on antitumor drug toxicity (apoptosis and necrosis) in U-937 human promonocytic cells. The role of intracellular oxidation.
Topics: Adenosine Triphosphate; Alkylating Agents; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antioxidants; Apoptosis; Buthionine Sulfoximine; Camptothecin; Cell Death; Cisplatin; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Doxorubicin; Enzyme Inhibitors; Etoposide; Flow Cytometry; Glutathione; Humans; Hydrogen Peroxide; Hypoxia; Immunoblotting; Melphalan; Membrane Potentials; Mitochondria; Monocytes; Necrosis; Nucleic Acid Synthesis Inhibitors; Oxygen; Radiation-Protective Agents; Reactive Oxygen Species; Spectrometry, Fluorescence; Time Factors; Topoisomerase I Inhibitors; U937 Cells | 2001 |
Unique action determinants of double acting topoisomerase inhibitor, TAS-103.
Topics: Aminoquinolines; Antineoplastic Agents, Phytogenic; Blotting, Northern; Blotting, Western; Buthionine Sulfoximine; Camptothecin; Drug Resistance; Enzyme Inhibitors; Etoposide; Fungal Proteins; Glutamate-Cysteine Ligase; Glutathione; GTP-Binding Proteins; Humans; Indenes; Irinotecan; Mitochondrial Proteins; RNA, Messenger; Saccharomyces cerevisiae Proteins; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 2001 |
Telomerase protects developing neurons against DNA damage-induced cell death.
Topics: Animals; Apoptosis; Camptothecin; Catalytic Domain; DNA Damage; DNA-Binding Proteins; Enzyme Inhibitors; Etoposide; Hippocampus; Humans; Mice; Neurons; Nucleic Acid Synthesis Inhibitors; PC12 Cells; Rats; Telomerase; Topoisomerase I Inhibitors; Transfection | 2001 |
Phorbol 12-myristate 13-acetate inhibits death receptor-mediated apoptosis in Jurkat cells by disrupting recruitment of Fas-associated polypeptide with death domain.
Topics: Adaptor Proteins, Signal Transducing; Antigens, CD; Apoptosis; Apoptosis Regulatory Proteins; Binding Sites; Camptothecin; Carrier Proteins; Cell Line; Cycloheximide; Etoposide; fas Receptor; Fas-Associated Death Domain Protein; Gamma Rays; HSP90 Heat-Shock Proteins; Humans; Jurkat Cells; Kinetics; Membrane Glycoproteins; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; Tetradecanoylphorbol Acetate; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2002 |
Nuclear translocation of PDCD5 (TFAR19): an early signal for apoptosis?
Topics: Active Transport, Cell Nucleus; Apoptosis; Apoptosis Regulatory Proteins; Camptothecin; Cell Nucleus; Cisplatin; Culture Media, Serum-Free; DNA Fragmentation; Etoposide; HeLa Cells; Humans; Membrane Potentials; Mitochondria; Neoplasm Proteins; Phosphatidylserines; Signal Transduction; Staurosporine; Time Factors; Tumor Cells, Cultured; Ultraviolet Rays | 2001 |
Lung cancer--time to move on from chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Etoposide; Humans; Irinotecan; Lung Neoplasms; Smoking; Survival Rate | 2002 |
The proline-rich domain of p53 is required for cooperation with anti-neoplastic agents to promote apoptosis of tumor cells.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Clone Cells; Colchicine; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Daunorubicin; DNA Damage; DNA, Neoplasm; Etoposide; Fluorouracil; Gene Expression Regulation, Neoplastic; Genes, p53; Humans; Lung Neoplasms; Models, Biological; Proline; Promoter Regions, Genetic; Protein Structure, Tertiary; Recombinant Fusion Proteins; Structure-Activity Relationship; Tetracycline; Transcription, Genetic; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2002 |
Cell-based assays for identification of novel double-strand break-inducing agents.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Cycle; DNA Damage; DNA Repair; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Etoposide; Idarubicin; Mutation; Saccharomyces cerevisiae; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan | 2002 |
X-ray repair cross-complementing gene I protein plays an important role in camptothecin resistance.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cisplatin; DNA Repair; DNA-Binding Proteins; DNA, Neoplasm; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Humans; KB Cells; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Topotecan; Transfection; X-ray Repair Cross Complementing Protein 1 | 2002 |
Sensitive markers used to identify compounds that trigger apoptosis in cultured hepatocytes.
Topics: Animals; Apoptosis; bcl-X Protein; Biomarkers; Camptothecin; Caspase 3; Caspases; Cells, Cultured; Curcumin; Cytochrome c Group; DNA; DNA Fragmentation; Down-Regulation; Etoposide; Flow Cytometry; Galactosamine; Hepatocytes; Male; Mitochondria; Proto-Oncogene Proteins c-bcl-2; Rats; Rats, Sprague-Dawley; Sensitivity and Specificity; tert-Butylhydroperoxide; Xenobiotics | 2002 |
Expression level of c-FLIP versus Fas determines susceptibility to Fas ligand-induced cell death in murine thymoma EL-4 cells.
Topics: Animals; Apoptosis; Camptothecin; Carrier Proteins; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase Inhibitors; Cell Membrane; Cycloheximide; Down-Regulation; Doxorubicin; Etoposide; Fas Ligand Protein; fas Receptor; Gene Expression; Intracellular Signaling Peptides and Proteins; Membrane Glycoproteins; Mice; Mitomycin; Protein Synthesis Inhibitors; Thymoma; Transcriptional Activation; Transfection; Tumor Cells, Cultured; Up-Regulation | 2002 |
An MCL1-overexpressing Burkitt lymphoma subline exhibits enhanced survival on exposure to serum deprivation, topoisomerase inhibitors, or staurosporine but remains sensitive to 1-beta-D-arabinofuranosylcytosine.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Burkitt Lymphoma; Camptothecin; Cell Survival; Culture Media, Serum-Free; Cytarabine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Humans; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Proto-Oncogene Proteins c-bcl-2; Staurosporine; Topoisomerase Inhibitors; Tumor Cells, Cultured | 2002 |
Werner and Bloom helicases are involved in DNA repair in a complementary fashion.
Topics: 4-Nitroquinoline-1-oxide; Adenosine Triphosphatases; Amino Acid Sequence; Animals; B-Lymphocytes; Bloom Syndrome; Camptothecin; Cell Cycle; Cell Line; Chickens; Chromosome Aberrations; Clone Cells; Coculture Techniques; DNA; DNA Damage; DNA Helicases; DNA Repair; Drug Resistance; Etoposide; Gene Targeting; Humans; Methyl Methanesulfonate; Molecular Sequence Data; Mutagenicity Tests; Radiation Tolerance; RecQ Helicases; Sequence Alignment; Sequence Homology, Amino Acid; Sister Chromatid Exchange; Species Specificity; Ultraviolet Rays; Werner Syndrome | 2002 |
[Globalization of anti-cancer therapies].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carboplatin; Cisplatin; Colorectal Neoplasms; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Neoplasms; Ovarian Neoplasms; Paclitaxel; Prostatic Neoplasms; Stomach Neoplasms | 2002 |
Tumor-cell resistance to death receptor--induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; BH3 Interacting Domain Death Agonist Protein; Camptothecin; Carrier Proteins; Caspase 8; Caspase 9; Caspases; Colonic Neoplasms; Enzyme Activation; Etoposide; Fas-Associated Death Domain Protein; Female; Flow Cytometry; Humans; Membrane Glycoproteins; Mice; Mice, Nude; Mitochondria; Mutation; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Random Allocation; Receptors, Tumor Necrosis Factor; Signal Transduction; TNF-Related Apoptosis-Inducing Ligand; Transplantation, Heterologous; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2002 |
DNA damage is able to induce senescence in tumor cells in vitro and in vivo.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; beta-Galactosidase; Breast Neoplasms; Camptothecin; Cell Cycle; Cellular Senescence; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; DNA Damage; Etoposide; Humans; Irinotecan; Neoadjuvant Therapy; Tumor Suppressor Protein p53 | 2002 |
Stromal extracellular matrix reduces chemotherapy-induced apoptosis in colon cancer cell lines.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; bcl-X Protein; Camptothecin; Collagen; Colonic Neoplasms; Enzyme Inhibitors; Etoposide; Extracellular Matrix; Extracellular Matrix Proteins; Fibroblasts; Fibronectins; Fluorouracil; Genes, bcl-2; Hepatocytes; Humans; Neoplasm Proteins; Proto-Oncogene Proteins c-bcl-2; Rats; Rats, Inbred F344; Rats, Wistar; Stromal Cells; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 2002 |
Effect of non-steroidal anti-inflammatory drugs on colon carcinoma Caco-2 cell responsiveness to topoisomerase inhibitor drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Caco-2 Cells; Camptothecin; Cell Survival; Enzyme Inhibitors; Etoposide; Humans; Irinotecan; Nitrobenzenes; Sulfonamides; Topoisomerase Inhibitors | 2002 |
Influence of phenytoin on the disposition of irinotecan: a case report.
Topics: Adolescent; Anticonvulsants; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Brain Neoplasms; Camptothecin; Carboplatin; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dexamethasone; Disease Progression; Drug Interactions; Enzyme Induction; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Irinotecan; Male; Melphalan; Mixed Function Oxygenases; Neoplasm Recurrence, Local; Ondansetron; Phenobarbital; Phenytoin; Pineal Gland; Pinealoma; Prodrugs; Salvage Therapy; Seizures | 2002 |
Induction of apoptosis by nitric oxide in macrophages is independent of apoptotic volume decrease.
Topics: Apoptosis; Camptothecin; Cell Size; Etoposide; HeLa Cells; Humans; Jurkat Cells; Macrophages; Membrane Potentials; Nitric Oxide; Nitric Oxide Donors; S-Nitrosoglutathione; Staurosporine | 2002 |
Sensitivity to anticancer agents and resistance mechanisms in clear cell carcinoma of the ovary.
Topics: Adenocarcinoma, Clear Cell; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Cisplatin; Coloring Agents; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Etoposide; Female; Glutathione; Humans; Inhibitory Concentration 50; Irinotecan; Mitochondrial Proteins; Mitomycin; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Ovarian Neoplasms; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; Ribosomal Proteins; RNA, Messenger; Saccharomyces cerevisiae Proteins; Tetrazolium Salts; Thiazoles; Tumor Cells, Cultured | 2002 |
Influence of G2 arrest on the cytotoxicity of DNA topoisomerase inhibitors toward human carcinoma cells with different p53 status.
Topics: Alkaloids; Antineoplastic Agents; Apoptosis; Camptothecin; Carcinoma; Cell Cycle; Colonic Neoplasms; Etoposide; Humans; Staurosporine; Topoisomerase Inhibitors; Tumor Suppressor Protein p53 | 2002 |
Studies on fertilization in the teleost IV. Effects of aphidicolin and camptothecin on chromosome formation in fertilized medaka eggs.
Topics: Animals; Aphidicolin; Camptothecin; Chromosomes; DNA Polymerase I; DNA Topoisomerases; Etoposide; Fertilization; Meiosis; Mitogen-Activated Protein Kinases; Mitosis; Naphthoquinones; Oryzias; Protein Kinases; Topoisomerase Inhibitors; Zygote | 2002 |
Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ.
Topics: Amino Acid Sequence; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Camptothecin; Carrier Proteins; Caspase 3; Caspase 7; Caspase 9; Caspases; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Humans; Immunoblotting; Inhibitor of Apoptosis Proteins; Intracellular Signaling Peptides and Proteins; Irinotecan; Mitochondrial Proteins; Molecular Sequence Data; Paclitaxel; Peptides; Protein Binding; Protein Structure, Tertiary; Proteins; Recombinant Fusion Proteins; Sequence Homology, Amino Acid; Tumor Cells, Cultured; Ubiquitin-Protein Ligases; X-Linked Inhibitor of Apoptosis Protein | 2002 |
Chromosomal instability in B-lymphoblasotoid cell lines from Werner and Bloom syndrome patients.
Topics: 4-Nitroquinoline-1-oxide; B-Lymphocytes; Bloom Syndrome; Camptothecin; Carcinogens; Case-Control Studies; Cell Division; Cell Line; Chromosome Aberrations; Etoposide; Herpesvirus 4, Human; Humans; Karyotyping; Metaphase; Micronuclei, Chromosome-Defective; Mitomycin; Sister Chromatid Exchange; Werner Syndrome | 2002 |
Detection of topoisomerase inhibitor-induced DNA strand breaks and apoptosis by the alkaline comet assay.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Survival; CHO Cells; Comet Assay; Cricetinae; DNA Damage; DNA Fragmentation; Ellipticines; Enzyme Inhibitors; Etoposide; Formazans; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan | 2002 |
Inhibitory properties of antitumor prostaglandins against topoisomerases.
Topics: Animals; Antineoplastic Agents; Camptothecin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA, Superhelical; Doxorubicin; Enzyme Inhibitors; Ethidium; Etoposide; Humans; Mice; Prostaglandin D2; Prostaglandins; Prostaglandins A; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 2002 |
SN-38 induces cell cycle arrest and apoptosis in human testicular cancer.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Camptothecin; Cell Cycle; Cell Line; Cisplatin; DNA; Etoposide; G1 Phase; Humans; In Situ Nick-End Labeling; Irinotecan; Male; Testicular Neoplasms; Tetrazolium Salts; Thiazoles | 2002 |
Unexpected pleural effusions in 3 pediatric patients treated with STI-571.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow Transplantation; Camptothecin; Child; Combined Modality Therapy; Edema; Enzyme Inhibitors; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Irinotecan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemic Infiltration; Lung Neoplasms; Male; Neoplasm Proteins; Neuroectodermal Tumors, Primitive; Piperazines; Pleural Effusion; Proto-Oncogene Proteins c-kit; Pyrimidines; Remission Induction; Sarcoma, Ewing; Testis; Topotecan | 2002 |
Model of chemotherapy-induced myelosuppression with parameter consistency across drugs.
Topics: Antineoplastic Agents; Bone Marrow; Camptothecin; Deoxycytidine; Docetaxel; Etoposide; Humans; Irinotecan; Leukocytes; Models, Biological; Neutrophils; Paclitaxel; Taxoids; Vinblastine | 2002 |
[Cytokine-induced killer cells induce apoptosis of K562 cells expressed bcr-abl].
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Coculture Techniques; Cytotoxicity, Immunologic; Etoposide; Flow Cytometry; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; K562 Cells; Killer Cells, Lymphokine-Activated | 2002 |
Identification of new drug sensitivity genes using genetic suppressor elements: protein arginine N-methyltransferase mediates cell sensitivity to DNA-damaging agents.
Topics: Amino Acid Sequence; Antimetabolites, Antineoplastic; Camptothecin; Cell Division; DNA Damage; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Ellipticines; Etoposide; Humans; Molecular Sequence Data; Protein-Arginine N-Methyltransferases; Sequence Alignment; Sequence Homology, Amino Acid; Suppression, Genetic; Tumor Cells, Cultured | 2003 |
Endoplasmic reticulum chaperone protein GRP78 protects cells from apoptosis induced by topoisomerase inhibitors: role of ATP binding site in suppression of caspase-7 activation.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Binding Sites; Camptothecin; Carrier Proteins; Caspase 7; Caspases; Cell Membrane; Cricetinae; Doxorubicin; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP; Enzyme Precursors; Etoposide; G1 Phase; Gene Expression; Heat-Shock Proteins; Humans; Leukemia; Molecular Chaperones; Protein Structure, Tertiary; Subcellular Fractions; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Transfection; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2003 |
The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells.
Topics: Animals; Antineoplastic Agents; BRCA1 Protein; Busulfan; Camptothecin; Cell Division; Cell Line; Doxorubicin; Etoposide; Fibroblasts; Gene Deletion; Genes, BRCA1; Mice; Mitoxantrone; Topotecan; Tumor Suppressor Protein p53 | 2003 |
[Experimental studies on treatment of nasopharyngeal carcinoma with combination regimen of hydroxycamptothecin and etoposide].
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Survival; Disease Models, Animal; Drug Resistance, Neoplasm; Etoposide; Mice; Mice, Inbred BALB C; Mice, Nude; Nasopharyngeal Neoplasms; Neoplasm Transplantation; Neoplasms, Experimental; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2003 |
Dual inhibition of topoisomerase I and tubulin polymerization by BPR0Y007, a novel cytotoxic agent.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Cycle; DNA Damage; DNA, Neoplasm; Drug Resistance, Neoplasm; Etoposide; Humans; KB Cells; Microtubules; Topoisomerase I Inhibitors; Tubulin; Tumor Cells, Cultured | 2003 |
Elongation by RNA polymerase II on chromatin templates requires topoisomerase activity.
Topics: Camptothecin; Chromatin; DNA; DNA Topoisomerases; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Enzyme Inhibitors; Etoposide; HeLa Cells; Humans; Nucleic Acid Conformation; Nucleic Acid Synthesis Inhibitors; Nucleosomes; RNA; RNA Polymerase II; Templates, Genetic; Topoisomerase I Inhibitors; Topoisomerase Inhibitors; Transcription, Genetic | 2003 |
Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; bcl-X Protein; Breast Neoplasms; Camptothecin; Caspases; Doxorubicin; Drug Synergism; Enzyme Activation; Etoposide; Humans; Membrane Glycoproteins; Mice; Mice, Inbred BALB C; Mice, Nude; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Vinblastine; Vincristine; Xenograft Model Antitumor Assays | 2003 |
Cisplatin down-regulation of cellular Fas-associated death domain-like interleukin-1beta-converting enzyme-like inhibitory proteins to restore tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human melanoma cells.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Camptothecin; Caspases; Cell Line, Tumor; Cisplatin; Etoposide; Flow Cytometry; Humans; Melanoma; Membrane Glycoproteins; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha | 2003 |
Herpes simplex virus UL14 protein blocks apoptosis.
Topics: Apoptosis; Camptothecin; Caspase 3; Caspases; Cell Line, Tumor; Epithelial Cells; Etoposide; Herpesvirus 2, Human; Humans; Osmotic Pressure; Poly(ADP-ribose) Polymerases; Staurosporine; Viral Proteins | 2003 |
Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Regulatory Proteins; Base Pair Mismatch; bcl-2-Associated X Protein; Camptothecin; Carcinoma; Caspase 8; Caspase 9; Caspase Inhibitors; Caspases; Cell Death; Cell Line; Cell Line, Tumor; Colonic Neoplasms; DNA Damage; DNA Repair; Enzyme Inhibitors; Etoposide; Flow Cytometry; Humans; Irinotecan; Luciferases; Membrane Glycoproteins; Mice; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; RNA, Small Interfering; Time Factors; TNF-Related Apoptosis-Inducing Ligand; Transcription, Genetic; Transfection; Tumor Necrosis Factor-alpha; Tumor Suppressor Protein p53 | 2003 |
Enhancement of chemotherapeutic response of tumor cells by a heme oxygenase inhibitor, pegylated zinc protoporphyrin.
Topics: Animals; Annexin A5; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Body Weight; Camptothecin; Cell Line, Tumor; Cisplatin; Coloring Agents; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Etoposide; Heme Oxygenase (Decyclizing); Humans; Hydrogen Peroxide; Male; Metalloporphyrins; Mice; Mitomycin; Neoplasms; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxygen; Polyethylene Glycols; Proline; Reactive Oxygen Species; Tetrazolium Salts; Thiazoles | 2004 |
[A case of isolated hepatic malignant lymphoma representing characteristic findings on radiological imaging].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Irinotecan; L-Lactate Dehydrogenase; Liver Neoplasms; Lymphoma; Magnetic Resonance Imaging; Male; Neoplasm Recurrence, Local; Prednisolone; Tomography, X-Ray Computed; Treatment Outcome; Vincristine | 2003 |
DNA repair functions that control sensitivity to topoisomerase-targeting drugs.
Topics: Camptothecin; Cell Cycle; DNA Damage; DNA Repair; Dose-Response Relationship, Radiation; Enzyme Inhibitors; Etoposide; Genotype; Mutation; Plasmids; Recombination, Genetic; Schizosaccharomyces; Sensitivity and Specificity; Temperature; Time Factors; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; X-Rays | 2004 |
Phosphatidyl inositol 3-kinase-like serine/threonine protein kinases (PIKKs) are required for DNA damage-induced phosphorylation of the 32 kDa subunit of replication protein A at threonine 21.
Topics: Antibodies; Ataxia Telangiectasia Mutated Proteins; Camptothecin; Cell Cycle Proteins; Cell Line; DNA Damage; DNA Replication; DNA-Activated Protein Kinase; DNA-Binding Proteins; Etoposide; Humans; Nuclear Proteins; Phosphatidylinositol 3-Kinases; Phosphorylation; Phosphothreonine; Protein Serine-Threonine Kinases; Protein Subunits; Radiation, Ionizing; Replication Protein A; Threonine; Tumor Suppressor Proteins | 2004 |
DA-125, a new antitumor agent, inhibits topoisomerase II as topoisomerase poison and DNA intercalator simultaneously.
Topics: Animals; Antineoplastic Agents; Camptothecin; Chlorocebus aethiops; Dimerization; DNA; DNA Replication; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Haplorhini; Intercalating Agents; Methods; Protein Biosynthesis; Proteins; Simian virus 40; Topoisomerase II Inhibitors; Vero Cells | 2004 |
Alteration in copy numbers of genes as a mechanism for acquired drug resistance.
Topics: Apoptosis; ATP-Binding Cassette Transporters; Camptothecin; Cell Line, Tumor; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Gene Amplification; Gene Dosage; Genes, bcl-2; Humans | 2004 |
Rad9 protects cells from topoisomerase poison-induced cell death.
Topics: Animals; Apoptosis; Camptothecin; Cell Cycle Proteins; Cytarabine; DNA Damage; DNA Topoisomerases; Embryo, Mammalian; Etoposide; Humans; Mice; Mice, Knockout; Protective Agents; Stem Cells; Topoisomerase Inhibitors; Transfection; Transgenes | 2004 |
2070-DTI, a topoisomerase inhibitor produced by Streptomyces sp. strain No. 2070.
Topics: Animals; Camptothecin; Carbohydrate Sequence; Cattle; Cell Cycle; Chlorocebus aethiops; DNA; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Doxorubicin; Enzyme Inhibitors; Etoposide; HeLa Cells; Humans; Mice; Molecular Sequence Data; NIH 3T3 Cells; Oleanolic Acid; Saponins; Streptomyces; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Vero Cells | 2003 |
Adeno-associated virus mediated endostatin gene therapy in combination with topoisomerase inhibitor effectively controls liver tumor in mouse model.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Hepatocellular; Cell Line, Tumor; Combined Modality Therapy; Drug Synergism; Endostatins; Endothelium, Vascular; Enzyme Inhibitors; Etoposide; Gene Expression; Genetic Therapy; Humans; Liver Neoplasms; Mice; Sarcoma; Survival Rate; Topoisomerase Inhibitors; Umbilical Veins | 2004 |
IL-4 protects tumor cells from anti-CD95 and chemotherapeutic agents via up-regulation of antiapoptotic proteins.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; bcl-X Protein; Breast Neoplasms; Camptothecin; Carrier Proteins; CASP8 and FADD-Like Apoptosis Regulating Protein; Cell Line, Tumor; Cell Survival; Etoposide; fas Receptor; Female; Humans; Interleukin-4; Intracellular Signaling Peptides and Proteins; Male; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Recombinant Proteins; Up-Regulation | 2004 |
[Screening of DNA topoisomerase inhibitors].
Topics: Antineoplastic Agents; Camptothecin; Cell Cycle; DNA Topoisomerases; Doxorubicin; Drug Screening Assays, Antitumor; Etoposide; Humans; Irinotecan; Topoisomerase Inhibitors; Tumor Cells, Cultured | 2004 |
Topoisomerase inhibitor camptothecin sensitizes mouse hepatocytes in vitro and in vivo to TNF-mediated apoptosis.
Topics: Adenosine Triphosphate; Animals; Antigens, CD; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Carrier Proteins; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase Inhibitors; Caspases; Cells, Cultured; Down-Regulation; Enzyme Inhibitors; Etoposide; Gene Expression; Hepatocytes; Intracellular Signaling Peptides and Proteins; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; NF-kappa B; Proteins; Receptors, Tumor Necrosis Factor; Receptors, Tumor Necrosis Factor, Type I; RNA, Messenger; Specific Pathogen-Free Organisms; TNF Receptor-Associated Factor 2; Topoisomerase Inhibitors; Tumor Necrosis Factor-alpha; X-Linked Inhibitor of Apoptosis Protein | 2004 |
Dependence of the cytotoxicity of DNA-damaging agents on the mismatch repair status of human cells.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Base Pair Mismatch; Camptothecin; Carrier Proteins; Cell Line; Cisplatin; DNA Repair; Drug Screening Assays, Antitumor; Etoposide; Furocoumarins; Humans; Inhibitory Concentration 50; Melphalan; Mitomycin; MutL Protein Homolog 1; Neoplasm Proteins; Nitrosourea Compounds; Nuclear Proteins | 2004 |
[Chemotherapy for small cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Etoposide; Humans; Irinotecan; Lung Neoplasms | 2004 |
The in vitro effects of CRE-decoy oligonucleotides in combination with conventional chemotherapy in colorectal cancer cell lines.
Topics: Base Sequence; Camptothecin; Cell Division; Cell Line, Tumor; Colorectal Neoplasms; Cyclin-Dependent Kinases; Etoposide; Flow Cytometry; Fluorouracil; Humans; In Vitro Techniques; Irinotecan; Oligonucleotides | 2004 |
2-deoxy-D-glucose enhances the cytotoxicity of topoisomerase inhibitors in human tumor cell lines.
Topics: Adenosine Triphosphate; Antimetabolites; Antineoplastic Agents, Phytogenic; Benzimidazoles; Brain Neoplasms; Camptothecin; Carcinoma, Squamous Cell; Cell Survival; Deoxyglucose; DNA Damage; Drug Interactions; Enzyme Inhibitors; Etoposide; Glioma; Humans; Radiation-Sensitizing Agents; Topoisomerase Inhibitors; Tumor Cells, Cultured | 2004 |
Usefulness of collagen gel droplet embedded culture drug sensitivity testing in ovarian cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Culture Techniques; Cell Line, Tumor; Chemotherapy, Adjuvant; Cisplatin; Clinical Laboratory Techniques; Collagen; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Female; Gels; Humans; Irinotecan; Middle Aged; Ovarian Neoplasms; Paclitaxel; Pharmaceutical Preparations; Recurrence; Remission Induction; Sensitivity and Specificity; Time Factors; Treatment Outcome | 2004 |
Topoisomerase inhibitors enhance the cytocidal effect of AAV-HSVtk/ganciclovir on head and neck cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cell Survival; Dependovirus; Enzyme Inhibitors; Etoposide; Ganciclovir; Gene Expression; Genes, Transgenic, Suicide; Genetic Therapy; Genetic Vectors; Head and Neck Neoplasms; Humans; Thymidine Kinase; Topoisomerase I Inhibitors | 2004 |
Human T-cell leukemia virus type 1 (HTLV-1) and HTLV-2 tax oncoproteins modulate cell cycle progression and apoptosis.
Topics: Annexins; Apoptosis; Camptothecin; Cell Count; Cell Cycle; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Enzyme Inhibitors; Etoposide; Gene Expression Regulation; Gene Products, tax; Genes, Reporter; Giant Cells; Green Fluorescent Proteins; Human T-lymphotropic virus 1; Human T-lymphotropic virus 2; Humans; Jurkat Cells; Luciferases; Luminescent Proteins; Propidium; Transcription, Genetic; Up-Regulation | 2004 |
Predicting resistance or response to chemotherapy by proton magnetic resonance spectroscopy in neuroblastoma.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Choline; Cisplatin; Drug Resistance, Neoplasm; Etoposide; Hydrocarbons; Irinotecan; Magnetic Resonance Spectroscopy; Matched-Pair Analysis; Methane; Neuroblastoma; Predictive Value of Tests; Protons; Rats; Rats, Nude; Reproducibility of Results; Transplantation, Heterologous | 2004 |
GSK-3beta inhibition by lithium confers resistance to chemotherapy-induced apoptosis through the repression of CD95 (Fas/APO-1) expression.
Topics: Apoptosis; Camptothecin; Etoposide; fas Receptor; Gene Expression Regulation; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Lithium; Promoter Regions, Genetic; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Suppressor Protein p53 | 2004 |
TDP1 overexpression in human cells counteracts DNA damage mediated by topoisomerases I and II.
Topics: Bacterial Proteins; Binding Sites; Blotting, Western; Camptothecin; Cell Line; Cell Line, Tumor; Cell Nucleolus; Cell Nucleus; Cell Proliferation; Cloning, Molecular; DNA; DNA Damage; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA, Ribosomal; Etoposide; Green Fluorescent Proteins; Humans; Immunoblotting; Luminescent Proteins; Methylnitronitrosoguanidine; Microscopy, Fluorescence; Mitosis; Mutation; Phosphoric Diester Hydrolases; Time Factors | 2004 |
Differential impact of diverse anticancer chemotherapeutics on the Cdc25A-degradation checkpoint pathway.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Camptothecin; cdc25 Phosphatases; Cell Cycle; Cell Line, Transformed; Cell Line, Tumor; Checkpoint Kinase 1; Checkpoint Kinase 2; Cisplatin; Cyclin E; DNA; DNA Damage; Doxorubicin; Enzyme Activation; Etoposide; Flow Cytometry; Humans; Kinetics; Osteosarcoma; Paclitaxel; Protein Kinases; Protein Serine-Threonine Kinases; Radiation, Ionizing; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Ultraviolet Rays | 2005 |
[Clinical pathway based on evidence-based medicine (EBM) for chemotherapy for lung cancer].
Topics: Acute Kidney Injury; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Critical Pathways; Etoposide; Evidence-Based Medicine; Female; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Vomiting | 2004 |
Camptothecin- and etoposide-induced apoptosis in human leukemia cells is independent of cell death receptor-3 and -4 aggregation but accelerates tumor necrosis factor-related apoptosis-inducing ligand-mediated cell death.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Camptothecin; CASP8 and FADD-Like Apoptosis Regulating Protein; Etoposide; Fas-Associated Death Domain Protein; Gene Deletion; Genes, Dominant; HL-60 Cells; Humans; Intracellular Signaling Peptides and Proteins; Leukemia; Ligands; Membrane Glycoproteins; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; Receptors, Tumor Necrosis Factor, Member 25; TNF-Related Apoptosis-Inducing Ligand; Transfection; Tumor Necrosis Factor Ligand Superfamily Member 15; Tumor Necrosis Factor Receptor-Associated Peptides and Proteins; Tumor Necrosis Factor-alpha; TWEAK Receptor; U937 Cells | 2004 |
DNA lesion-specific co-localization of the Mre11/Rad50/Nbs1 (MRN) complex and replication protein A (RPA) to repair foci.
Topics: Acid Anhydride Hydrolases; Blotting, Western; Camptothecin; Cations; Cell Cycle Proteins; Cell Nucleus; Comet Assay; DNA; DNA Damage; DNA Repair; DNA Repair Enzymes; DNA-Binding Proteins; DNA, Single-Stranded; Etoposide; HeLa Cells; Humans; Hydroxyurea; Macromolecular Substances; Microscopy, Fluorescence; Mitomycin; Models, Biological; MRE11 Homologue Protein; Multiprotein Complexes; Nuclear Proteins; Phosphorylation; Protein Binding; Replication Protein A; Time Factors | 2005 |
Identification of a novel cardenolide (2''-oxovoruscharin) from Calotropis procera and the hemisynthesis of novel derivatives displaying potent in vitro antitumor activities and high in vivo tolerance: structure-activity relationship analyses.
Topics: Animals; Antineoplastic Agents; Calotropis; Camptothecin; Cardenolides; Cell Line, Tumor; Cell Proliferation; Cerebral Cortex; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Humans; Irinotecan; Magnetic Resonance Spectroscopy; Maximum Tolerated Dose; Mice; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Sodium-Potassium-Exchanging ATPase; Structure-Activity Relationship; Swine; Thiazoles | 2005 |
Methylseleninic acid potentiates apoptosis induced by chemotherapeutic drugs in androgen-independent prostate cancer cells.
Topics: Androgens; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Caspases; Drug Therapy, Combination; Enzyme Activation; Etoposide; Humans; JNK Mitogen-Activated Protein Kinases; Male; Organoselenium Compounds; p38 Mitogen-Activated Protein Kinases; Paclitaxel; Phosphorylation; Poly(ADP-ribose) Polymerases; Prostatic Neoplasms; Tumor Cells, Cultured | 2005 |
The effect of granisetron on in vitro metabolism of doxorubicin, irinotecan and etoposide.
Topics: Antibiotics, Antineoplastic; Antiemetics; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Culture Techniques; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Doxorubicin; Drug Interactions; Etoposide; Granisetron; Humans; Irinotecan; Microsomes, Liver | 2005 |
Cell cycle arrest in G2/M promotes early steps of infection by human immunodeficiency virus.
Topics: Aphidicolin; Camptothecin; Cell Cycle; Cell Division; Cell Line; Dose-Response Relationship, Drug; Enzyme Inhibitors; Etoposide; G2 Phase; HIV; HIV Infections; Humans; Nucleic Acid Synthesis Inhibitors; Paclitaxel; Time Factors; Transduction, Genetic; Virus Replication | 2005 |
Inhibition of p53 by lentiviral mediated shRNA abrogates G1 arrest and apoptosis in retinal pigmented epithelial cell line.
Topics: Apoptosis; Camptothecin; Cell Cycle; Cell Line; Cell Proliferation; DNA Damage; Etoposide; G1 Phase; Gene Expression Regulation; Genes, p53; Genetic Vectors; Humans; Lentivirus; Pigment Epithelium of Eye; Promoter Regions, Genetic; RNA Interference; RNA, Messenger; Tumor Suppressor Protein p53; Vitreoretinopathy, Proliferative | 2005 |
Effects of adeno-associated virus DNA hairpin structure on recombination.
Topics: Aphidicolin; Base Sequence; Camptothecin; Dependovirus; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA, Circular; DNA, Viral; Etoposide; Genes, Reporter; Genetic Vectors; Genome, Viral; HeLa Cells; Humans; Hydroxyurea; Nucleic Acid Conformation; Recombination, Genetic; Terminal Repeat Sequences | 2005 |
GSK-3beta reactivation with LY294002 sensitizes hepatoma cells to chemotherapy-induced apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Camptothecin; Carcinoma, Hepatocellular; Caspase 3; Caspase 8; Caspases; Cell Line, Tumor; Chromones; Cytochromes c; DNA Fragmentation; Enzyme Activation; Enzyme Inhibitors; Etoposide; fas Receptor; Flow Cytometry; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Morpholines; Mutation; Phosphatidylinositol 3-Kinases; Phosphorylation; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; Reverse Transcriptase Polymerase Chain Reaction; Serine; Transfection; Tumor Suppressor Protein p53 | 2005 |
Enhanced G2-M arrest by nuclear factor-{kappa}B-dependent p21waf1/cip1 induction.
Topics: Antibiotics, Antineoplastic; Apoptosis; Breast Neoplasms; Camptothecin; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Doxorubicin; Enzyme Inhibitors; Etoposide; Female; Flow Cytometry; G2 Phase; Humans; Mitosis; NF-kappa B; Nucleic Acid Synthesis Inhibitors; Radiation, Ionizing; RNA Interference; T-Lymphocytes; Time Factors; Tumor Necrosis Factor-alpha | 2005 |
Membrane blebbing in cancer cells treated with various apoptotic inducers.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Cell Membrane; Cytoskeleton; Etoposide; Humans; Microscopy, Video; Ultrasonography | 2005 |
Inhibition of apoptosis by Nur77 through NF-kappaB activity modulation.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Camptothecin; Cell Line; Cycloheximide; DNA Damage; DNA-Binding Proteins; Endoplasmic Reticulum; Etoposide; Fas Ligand Protein; Fibroblasts; Gene Expression Regulation; Humans; Inhibitor of Apoptosis Proteins; Membrane Glycoproteins; NF-kappa B; Nuclear Receptor Subfamily 4, Group A, Member 1; Receptors, Cytoplasmic and Nuclear; Receptors, Steroid; Thapsigargin; Transcription Factors; Transfection; Tumor Necrosis Factors | 2006 |
[Surgical treatment for locally advanced lung cancer; therapeutic response of induction chemotherapy and postoperative chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pneumonectomy; Postoperative Period; Survival Rate | 2005 |
Evaluation of the role of caspase-6 in anticancer drug-induced apoptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Caspase 6; Caspases; Cell Line, Tumor; Chickens; Etoposide; Gene Expression Regulation, Neoplastic; Lymphoma | 2006 |
Direct activation of the human major vault protein gene by DNA-damaging agents.
Topics: Antineoplastic Agents; Binding Sites; Butyrates; Camptothecin; Cell Line, Tumor; Cell Survival; Cisplatin; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; Irinotecan; Luciferases; Promoter Regions, Genetic; Recombinant Fusion Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA Stability; RNA, Messenger; Transfection; Vault Ribonucleoprotein Particles | 2006 |
Nur77 forms novel nuclear structures upon DNA damage that cause transcriptional arrest.
Topics: Apoptosis; Camptothecin; Cell Line; Cell Line, Tumor; Cell Nucleus; Cisplatin; Cyclic AMP Response Element-Binding Protein; DNA Damage; DNA-Binding Proteins; Etoposide; Green Fluorescent Proteins; HeLa Cells; Humans; Microscopy, Confocal; Mutation; Neoplasm Proteins; Nerve Tissue Proteins; Nuclear Matrix; Nuclear Proteins; Nuclear Receptor Subfamily 4, Group A, Member 1; Nucleic Acid Synthesis Inhibitors; Phosphoproteins; Promyelocytic Leukemia Protein; Protein Binding; Receptors, Cytoplasmic and Nuclear; Receptors, Steroid; RNA-Binding Proteins; Serine-Arginine Splicing Factors; SMN Complex Proteins; Transcription Factors; Transcription, Genetic; Transfection; Tumor Suppressor Proteins | 2006 |
Optimal combination chemotherapy and chemoradiotherapy with etoposide for advanced cervical squamous cancer cells in vitro.
Topics: Antigens, CD20; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; CD40 Antigens; Cell Survival; Clone Cells; Combined Modality Therapy; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Drug Resistance, Neoplasm; Etoposide; Female; Flow Cytometry; Fluorouracil; Humans; Integrin alpha1; Integrin alpha6; Irinotecan; Mitomycin; Uterine Cervical Neoplasms; X-Rays | 2006 |
Genotoxic profile of inhibitors of topoisomerases I (camptothecin) and II (etoposide) in a mitotic recombination and sex-chromosome loss somatic eye assay of Drosophila melanogaster.
Topics: Animals; Camptothecin; Crosses, Genetic; Drosophila melanogaster; Enzyme Inhibitors; Etoposide; Eye; Female; Male; Mitosis; Mutagens; Recombination, Genetic; Sex Chromosome Aberrations; Topoisomerase I Inhibitors | 2006 |
[A case of small-cell lung cancer effectively treated by bi-weekly administration of amrubicin].
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Camptothecin; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Etoposide; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged | 2006 |
Elk-1 associates with the mitochondrial permeability transition pore complex in neurons.
Topics: Animals; Brain; Camptothecin; Cell Membrane Permeability; Cell Survival; Cells, Cultured; DNA Damage; Etoposide; ets-Domain Protein Elk-1; Ion Channels; Mitochondria; Mitochondrial Membrane Transport Proteins; Mitochondrial Membranes; Mitochondrial Permeability Transition Pore; Neurons; Protein Binding; Rats; RNA, Small Interfering | 2006 |
MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Camptothecin; Carboplatin; Drug Therapy, Combination; Etoposide; Female; Glioma; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Vascular Endothelial Growth Factor A | 2006 |
Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Blotting, Western; Camptothecin; Cell Line, Tumor; Cell Survival; Cells, Cultured; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Etoposide; Fluorouracil; Gemcitabine; Gene Expression; GPI-Linked Proteins; Hepatocytes; Humans; Immunohistochemistry; Irinotecan; Membrane Glycoproteins; Organoplatinum Compounds; Oxaliplatin; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; Receptors, Tumor Necrosis Factor, Member 10c; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor Decoy Receptors; Tumor Necrosis Factor-alpha | 2006 |
[Development of acute type, CD 8 positive adult T-cell leukemia in a carrier of hepatitis B virus--possible therapeutic effect of lamivudine combined with chemotherapy].
Topics: Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carrier State; CD8-Positive T-Lymphocytes; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Hepatitis B; HTLV-I Antibodies; Humans; Irinotecan; Lamivudine; Leukemia-Lymphoma, Adult T-Cell; Male; Middle Aged; Mitoxantrone; Nitrosourea Compounds; Pentostatin; Prednisone; Vincristine | 2006 |
[From ASCO and WCLC 2005 to clinical practice: "conventional" treatments].
Topics: Administration, Oral; Age Factors; Aged; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Etoposide; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Lung; Lung Neoplasms; Mediastinoscopy; Meta-Analysis as Topic; Middle Aged; Neoplasm Staging; Palliative Care; Pneumonectomy; Radiotherapy Dosage; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Taxoids; Time Factors; Topotecan | 2006 |
Inhibition of glutathione synthesis overcomes Bcl-2-mediated topoisomerase inhibitor resistance and induces nonapoptotic cell death via mitochondrial-independent pathway.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis Regulatory Proteins; Buthionine Sulfoximine; Camptothecin; Caspase 3; Caspase 7; Caspases; Cell Death; Cell Line, Tumor; DNA Topoisomerases, Type I; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Activation; Etoposide; Gene Expression Regulation, Leukemic; Glutathione; Humans; Irinotecan; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Topoisomerase I Inhibitors; Tumor Suppressor Protein p53 | 2006 |
[Collision cancer of squamous cell carcinoma and small cell carcinoma of the lung; report of a case].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Humans; Irinotecan; Lung Neoplasms; Lymph Node Excision; Male; Neoplasms, Multiple Primary; Pneumonectomy | 2006 |
DNA damage-inducing agent-elicited gamma-secretase activity is dependent on Bax/Bcl-2 pathway but not on caspase cascades.
Topics: Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Apoptosis; bcl-2-Associated X Protein; Camptothecin; Caspases; CHO Cells; Cricetinae; Cricetulus; DNA Damage; Etoposide; Signal Transduction | 2007 |
Development of an etoposide prodrug for dual prodrug-enzyme antitumor therapy.
Topics: Animals; Camptothecin; Carboxylesterase; Catalysis; Cell Division; Etoposide; Humans; Inhibitory Concentration 50; Irinotecan; Molecular Structure; Neuroblastoma; Prodrugs; Rabbits; Tumor Cells, Cultured | 2006 |
[A case of inoperable gastric small cell carcinoma effectively treated by chemotherapy and radiotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Drug Administration Schedule; Drug Combinations; Etoposide; Humans; Irinotecan; Lymph Nodes; Lymphatic Metastasis; Male; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Tegafur | 2006 |
The extracellular release of HMGB1 during apoptotic cell death.
Topics: Amino Acid Chloromethyl Ketones; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Line; Cycloheximide; Cysteine Proteinase Inhibitors; Enzyme Inhibitors; Etoposide; HMGB1 Protein; Humans; Hydroxamic Acids; Protein Synthesis Inhibitors; Staurosporine; Tumor Necrosis Factor-alpha | 2006 |
Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia/lymphoma agents against human leukemia/lymphoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Camptothecin; Carboplatin; Cell Line, Tumor; Cell Survival; Cyclophosphamide; Cytarabine; Depsipeptides; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Etoposide; Histone Deacetylase Inhibitors; HL-60 Cells; Humans; Imatinib Mesylate; Irinotecan; K562 Cells; Leukemia; Lymphoma; Mercaptopurine; Piperazines; Pyrimidines; Time Factors | 2007 |
[Lung cancer with bone metastasis].
Topics: Analgesics; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Diphosphonates; Docetaxel; Drug Administration Schedule; Etoposide; Fractures, Bone; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Pain, Intractable; Prognosis; Quinazolines; Radiotherapy Dosage; Taxoids | 2006 |
A non-invasive method for detection of intestinal mucositis induced by different classes of chemotherapy drugs in the rat.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Breath Tests; Camptothecin; Cyclophosphamide; Disease Models, Animal; DNA Topoisomerases, Type I; Doxorubicin; Etoposide; Female; Intestine, Small; Irinotecan; Mucositis; Rats; Sucrase; Sucrose; Topoisomerase I Inhibitors | 2006 |
Protocol consisting of cisplatin, etoposide and irinotecan induced complete pathological remission of primary small cell carcinoma of the bladder.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cisplatin; Etoposide; Humans; Irinotecan; Male; Neoadjuvant Therapy; Remission Induction; Urinary Bladder Neoplasms | 2006 |
Embryonic stem cells deficient for Brca2 or Blm exhibit divergent genotoxic profiles that support opposing activities during homologous recombination.
Topics: Adenosine Triphosphatases; Alkylating Agents; Animals; Antineoplastic Agents; BRCA2 Protein; Camptothecin; Cross-Linking Reagents; DNA Damage; DNA Helicases; Embryonic Stem Cells; Etoposide; Gene Expression Profiling; Mice; Nuclear Proteins; Reactive Oxygen Species; Recombination, Genetic; RecQ Helicases; Topoisomerase Inhibitors | 2006 |
Endonuclease G promotes cell death of non-invasive human breast cancer cells.
Topics: Animals; Apoptosis; Breast; Breast Neoplasms; Camptothecin; Cell Death; Cell Line, Tumor; Cell Movement; DNA Fragmentation; Endodeoxyribonucleases; Etoposide; Humans; Mice; Mice, Knockout; Transfection | 2006 |
Calcium-dependent regulation of NEMO nuclear export in response to genotoxic stimuli.
Topics: Active Transport, Cell Nucleus; Animals; Calcium Signaling; Camptothecin; Cell Line; Cell Nucleus; Chelating Agents; DNA Damage; Egtazic Acid; Enzyme Activation; Etoposide; Guanine Nucleotide Exchange Factors; Humans; I-kappa B Kinase; Ionomycin; Ionophores; NF-kappa B; Protein Binding; Protein Structure, Tertiary; Thapsigargin | 2007 |
Mode of action of the novel phenazine anticancer agents XR11576 and XR5944.
Topics: Annexin A5; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; ATP-Binding Cassette Transporters; bcl-X Protein; Blotting, Western; Camptothecin; Caspase 9; Cell Cycle; Cell Line, Tumor; DNA, Neoplasm; Drug Resistance, Neoplasm; Etoposide; Humans; Indicators and Reagents; Neoplasm Proteins; Phenazines; Topoisomerase I Inhibitors | 2007 |
Automated laser scanning cytometry: a powerful tool for multi-parameter analysis of drug-induced apoptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Membrane Permeability; CHO Cells; Cricetinae; Cricetulus; DNA Fragmentation; Etoposide; Laser Scanning Cytometry; Membrane Potential, Mitochondrial; Pyridines; Thiones | 2007 |
[Superficial small cell carcinoma of esophagus treated by endoscopic mucosal resection combined with chemoradiotherapy--a case report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Esophageal Neoplasms; Esophagectomy; Esophagoscopes; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Mucous Membrane | 2007 |
Iodine-131-metaiodobenzylguanidine therapy with reduced-intensity allogeneic stem cell transplantation in recurrent neuroblastoma.
Topics: 3-Iodobenzylguanidine; Adrenal Gland Neoplasms; Adrenalectomy; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Camptothecin; Child, Preschool; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Doxorubicin; Etoposide; Fatal Outcome; Female; Humans; Iodine Radioisotopes; Irinotecan; Neuroblastoma; Recurrence; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Vincristine | 2008 |
Does consolidation with autologous stem cell transplantation improve the outcome of children with metastatic or relapsed Ewing sarcoma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Carboplatin; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Epirubicin; Etoposide; Follow-Up Studies; Humans; Ifosfamide; Infection Control; Kaplan-Meier Estimate; Melphalan; Neoplasm Recurrence, Local; Peripheral Blood Stem Cell Transplantation; Postoperative Care; Retrospective Studies; Risk; Salvage Therapy; Sarcoma, Ewing; Topotecan; Transplantation Conditioning; Transplantation, Autologous; Treatment Failure; Vincristine | 2007 |
A novel form of ataxia oculomotor apraxia characterized by oxidative stress and apoptosis resistance.
Topics: Antineoplastic Agents, Phytogenic; Antioxidants; Apoptosis; Apraxias; Ataxia; Blotting, Western; Camptothecin; Cells, Cultured; DNA Breaks, Single-Stranded; DNA Damage; DNA Repair; Etoposide; Female; Flow Cytometry; Humans; Hydrogen Peroxide; Male; Membrane Potential, Mitochondrial; Methylnitronitrosoguanidine; Mitomycin; Oxidative Stress; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Radiation, Ionizing; Reactive Nitrogen Species | 2007 |
[Outpatient chemotherapy for lung cancer].
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Administration Schedule; Etoposide; Gefitinib; Gemcitabine; Humans; Informed Consent; Irinotecan; Lung Neoplasms; Neutropenia; Paclitaxel; Quality of Life; Quinazolines; Taxoids; Vinblastine; Vinorelbine | 2007 |
DNA topoisomerase inhibitor, etoposide, enhances GC-box-dependent promoter activity via Sp1 phosphorylation.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; DNA-Activated Protein Kinase; Enzyme Inhibitors; Etoposide; GC Rich Sequence; Humans; Irinotecan; Phosphorylation; Promoter Regions, Genetic; Sp1 Transcription Factor; Topoisomerase I Inhibitors; Transfection; Tumor Cells, Cultured | 2007 |
Cellular FLICE-inhibitory protein regulates chemotherapy-induced apoptosis in breast cancer cells.
Topics: Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Camptothecin; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase 8; Cell Line, Tumor; Dose-Response Relationship, Drug; Down-Regulation; Etoposide; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Interferon-gamma; Irinotecan; Mitoxantrone | 2007 |
A case of small cell carcinoma of the kidney.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Etoposide; Humans; Irinotecan; Kidney Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Piperidines | 2007 |
Isolated metastasis of lung cancer to the thyroid gland.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Large Cell; Carcinoma, Small Cell; CD56 Antigen; Chemotherapy, Adjuvant; Chromogranin A; Cisplatin; Combined Modality Therapy; Etoposide; Humans; Irinotecan; Lung Neoplasms; Male; Thyroid Neoplasms | 2007 |
Combination of topotecan and etoposide as a salvage treatment for patients with recurrent small cell lung cancer following irinotecan and platinum first-line chemotherapy.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Combined Modality Therapy; Endpoint Determination; Etoposide; Female; Hematologic Diseases; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Patient Compliance; Salvage Therapy; Topotecan | 2008 |
Effect of platinum combined with irinotecan or paclitaxel against large cell neuroendocrine carcinoma of the lung.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Cisplatin; Docetaxel; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Retrospective Studies; Taxoids; Vinblastine; Vinorelbine | 2007 |
DNA topoisomerases I and II in human mature sperm cells: characterization and unique properties.
Topics: Camptothecin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Etoposide; Humans; Male; Molecular Weight; Spermatozoa; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2007 |
Drug-induced Myc-mediated apoptosis of cancer cells is inhibited by stress protein Hsp70.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Camptothecin; Caspases; Cytochromes c; Enzyme Activation; Enzyme Inhibitors; Estrogens; Etoposide; Gene Expression Regulation, Neoplastic; HSP70 Heat-Shock Proteins; Humans; Lymphoma, Large B-Cell, Diffuse; Oncogene Proteins, Fusion; Proto-Oncogene Proteins c-myc; Translocation, Genetic; U937 Cells; Up-Regulation | 2007 |
Spinocerebellar ataxia with axonal neuropathy: consequence of a Tdp1 recessive neomorphic mutation?
Topics: Animals; Antineoplastic Agents; Axons; Bleomycin; Brain; Camptothecin; Cells, Cultured; Comet Assay; Embryo, Mammalian; Etoposide; Fibroblasts; Genes, Recessive; Humans; Irinotecan; Mice; Mice, Knockout; Mutation; Phosphoric Diester Hydrolases; Polyneuropathies; RNA, Messenger; Spinocerebellar Ataxias; Topotecan | 2007 |
Human mitochondrial transcription factor A possesses multiple subcellular targeting signals.
Topics: Amino Acid Sequence; Antineoplastic Agents; Camptothecin; Cell Line; Cell Nucleus; Cell Survival; Cisplatin; DNA-Binding Proteins; Drug Resistance; Etoposide; Green Fluorescent Proteins; HeLa Cells; Humans; Intracellular Space; Methionine; Microscopy, Confocal; Mitochondria; Mitochondrial Proteins; Molecular Sequence Data; Mutagenesis, Site-Directed; Mutation; Nuclear Localization Signals; Protein Biosynthesis; Recombinant Fusion Proteins; Sequence Homology, Amino Acid; Transcription Factors; Transfection | 2007 |
Ionizing radiation sensitivity of DNA polymerase lambda-deficient cells.
Topics: Animals; Camptothecin; Cell Line; Cell Survival; DNA Damage; DNA Polymerase beta; Etoposide; Genome; Genotype; Hydrogen Peroxide; Mice; Radiation Tolerance; Radiation, Ionizing | 2007 |
[A case of long-term survival of postoperative brain metastasis of small cell lung cancer effectively treated with chemotherapy, whole brain radiotherapy and stereotactic radiosurgery].
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Magnetic Resonance Imaging; Middle Aged; Radiosurgery; Time Factors; Tomography, X-Ray Computed | 2008 |
Costs associated with intravenous chemotherapy administration in patients with small cell lung cancer: a retrospective claims database analysis.
Topics: Administration, Oral; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Cisplatin; Cost-Benefit Analysis; Cyclophosphamide; Doxorubicin; Etoposide; Female; Health Care Costs; Humans; Infusions, Intravenous; Insurance Claim Review; Irinotecan; Male; Middle Aged; Retrospective Studies; Topotecan; United States; Vincristine | 2008 |
Topoisomerase inhibitors as anti-arthritic agents.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Camptothecin; Cattle; Cell Proliferation; Cells, Cultured; Chick Embryo; Chondrocytes; Doxorubicin; Enzyme Inhibitors; Etoposide; Interleukin-1; Naphthoquinones; Neutrophils; Rabbits; Synovial Membrane; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Vitamin K 3 | 2008 |
DNA damage-inducing agents elicit gamma-secretase activation mediated by oxidative stress.
Topics: Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Apoptosis; Camptothecin; CHO Cells; Cricetinae; Cricetulus; Cytochromes c; DNA Damage; Enzyme Activation; Etoposide; Glutathione; Humans; Mice; Mitochondria; Mitochondrial Membrane Transport Proteins; Mitochondrial Permeability Transition Pore; Oxidative Stress; Reactive Oxygen Species | 2008 |
Primary small cell carcinoma of the breast.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carboplatin; Carcinoma, Small Cell; Etoposide; Fatal Outcome; Female; Humans; Irinotecan; Liver Neoplasms; Mastectomy; Middle Aged; Neoplasm Recurrence, Local; Thoracic Wall | 2009 |
Cleavage-mediated activation of Chk1 during apoptosis.
Topics: Animals; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Camptothecin; Caspases; Cell Cycle Proteins; Cell Line; Checkpoint Kinase 1; Chickens; Cysteine Proteinase Inhibitors; Etoposide; Histones; Humans; Jurkat Cells; Models, Biological; Phosphorylation; Protein Kinases; Protein Serine-Threonine Kinases | 2008 |
[A case of small cell carcinoma of the ureter].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Etoposide; Humans; Irinotecan; Male; Ureteral Neoplasms | 2008 |
The Werner's syndrome 4330T>C (Cys1367Arg) gene variant does not affect the in vitro cytotoxicity of topoisomerase inhibitors and platinum compounds.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; B-Lymphocytes; Camptothecin; Carboplatin; Cell Proliferation; Cell Survival; Cells, Cultured; Cisplatin; Daunorubicin; Enzyme Inhibitors; Etoposide; Exodeoxyribonucleases; Genotype; Humans; Platinum Compounds; Polymorphism, Single Nucleotide; RecQ Helicases; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Topoisomerase Inhibitors; Werner Syndrome; Werner Syndrome Helicase | 2009 |
Enhanced antitumor therapy by inhibition of p21waf1 in human malignant mesothelioma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Cycle; Cell Line, Tumor; Cellular Senescence; Cyclin-Dependent Kinase Inhibitor p21; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Humans; Immunoblotting; In Situ Nick-End Labeling; Irinotecan; Male; Mesothelioma; Mice; Mice, Nude; RNA Interference; Transfection; Xenograft Model Antitumor Assays | 2008 |
2,2-dimethyl-2H-pyran-derived alkaloids I. Practical synthesis of acronycine and benzo[b]acronycine and their biological properties.
Topics: Acronine; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA; Drug Screening Assays, Antitumor; Etoposide; Humans; Indicators and Reagents; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2008 |
Distinct requirements for the Rad32(Mre11) nuclease and Ctp1(CtIP) in the removal of covalently bound topoisomerase I and II from DNA.
Topics: Camptothecin; Cell Nucleolus; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; DNA, Fungal; Etoposide; Exodeoxyribonucleases; Gamma Rays; Methyl Methanesulfonate; Mutant Proteins; Mutation; Protein Binding; Schizosaccharomyces; Schizosaccharomyces pombe Proteins | 2009 |
cIAP1, cIAP2, and XIAP act cooperatively via nonredundant pathways to regulate genotoxic stress-induced nuclear factor-kappaB activation.
Topics: Animals; Antineoplastic Agents; Baculoviral IAP Repeat-Containing 3 Protein; Camptothecin; Cells, Cultured; Doxorubicin; Etoposide; Extracellular Signal-Regulated MAP Kinases; Humans; I-kappa B Kinase; Inhibitor of Apoptosis Proteins; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Mice; NF-kappa B; Signal Transduction; Ubiquitin; Ubiquitin-Protein Ligases; X-Linked Inhibitor of Apoptosis Protein | 2009 |
PU.1, a novel caspase-3 substrate, partially contributes to chemotherapeutic agents-induced apoptosis in leukemic cells.
Topics: Antineoplastic Agents; Apoptosis; Aspartic Acid; Camptothecin; Caspase 3; Caspase Inhibitors; Cell Line, Tumor; Cysteine Proteinase Inhibitors; Etoposide; Humans; Leukemia; Mutagenesis, Site-Directed; Oligopeptides; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; RNA, Small Interfering; Trans-Activators | 2009 |
Nuclear translocation of dihydrofolate reductase is not a pre-requisite for DNA damage induced apoptosis.
Topics: Amino Acid Sequence; Apoptosis; Camptothecin; Caspase 3; Cell Line, Tumor; Cell Nucleus; DNA Damage; Dose-Response Relationship, Drug; Endoplasmic Reticulum; Enzyme Activation; Etoposide; Humans; Leukemia; Methotrexate; Microtubules; Molecular Sequence Data; Neoplasm Proteins; Protein Transport; Tetrahydrofolate Dehydrogenase | 2009 |
Cell-surface expression of Hsp70 on hematopoietic cancer cells after inhibition of HDAC activity.
Topics: Annexin A5; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; CD4-Positive T-Lymphocytes; Enzyme Inhibitors; Etoposide; Gene Expression Regulation, Neoplastic; Hematopoietic Stem Cells; Histone Deacetylase Inhibitors; Histone Deacetylases; HSP70 Heat-Shock Proteins; Humans; Jurkat Cells; K562 Cells; Neoplasm Proteins; Neoplastic Stem Cells; Sp1 Transcription Factor | 2009 |
Alveolar rhabdomyosarcoma of the extremity and nodal metastasis: Is the in-transit lymphatic system at risk?
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Camptothecin; Child; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Dactinomycin; Etoposide; Fatal Outcome; Female; Foot; Groin; Humans; Ifosfamide; Irinotecan; Lymph Node Excision; Lymphatic Metastasis; Lymphatic System; Male; Niacinamide; Phenylurea Compounds; Pyridines; Radiotherapy, Adjuvant; Radiotherapy, High-Energy; Rhabdomyosarcoma, Alveolar; Salvage Therapy; Soft Tissue Neoplasms; Sorafenib; Temozolomide; Thigh; Vincristine | 2009 |
The cellular phenotype of Roberts syndrome fibroblasts as revealed by ectopic expression of ESCO2.
Topics: Acetyltransferases; Camptothecin; Cell Cycle Proteins; Chromosomal Proteins, Non-Histone; Chromosome Aberrations; Chromosome Segregation; Cohesins; Congenital Abnormalities; DNA Damage; Etoposide; Fibroblasts; Growth Disorders; Humans; Infant; Male; Mitomycin; Nucleic Acid Synthesis Inhibitors; Sister Chromatid Exchange; Syndrome | 2009 |
Binding of DNA topoisomerases I and II to replication origins.
Topics: Animals; Antineoplastic Agents, Phytogenic; Base Sequence; Biological Assay; Camptothecin; Cell Cycle; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Enzyme Inhibitors; Etoposide; HeLa Cells; Humans; Lamin Type B; Molecular Sequence Data; Protein Binding; Replication Origin; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2009 |
Tunicamycin induces resistance to camptothecin and etoposide in human hepatocellular carcinoma cells: role of cell-cycle arrest and GRP78.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Drug Resistance, Neoplasm; Endoplasmic Reticulum Chaperone BiP; Etoposide; G1 Phase; Heat-Shock Proteins; Humans; Liver Neoplasms; Tunicamycin | 2009 |
Chemotherapy: Irinotecan or etoposide as front-line therapy for SCLC?
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Camptothecin; Carboplatin; Cisplatin; Clinical Trials, Phase III as Topic; Diarrhea; Drug Therapy; Drug Therapy, Combination; Enzyme Inhibitors; Ethnicity; Etoposide; Female; Follow-Up Studies; Glucuronosyltransferase; Humans; Irinotecan; Lung Neoplasms; Male; Neutropenia; Polymorphism, Genetic; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Survival Analysis; Therapeutic Equivalency; Time Factors; Treatment Outcome | 2009 |
A human 5'-tyrosyl DNA phosphodiesterase that repairs topoisomerase-mediated DNA damage.
Topics: Animals; Camptothecin; Cell Extracts; Cell Line, Tumor; DNA Breaks, Double-Stranded; DNA Breaks, Single-Stranded; DNA Damage; DNA Repair; DNA Topoisomerases; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Etoposide; Female; Gene Library; Genetic Complementation Test; Humans; Male; Mice; Nuclear Proteins; Phosphoric Diester Hydrolases; Saccharomyces cerevisiae; Suppression, Genetic; Transcription Factors | 2009 |
Differential modulation of BRCA1 and BARD1 nuclear localisation and foci assembly by DNA damage.
Topics: Active Transport, Cell Nucleus; Apoptosis; BRCA1 Protein; Camptothecin; Cell Line, Tumor; Cell Nucleolus; DNA Damage; DNA Repair; Down-Regulation; Etoposide; Humans; Leupeptins; Phosphorylation; Radiation, Ionizing; RNA, Small Interfering; Tumor Suppressor Proteins; Ubiquitin-Protein Ligases; Ultraviolet Rays | 2010 |
[Chemotherapy-induced myelosuppression and treatment efficacy in extensive-stage small cell lung cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Camptothecin; Carboplatin; Cisplatin; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Prognosis; Retrospective Studies; Small Cell Lung Carcinoma | 2009 |
Mechanism of action of an imidopiperidine inhibitor of human polynucleotide kinase/phosphatase.
Topics: Adenosine Triphosphate; Antineoplastic Agents, Phytogenic; Binding Sites; Camptothecin; Cell Survival; Circular Dichroism; DNA Ligase ATP; DNA Ligases; DNA Polymerase beta; DNA Repair; DNA Repair Enzymes; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Fluorescence Resonance Energy Transfer; Humans; Lung Neoplasms; Mutagenesis, Site-Directed; Phosphotransferases (Alcohol Group Acceptor); Photoelectron Spectroscopy; Piperidines; Poly-ADP-Ribose Binding Proteins; Protein Conformation; Pyrroles; Radiation-Sensitizing Agents; Tumor Cells, Cultured; Xenopus Proteins | 2010 |
[Chemotherapy-induced myelosuppression and treatment efficacy in limited-stage disease small cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Camptothecin; Etoposide; Female; Granulocyte Precursor Cells; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Platinum Compounds; Prognosis; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate | 2010 |
Dual inhibition of topoisomerases enhances apoptosis in melanoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Caspases; Cell Proliferation; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Etoposide; Humans; Immunoblotting; JNK Mitogen-Activated Protein Kinases; MAP Kinase Signaling System; Melanoma; Membrane Potential, Mitochondrial; Mutation; Oxidative Stress; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2010 |
Inhibition of hypoxia-inducible factor-1alpha (HIF-1alpha) protein synthesis by DNA damage inducing agents.
Topics: 5' Untranslated Regions; Apoptosis; Camptothecin; Cell Hypoxia; Cell Line; Cyclin-Dependent Kinases; DNA Damage; Etoposide; Eukaryotic Initiation Factor-2; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mitomycin; Phosphorylation; Protein Biosynthesis; Protein Processing, Post-Translational; Signal Transduction; Transcription, Genetic; Tumor Suppressor Protein p53 | 2010 |
[Hematological toxicity of some combined chemotherapy schemes involving aranoza].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Etoposide; Glycosides; Hematologic Tests; Irinotecan; Lymphopenia; Male; Methylnitrosourea; Mice; Mice, Inbred BALB C; Neutropenia; Topotecan | 2010 |
Poorly differentiated endocrine carcinoma of the pancreas responded to gemcitabine: Case report.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Differentiation; Cisplatin; Deoxycytidine; Drug Administration Schedule; Endocrine Gland Neoplasms; Etoposide; Gemcitabine; Humans; Ileus; Irinotecan; Male; Middle Aged; Pancreatic Neoplasms; Tomography, X-Ray Computed; Treatment Failure | 2010 |
Common arm comparative outcomes analysis of phase 3 trials of cisplatin + irinotecan versus cisplatin + etoposide in extensive stage small cell lung cancer: final patient-level results from Japan Clinical Oncology Group 9511 and Southwest Oncology Group 0
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Etoposide; Female; Humans; Irinotecan; Japan; Lung Neoplasms; Male; Middle Aged; Small Cell Lung Carcinoma; Treatment Outcome | 2010 |
ATM- and NEMO-dependent ELKS ubiquitination coordinates TAK1-mediated IKK activation in response to genotoxic stress.
Topics: Adaptor Proteins, Signal Transducing; Animals; Ataxia Telangiectasia Mutated Proteins; Camptothecin; Carrier Proteins; Cell Cycle Proteins; Cell Line; DNA Damage; DNA-Binding Proteins; Enzyme Activation; Etoposide; Humans; I-kappa B Kinase; Intracellular Signaling Peptides and Proteins; Male; MAP Kinase Kinase Kinases; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Morpholines; Mutation; Nerve Tissue Proteins; NF-kappa B; Phosphorylation; Protein Binding; Protein Serine-Threonine Kinases; Pyrones; rab GTP-Binding Proteins; RNA Interference; Signal Transduction; Time Factors; Transfection; Tumor Necrosis Factor-alpha; Tumor Suppressor Proteins; Ubiquitin-Conjugating Enzymes; Ubiquitination; X-Linked Inhibitor of Apoptosis Protein | 2010 |
Phase II study of dose-intense chemotherapy with sequential topoisomerase-targeting regimens with irinotecan/oxaliplatin followed by etoposide/carboplatin in chemotherapy naive patients with extensive small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antigens, Neoplasm; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Disease-Free Survival; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Endonucleases; Etoposide; Female; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Analysis | 2011 |
A retrospective analysis of non-platinum-based first- and second-line chemotherapy in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Etoposide; Female; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pemetrexed; Piperidines; Quinazolines; Retrospective Studies; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
Effects of camptothecin, etoposide and Ca2+ on caspase-3 activity and myofibrillar disruption of chicken during postmortem ageing.
Topics: Animals; Apoptosis; Avian Proteins; Calcium Chloride; Camptothecin; Caspase 3; Caspase Inhibitors; Chickens; Etoposide; Female; Food Handling; Meat; Microscopy, Electron, Transmission; Muscle Proteins; Myofibrils; Peptide Fragments; Spectrin; Time Factors; Topoisomerase Inhibitors; Troponin T | 2011 |
Infratentorial brain metastases of pediatric non-epithelial malignant tumors: three case reports.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carboplatin; Chemotherapy, Adjuvant; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Dactinomycin; Doxorubicin; Etoposide; Humans; Ifosfamide; Infant; Infratentorial Neoplasms; Irinotecan; Melphalan; Neoplasm Metastasis; Neuroblastoma; Rhabdomyosarcoma; Thiotepa; Topotecan; Vincristine | 2011 |
Apoptosis induced clustering of IP(3)R1 in nuclei of non-differentiated PC12 cells.
Topics: Active Transport, Cell Nucleus; Animals; Apoptosis; bcl-2-Associated X Protein; Boron Compounds; Calcium; Camptothecin; Caspase 3; Cell Differentiation; Cell Nucleus; Cycloheximide; Dactinomycin; Dexamethasone; Etoposide; Inositol 1,4,5-Trisphosphate Receptors; PC12 Cells; Permeability; Rats; RNA, Messenger; Time Factors; Up-Regulation | 2011 |
Inhibition of unwinding and ATPase activities of pea MCM6 DNA helicase by actinomycin and nogalamycin.
Topics: Adenosine Triphosphatases; Camptothecin; Cisplatin; Dactinomycin; Daunorubicin; DNA Helicases; Ellipticines; Enzyme Inhibitors; Etoposide; Intercalating Agents; Mitoxantrone; Nogalamycin; Novobiocin; Pisum sativum; Plant Proteins | 2011 |
Amyloid precursor protein binding protein Fe65 is cleaved by caspases during DNA damage-induced apoptosis.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Apoptosis; Camptothecin; Caspases; Cell Line, Tumor; Cytotoxins; DNA Damage; Dose-Response Relationship, Drug; Enzyme Inhibitors; Etoposide; Humans; Nerve Tissue Proteins; Neuroblastoma; Neurons; Nuclear Proteins; Signal Transduction | 2011 |
Cytotoxic T lymphocytes efficiently recognize human colon cancer stem-like cells.
Topics: Animals; Antigens; Antineoplastic Agents; Benzimidazoles; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Etoposide; Humans; Irinotecan; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Transplantation; Neoplastic Stem Cells; Peptides; T-Lymphocytes, Cytotoxic | 2011 |
A FGFR2 inhibitor, Ki23057, enhances the chemosensitivity of drug-resistant gastric cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Camptothecin; Cell Proliferation; Deoxycytidine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Drug Synergism; Endonucleases; Etoposide; Gemcitabine; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Quinolines; Receptor, Fibroblast Growth Factor, Type 2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Stomach Neoplasms; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2011 |
Impact of induction chemotherapy on estimated risk of radiation pneumonitis in small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Combined Modality Therapy; Etoposide; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiation Pneumonitis; Radiotherapy, Conformal; Retrospective Studies; Risk Assessment; Small Cell Lung Carcinoma; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
Wipe sampling procedure coupled to LC-MS/MS analysis for the simultaneous determination of 10 cytotoxic drugs on different surfaces.
Topics: Antineoplastic Agents; Camptothecin; Chromatography, Liquid; Cyclophosphamide; Cytarabine; Deoxycytidine; Doxorubicin; Epirubicin; Etoposide; Gemcitabine; Ifosfamide; Irinotecan; Methotrexate; Organophosphorus Compounds; Surface Properties; Tandem Mass Spectrometry; Vincristine | 2012 |
Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Camptothecin; Carcinoma, Hepatocellular; Cell Death; Cell Nucleus; Cytoplasm; Deoxycytidine; Doxorubicin; Drug Synergism; Etoposide; Female; Fluorouracil; Gemcitabine; Genes, p53; Humans; Irinotecan; Liver Neoplasms; Mice; Microtubule-Associated Proteins; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Pyridines; Quinacrine; Receptors, TNF-Related Apoptosis-Inducing Ligand; RNA, Small Interfering; Sorafenib; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2011 |
Suppression of autophagy by FIP200 deletion impairs DNA damage repair and increases cell death upon treatments with anticancer agents.
Topics: Animals; Anticarcinogenic Agents; Autophagy; Autophagy-Related Proteins; Camptothecin; DNA Damage; DNA Repair; Etoposide; Fibroblasts; Intracellular Signaling Peptides and Proteins; Mice; RNA, Small Interfering; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Transcription Factor TFIIH; Transcription Factors | 2011 |
Five hundred patients with Merkel cell carcinoma evaluated at a single institution.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Merkel Cell; Cisplatin; Etoposide; Female; Follow-Up Studies; Humans; Infusion Pumps; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Research Design; Skin Neoplasms; Treatment Outcome | 2011 |
Higher DNA repair activity is related with longer replicative life span in mammalian embryonic fibroblast cells.
Topics: Animals; Camptothecin; Cell Proliferation; Cell Survival; Cells, Cultured; Cellular Senescence; Cisplatin; DNA Damage; DNA Repair; Dogs; Dose-Response Relationship, Drug; Embryo, Mammalian; Etoposide; Fibroblasts; Humans; Hydrogen Peroxide; Mice; Mice, Inbred ICR; Rats; Rats, Sprague-Dawley | 2011 |
Enhanced antitumor efficacy of low-dose Etoposide with oncolytic herpes simplex virus in human glioblastoma stem cell xenografts.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Brain Neoplasms; Camptothecin; Cell Cycle; Cell Line, Tumor; Combined Modality Therapy; Etoposide; Glioblastoma; Humans; Irinotecan; Mice; Mice, Nude; Neural Stem Cells; Oncolytic Virotherapy; Oncolytic Viruses; Simplexvirus; Topoisomerase I Inhibitors; Xenograft Model Antitumor Assays | 2011 |
Overexpression of BMI-1 correlates with drug resistance in B-cell lymphoma cells through the stabilization of survivin expression.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Camptothecin; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; Irinotecan; Lymphoma, B-Cell; Nuclear Proteins; Organoplatinum Compounds; Oxaliplatin; Polycomb Repressive Complex 1; Proto-Oncogene Proteins; Repressor Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Survivin; Tumor Cells, Cultured | 2012 |
Avastin: more questions than answers. . .
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Chemoradiotherapy; Dacarbazine; Etoposide; Female; Glioblastoma; Glioma; Humans; Male; Neoplasm Recurrence, Local; Salvage Therapy; Supratentorial Neoplasms; Temozolomide | 2012 |
Rapid detection of apoptosis in mammalian cells by using intact cell MALDI mass spectrometry.
Topics: Animals; Apoptosis; Camptothecin; Cell Line; Diterpenes; Dogs; Etoposide; Humans; Mice; Propidium; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2011 |
Relationship of DNA damage signaling to DNA replication following treatment with DNA topoisomerase inhibitors camptothecin/topotecan, mitoxantrone, or etoposide.
Topics: Camptothecin; Cell Line, Tumor; DNA Damage; DNA Replication; Etoposide; Histones; Humans; Mitoxantrone; Phosphorylation; Signal Transduction; Topoisomerase Inhibitors; Topotecan | 2012 |
Reliability of tumor primary cultures as a model for drug response prediction: expression profiles comparison of tissues versus primary cultures from colorectal cancer patients.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Down-Regulation; Doxorubicin; Etoposide; Floxuridine; Fluorescent Antibody Technique; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genomic Instability; Humans; Irinotecan; Metaphase; Paclitaxel; Polymerase Chain Reaction; Predictive Value of Tests; Protein Array Analysis; Reproducibility of Results; Tegafur; Tissue Array Analysis; Tumor Cells, Cultured; Up-Regulation; Uracil | 2012 |
Dual-mode interaction between quercetin and DNA-damaging drugs in cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Cyclin B1; Cyclin-Dependent Kinase Inhibitor p21; DNA Damage; Drug Synergism; Etoposide; Flow Cytometry; Fluorouracil; Humans; Inhibitor of Apoptosis Proteins; Male; Prostatic Neoplasms; Quercetin; Survivin; Tumor Stem Cell Assay; Tumor Suppressor Protein p53 | 2012 |
Hypoxia-inducible factor-1α and excision repair cross-complementing 1 in patients with small cell lung cancer who received front-line platinum-based chemotherapy: a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Brain Neoplasms; Camptothecin; Carboplatin; Cisplatin; DNA-Binding Proteins; Endonucleases; Etoposide; Female; Follow-Up Studies; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunoenzyme Techniques; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate | 2012 |
HADHA is a potential predictor of response to platinum-based chemotherapy for lung cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Electrophoresis, Gel, Two-Dimensional; Etoposide; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Mitochondrial Trifunctional Protein; Mitochondrial Trifunctional Protein, alpha Subunit; Multienzyme Complexes; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Small Cell Lung Carcinoma; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tumor Cells, Cultured | 2011 |
Characterization of DDRI-18 (3,3'-(1H,3'H-5,5'-bibenzo[d]imidazole-2,2'-diyl)dianiline), a novel small molecule inhibitor modulating the DNA damage response.
Topics: Aniline Compounds; Antineoplastic Agents; Benzimidazoles; Bleomycin; Camptothecin; Cell Line, Tumor; DNA Damage; DNA Repair; Drug Synergism; Etoposide; Humans | 2012 |
Comparison of caspase-3 activation in tumor cells upon treatment of chemotherapeutic drugs using capillary electrophoresis.
Topics: Antineoplastic Agents; Camptothecin; Caspase 3; Cisplatin; Drug Screening Assays, Antitumor; Electrophoresis, Capillary; Enzyme Activation; Etoposide; HeLa Cells; Hep G2 Cells; Humans; Neoplasms; Time Factors; Tumor Necrosis Factor-alpha | 2012 |
p21 promotes error-free replication-coupled DNA double-strand break repair.
Topics: Animals; BRCA2 Protein; Camptothecin; Chromosomal Instability; Cross-Linking Reagents; Cyclin-Dependent Kinase Inhibitor p21; DNA Breaks, Double-Stranded; DNA End-Joining Repair; DNA Repair; DNA Repair Enzymes; DNA Replication; DNA-Binding Proteins; Etoposide; G1 Phase Cell Cycle Checkpoints; HCT116 Cells; HeLa Cells; Humans; Mice; Mitomycin; MRE11 Homologue Protein; Phosphorylation; Recombinational DNA Repair; Topoisomerase Inhibitors | 2012 |
Functional switching of ATM: sensor of DNA damage in proliferating cells and mediator of Akt survival signal in post-mitotic human neuron-like cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Ataxia Telangiectasia; Ataxia Telangiectasia Mutated Proteins; Camptothecin; Cell Cycle Proteins; Cell Differentiation; Cell Line, Tumor; DNA Damage; DNA-Binding Proteins; Etoposide; Histones; Humans; Morpholines; Neuroblastoma; Neurons; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Pyrones; Signal Transduction; Topoisomerase Inhibitors; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2012 |
Normal serum CA125 half-life and normal serum nadir CA125 level in patients with ovarian cancers.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-125 Antigen; Camptothecin; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Cyclophosphamide; Docetaxel; Doxorubicin; Etoposide; Female; Half-Life; Humans; Irinotecan; Linear Models; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Reference Values; Remission Induction; Taxoids | 2012 |
A high-throughput, flow cytometry-based method to quantify DNA-end resection in mammalian cells.
Topics: Camptothecin; Cell Line, Tumor; Cell Proliferation; DNA Breaks, Double-Stranded; DNA Damage; DNA Repair; DNA, Single-Stranded; Etoposide; Flow Cytometry; High-Throughput Screening Assays; Homologous Recombination; Humans; Replication Protein A; Staining and Labeling | 2012 |
FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Camptothecin; Carcinoma, Neuroendocrine; Disease-Free Survival; Etoposide; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Grading; Pancreatic Neoplasms; Pelvic Neoplasms; Platinum; Treatment Outcome | 2012 |
Subpopulation of small-cell lung cancer cells expressing CD133 and CD87 show resistance to chemotherapy.
Topics: AC133 Antigen; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Animals; Anthracyclines; Antigens, CD; Biomarkers, Tumor; Camptothecin; Cell Cycle; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Etoposide; Glycoproteins; Humans; Irinotecan; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Neoplastic Stem Cells; Paclitaxel; Peptides; Receptors, Urokinase Plasminogen Activator; Retinal Dehydrogenase; RNA, Messenger; Small Cell Lung Carcinoma | 2013 |
α6 Integrin and CD44 enrich for a primary keratinocyte population that displays resistance to UV-induced apoptosis.
Topics: Androstadienes; Antineoplastic Agents; Apoptosis; Benzamides; Camptothecin; Cell Proliferation; Cells, Cultured; Cisplatin; Drug Resistance; Etoposide; Fluorescent Antibody Technique; Gene Expression; Humans; Hyaluronan Receptors; Imatinib Mesylate; Integrin alpha6; Keratinocytes; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Primary Cell Culture; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Transcription Factors; Tumor Suppressor Proteins; Ultraviolet Rays; Wortmannin | 2012 |
5-day/5-drug myeloablative outpatient regimen for resistant neuroblastoma.
Topics: 3-Iodobenzylguanidine; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Irinotecan; Male; Neuroblastoma; Outpatients; Radionuclide Imaging; Radiopharmaceuticals; Retrospective Studies; Salvage Therapy; Temozolomide | 2013 |
Pharmacological inhibition of GSK3 attenuates DNA damage-induced apoptosis via reduction of p53 mitochondrial translocation and Bax oligomerization in neuroblastoma SH-SY5Y cells.
Topics: Antibiotics, Antineoplastic; Apoptosis; bcl-2-Associated X Protein; bcl-Associated Death Protein; Camptothecin; Caspase 3; Cell Line, Tumor; Cytochromes c; DNA Damage; Doxorubicin; Etoposide; Gene Expression Regulation; Glycogen Synthase Kinase 3; Humans; Mitochondria; Neuroblastoma; Poly(ADP-ribose) Polymerases; Protein Multimerization; Protein Transport; Signal Transduction; Tumor Suppressor Protein p53 | 2013 |
Quantification and study of the L-DOPA decarboxylase expression in gastric adenocarcinoma cells treated with chemotherapeutic substances.
Topics: Adenocarcinoma; Antineoplastic Agents; Camptothecin; Cisplatin; Dopa Decarboxylase; Dose-Response Relationship, Drug; Etoposide; Fluorouracil; Gene Expression Regulation, Enzymologic; Humans; Irinotecan; Leucovorin; Paclitaxel; Real-Time Polymerase Chain Reaction; RNA, Messenger; Stomach Neoplasms | 2013 |
Evaluation of novel orthotopic nude mouse models for human small-cell lung cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Proliferation; Cisplatin; Etoposide; Humans; Irinotecan; Lung Neoplasms; Mice; Mice, Nude; Necrosis; Paclitaxel; Small Cell Lung Carcinoma; Tumor Cells, Cultured | 2013 |
STK295900, a dual inhibitor of topoisomerase 1 and 2, induces G(2) arrest in the absence of DNA damage.
Topics: Aniline Compounds; Antineoplastic Agents, Phytogenic; Benzimidazoles; Camptothecin; CDC2 Protein Kinase; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Damage; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA, Neoplasm; Dose-Response Relationship, Drug; Etoposide; G2 Phase Cell Cycle Checkpoints; HCT116 Cells; HeLa Cells; Hep G2 Cells; HT29 Cells; Humans; Immunoblotting; MCF-7 Cells; Molecular Structure; Neoplasms; Phosphorylation; Topoisomerase Inhibitors | 2013 |
Efficacy of rechallenge chemotherapy in patients with sensitive relapsed small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Cohort Studies; Etoposide; Female; Humans; Induction Chemotherapy; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Small Cell Lung Carcinoma; Time Factors; Topotecan; Treatment Outcome | 2015 |
NF-κB is a critical mediator of BRCA1-induced chemoresistance.
Topics: Apoptosis; BRCA1 Protein; Camptothecin; Cell Line, Tumor; DNA Damage; Drug Resistance, Neoplasm; Etoposide; HEK293 Cells; Humans; NF-kappa B; NF-kappa B p50 Subunit; Promoter Regions, Genetic; Proto-Oncogene Proteins c-bcl-2; Transcription Factor RelA; Transcription, Genetic; Transfection | 2014 |
Preclinical evaluation of a novel ATM inhibitor, KU59403, in vitro and in vivo in p53 functional and dysfunctional models of human cancer.
Topics: Animals; Ataxia Telangiectasia Mutated Proteins; Camptothecin; Clinical Trials as Topic; DNA-Binding Proteins; Doxorubicin; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; HCT116 Cells; Heterocyclic Compounds, 3-Ring; Humans; Mice; Neoplasms; Pyrones; Radiation-Sensitizing Agents; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2013 |
Relapse in medulloblastoma: what can be done after abandoning high-dose chemotherapy? A mono-institutional experience.
Topics: Administration, Intravenous; Administration, Oral; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Cerebellar Neoplasms; Child; Child, Preschool; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cranial Irradiation; Dacarbazine; Deoxycytidine; Disease Progression; Disease-Free Survival; Etoposide; Female; Gemcitabine; Humans; Irinotecan; Male; Medulloblastoma; Melphalan; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Quality of Life; Radiotherapy; Retrospective Studies; Salvage Therapy; Temozolomide; Young Adult | 2013 |
Lab-on-a-Chip for anticancer drug screening using quantum dots probe based apoptosis assay.
Topics: Antineoplastic Agents; Apoptosis; Biological Assay; Camptothecin; Cell Line, Tumor; Cell Survival; Computer Simulation; Drug Screening Assays, Antitumor; Etoposide; Humans; Lab-On-A-Chip Devices; Quantum Dots | 2013 |
Treatment of small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Combined Modality Therapy; Etoposide; Evidence-Based Medicine; Humans; Irinotecan; Lung Neoplasms; Neoplasm Staging; Patient Selection; Platinum Compounds; Positron-Emission Tomography | 2013 |
Chiral ruthenium(II) complexes with phenolic hydroxyl groups as dual poisons of topoisomerases I and IIα.
Topics: Apoptosis; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Chemistry, Pharmaceutical; Comet Assay; DNA; DNA Damage; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Design; Drug Screening Assays, Antitumor; Etoposide; Humans; Inhibitory Concentration 50; Protein Binding; Ruthenium; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2013 |
Irinotecan, vincristine, cisplatin, cyclophosphamide, and etoposide for refractory or relapsed medulloblastoma/PNET in pediatric patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Chemoradiotherapy; Child; Child, Preschool; Cisplatin; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Irinotecan; Male; Medulloblastoma; Neoplasm Recurrence, Local; Neuroectodermal Tumors, Primitive, Peripheral; Radiotherapy; Retrospective Studies; Salvage Therapy; Vincristine; Young Adult | 2013 |
Eukaryotic translation elongation factor 1-alpha 1 inhibits p53 and p73 dependent apoptosis and chemotherapy sensitivity.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cisplatin; DNA-Binding Proteins; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Gene Expression; Gene Knockdown Techniques; HEK293 Cells; HeLa Cells; Humans; Nuclear Proteins; Peptide Elongation Factor 1; RNA, Small Interfering; Tumor Protein p73; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2013 |
Sequential chemotherapies for advanced gastric cancer: a retrospective analysis of 111 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Epirubicin; Etoposide; Female; Fluorouracil; Gemcitabine; Germany; Hospitals, University; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Prognosis; Retrospective Studies; Salvage Therapy; Stomach Neoplasms; Taxoids; Treatment Outcome | 2013 |
CARS based label-free assay for assessment of drugs by monitoring lipid droplets in tumour cells.
Topics: Algorithms; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cytoplasm; Drug Screening Assays, Antitumor; Etoposide; Fluorescent Dyes; HCT116 Cells; Humans; Lipid Droplets; Lipids; Microscopy, Fluorescence; Neoplasms; Spectrum Analysis, Raman; Staurosporine | 2014 |
Long-term survival of a patient with extensive small cell carcinoma of unknown primary etiology complicated by nephrotic syndrome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Combined Modality Therapy; Cranial Irradiation; Edema; Etoposide; Glomerulonephritis, Membranous; Humans; Irinotecan; Lymphatic Metastasis; Neoplasms, Unknown Primary; Nephrotic Syndrome; Paraneoplastic Syndromes; Pleural Effusion, Malignant; Proteinuria; Radiotherapy, Adjuvant; Remission Induction; Tomography, X-Ray Computed | 2014 |
DNA damage response (DDR) via NKX3.1 expression in prostate cells.
Topics: Acid Anhydride Hydrolases; Ataxia Telangiectasia Mutated Proteins; Camptothecin; Cell Cycle; Cell Line, Tumor; Cyclin D1; DNA Damage; DNA Repair; DNA Repair Enzymes; DNA-Activated Protein Kinase; DNA-Binding Proteins; Doxorubicin; Etoposide; Histones; Homeodomain Proteins; Humans; Hydrogen Peroxide; Irinotecan; Male; Metribolone; Mutagens; Phosphorylation; Prostatic Neoplasms; Protein Processing, Post-Translational; Testosterone Congeners; Transcription Factors | 2014 |
Cisplatin versus carboplatin-based regimens for the treatment of patients with metastatic lung cancer. An analysis of Veterans Health Administration data.
Topics: Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Etoposide; Female; Gemcitabine; Glutamates; Guanine; Hospitalization; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pemetrexed; Registries; Retrospective Studies; Survival Rate; Taxoids; United States; United States Department of Veterans Affairs; Vinblastine; Vinorelbine | 2014 |
Survivin family proteins as novel molecular determinants of doxorubicin resistance in organotypic human breast tumors.
Topics: Alternative Splicing; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Damage; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Female; High-Throughput Screening Assays; Humans; Imidazoles; Inhibitor of Apoptosis Proteins; MCF-7 Cells; Naphthoquinones; Paclitaxel; Receptor, ErbB-2; Survivin; Tumor Suppressor Protein p53 | 2014 |
UGT1A1 *6 polymorphism predicts outcome in elderly patients with relapsed or refractory diffuse large B-cell lymphoma treated with carboplatin, dexamethasone, etoposide and irinotecan.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Dexamethasone; Etoposide; Female; Follow-Up Studies; Glucuronosyltransferase; Humans; Irinotecan; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Polymorphism, Genetic; Prospective Studies; Recurrence; Treatment Outcome | 2015 |
Inhibitors of histone deacetylases enhance neurotoxicity of DNA damage.
Topics: Animals; Animals, Newborn; Antineoplastic Agents; Apoptosis; Benzamides; Camptothecin; Cells, Cultured; Cerebral Cortex; Cisplatin; Dizocilpine Maleate; DNA Breaks, Double-Stranded; Etoposide; Genes, p53; Histone Deacetylase 1; Histone Deacetylase Inhibitors; Hydroxamic Acids; Injections, Intraventricular; Neurons; Phosphorylation; Point Mutation; Protein Processing, Post-Translational; Pyridines; Rats; Rats, Sprague-Dawley; Tumor Suppressor Protein p53; Vorinostat | 2014 |
Adjuvant chemotherapy in patients with completely resected small cell lung cancer: a retrospective analysis of 26 consecutive cases.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Small Cell Lung Carcinoma; Treatment Outcome | 2014 |
Modification of topoisomerases in mammospheres derived from breast cancer cell line: clinical implications for combined treatments with tyrosine kinase inhibitors.
Topics: Animals; Antigens, Surface; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Cell Survival; DNA Topoisomerases; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Synergism; Enzyme Activation; Etoposide; Female; Gefitinib; Humans; Immunophenotyping; MCF-7 Cells; Mice; Neoplastic Stem Cells; Quinazolines; Spheroids, Cellular; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 2014 |
BMX Negatively Regulates BAK Function, Thereby Increasing Apoptotic Resistance to Chemotherapeutic Drugs.
Topics: Antineoplastic Agents; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Male; Phosphorylation; Prostatic Neoplasms; Protein Processing, Post-Translational; Protein Tyrosine Phosphatases, Non-Receptor; Protein-Tyrosine Kinases | 2015 |
Extrapulmonary small cell carcinoma in head and neck.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Disease Progression; Drug Combinations; Etoposide; Female; Head and Neck Neoplasms; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Radiotherapy, Adjuvant; Survival Rate; Tegafur | 2015 |
Telomerase reverse transcriptase expression protects transformed human cells against DNA-damaging agents, and increases tolerance to chromosomal instability.
Topics: Camptothecin; Cell Line, Transformed; Chromosomal Instability; DNA Breaks, Double-Stranded; DNA Damage; DNA Repair; Etoposide; Humans; Irinotecan; Mitosis; Mutation; Organoplatinum Compounds; Oxaliplatin; Recombinant Proteins; Telomerase; Telomere | 2016 |
Prognosis of small cell lung cancer patients with diabetes treated with metformin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Case-Control Studies; Chemotherapy, Adjuvant; Cohort Studies; Diabetes Mellitus, Type 2; Etoposide; Female; Humans; Hypoglycemic Agents; Irinotecan; Lung Neoplasms; Male; Metformin; Middle Aged; Multivariate Analysis; Platinum Compounds; Pneumonectomy; Prognosis; Proportional Hazards Models; Retrospective Studies; Small Cell Lung Carcinoma | 2015 |
Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Etoposide; Female; Fluorouracil; Humans; Ki-67 Antigen; Leucovorin; Male; Middle Aged; Neuroendocrine Tumors; Organoplatinum Compounds; Pancreatic Neoplasms; Prognosis; Survival Analysis; Young Adult | 2015 |
Irinotecan and nedaplatin as salvage therapy for patients with advanced germ cell tumors following intensive treatment with cisplatin-based combination chemotherapies.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bleomycin; Camptothecin; Cisplatin; Etoposide; Humans; Ifosfamide; Irinotecan; Middle Aged; Neoplasms, Germ Cell and Embryonal; Organoplatinum Compounds; Paclitaxel; Retreatment; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome; Young Adult | 2016 |
Restoration of CBX7 expression increases the susceptibility of human lung carcinoma cells to irinotecan treatment.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Lung Neoplasms; Polycomb Repressive Complex 1; RNA, Messenger | 2015 |
Modified 2,4-diaryl-5H-indeno[1,2-b]pyridines with hydroxyl and chlorine moiety: Synthesis, anticancer activity, and structure-activity relationship study.
Topics: Antineoplastic Agents; Camptothecin; Etoposide; HeLa Cells; Humans; Indenes; Pyridines; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2015 |
Chemoradiation for High-grade Neuroendocrine Carcinoma of the Rectum and Anal Canal.
Topics: Adult; Aged; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Camptothecin; Capecitabine; Carboplatin; Carcinoma, Neuroendocrine; Chemoradiotherapy; Cisplatin; Consolidation Chemotherapy; Diarrhea; Digestive System Surgical Procedures; Disease-Free Survival; Etoposide; Female; Fluorouracil; Humans; Induction Chemotherapy; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Pelvis; Radiation Injuries; Radiodermatitis; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Rectal Neoplasms; Rectum; Retrospective Studies; Survival Rate; Tumor Burden | 2017 |
Comparison of the Efficacy between Pemetrexed plus Platinum and Non-Pemetrexed plus Platinum as First-Line Treatment in Patients with Wild-Type Epidermal Growth Factor Receptor Nonsquamous Non-Small Cell Lung Cancer: A Retrospective Analysis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; ErbB Receptors; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Pemetrexed; Prognosis; Retrospective Studies; Survival Rate; Vinblastine; Vinorelbine | 2016 |
Nitric Oxide Down-Regulates Topoisomerase I and Induces Camptothecin Resistance in Human Breast MCF-7 Tumor Cells.
Topics: Breast Neoplasms; Camptothecin; Cell Survival; DNA Topoisomerases, Type I; Down-Regulation; Drug Resistance, Neoplasm; Etoposide; HT29 Cells; Humans; MCF-7 Cells; Nitric Oxide; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Up-Regulation | 2015 |
Mesenchymal stem cells exhibit resistance to topoisomerase inhibition.
Topics: Apoptosis; Camptothecin; Cell Adhesion; Cell Differentiation; Cell Movement; Cells, Cultured; Drug Resistance; Etoposide; Fibroblasts; Humans; Irinotecan; MCF-7 Cells; Mesenchymal Stem Cells; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2016 |
Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a new pair of resistance-associated mutations.
Topics: Benzodioxoles; Binding Sites; Camptothecin; Cell Line, Tumor; Chromosome Deletion; Colonic Neoplasms; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Epirubicin; Etoposide; Gene Dosage; Guanidines; HCT116 Cells; HT29 Cells; Humans; Hydrazones; Irinotecan; Isoquinolines; Mutation | 2016 |
The Shu complex promotes error-free tolerance of alkylation-induced base excision repair products.
Topics: Adenine; Alkylation; Camptothecin; Cisplatin; DNA Damage; DNA Polymerase beta; DNA Repair; DNA, Fungal; Epistasis, Genetic; Etoposide; Genes, Fungal; Genetic Loci; Homologous Recombination; Humans; Hydrogen Peroxide; Hydroxyurea; Methyl Methanesulfonate; Models, Biological; Mutation; Mutation Rate; Protein Binding; Radiation, Ionizing; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Ultraviolet Rays | 2016 |
Low level phosphorylation of histone H2AX on serine 139 (γH2AX) is not associated with DNA double-strand breaks.
Topics: A549 Cells; Camptothecin; DNA Breaks, Double-Stranded; DNA Damage; Etoposide; Histones; Humans; Microscopy, Confocal; Mitoxantrone; Phosphorylation; Serine; Tumor Suppressor p53-Binding Protein 1 | 2016 |
Comparison of Amrubicin and Weekly Cisplatin/Etoposide/Irinotecan in Patients With Relapsed Small-cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Etoposide; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate; Young Adult | 2017 |
DNA breaks and chromatin structural changes enhance the transcription of autoimmune regulator target genes.
Topics: AIRE Protein; Alternative Splicing; Antigens, Neoplasm; Camptothecin; Carcinoembryonic Antigen; Chromatin; DNA Damage; DNA Topoisomerases, Type II; DNA-Binding Proteins; Etoposide; Gene Expression Profiling; GPI-Linked Proteins; HEK293 Cells; Histones; HMGB1 Protein; Humans; Multigene Family; Mutation; Poly-ADP-Ribose Binding Proteins; Promoter Regions, Genetic; Protein Domains; Sequence Analysis, RNA; Transcription Factors; Transcription, Genetic; Transcriptional Activation | 2017 |
Sensitivity to
Topics: Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Brain Neoplasms; Camptothecin; Cell Cycle Proteins; Cell Line, Tumor; Etoposide; Gene Expression Profiling; Glioblastoma; Humans; Irinotecan; Protein Serine-Threonine Kinases; RNA, Messenger | 2017 |
Paclitaxel as third-line chemotherapy for small cell lung cancer failing both etoposide- and camptothecin-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease-Free Survival; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Paclitaxel; Retrospective Studies; Small Cell Lung Carcinoma; Treatment Outcome | 2017 |
Monophosphorylation by deoxycytidine kinase affects apparent cellular uptake of decitabine in HCT116 colon cancer cells.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Camptothecin; Colonic Neoplasms; Cytarabine; Decitabine; Deoxycytidine; Deoxycytidine Kinase; Equilibrative Nucleoside Transporter 1; Etoposide; Gemcitabine; HCT116 Cells; Humans; Irinotecan; Phosphorylation | 2017 |
Efficacy of Platinum-Based Chemotherapy for Relapsed Small-Cell Lung Cancer after Amrubicin Monotherapy in Elderly Patients and Patients with Poor Performance Status.
Topics: Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Disease-Free Survival; Etoposide; Female; Health Status; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate; Thrombocytopenia | 2018 |
Silencing Artemis Enhances Colorectal Cancer Cell Sensitivity to DNA-Damaging Agents.
Topics: Bleomycin; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; DNA Damage; DNA End-Joining Repair; DNA-Binding Proteins; Endonucleases; Etoposide; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Nuclear Proteins; Radiation Tolerance; Radiation, Ionizing; Treatment Outcome | 2018 |
Novel oxindole derivatives prevent oxidative stress-induced cell death in mouse hippocampal HT22 cells.
Topics: Animals; Antioxidant Response Elements; Apoptosis; Calcium; Camptothecin; Cell Death; Cell Line; Etoposide; Hippocampus; Mice; Neurons; Neuroprotective Agents; Oxidative Stress; Oxindoles; Reactive Oxygen Species; Staurosporine; Tunicamycin | 2018 |
Rechallenge treatment with a platinum-based regimen in patients with sensitive relapsed small-cell lung cancer.
Topics: Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Disease-Free Survival; Etoposide; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Paclitaxel; Recurrence; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate | 2018 |
Nucleolar TRF2 attenuated nucleolus stress-induced HCC cell-cycle arrest by altering rRNA synthesis.
Topics: Amino Acid Sequence; Antineoplastic Agents; Camptothecin; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Nucleolus; Cell Proliferation; Dactinomycin; Etoposide; Gene Expression Regulation, Neoplastic; HEK293 Cells; Hep G2 Cells; Humans; Nuclear Proteins; Phosphoproteins; Protein Binding; Protein Transport; Ribosomes; RNA, Ribosomal; RNA, Small Interfering; Signal Transduction; Telomeric Repeat Binding Protein 2 | 2018 |
Neuroblastoma Cell Lines Are Refractory to Genotoxic Drug-Mediated Induction of Ligands for NK Cell-Activating Receptors.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cisplatin; Cytotoxicity, Immunologic; DNA Damage; Etoposide; Humans; Immunotherapy, Adoptive; Irinotecan; Killer Cells, Natural; Neuroblastoma; Reactive Oxygen Species; Topotecan; Tumor Suppressor Protein p53 | 2018 |
TSPYL2 is a novel regulator of SIRT1 and p300 activity in response to DNA damage.
Topics: A549 Cells; Acetylation; Apoptosis; Camptothecin; Cell Proliferation; Chromatin Assembly and Disassembly; Deoxycytidine; DNA Damage; DNA-Binding Proteins; E1A-Associated p300 Protein; Etoposide; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Nuclear Proteins; Protein Processing, Post-Translational; Sirtuin 1; Transcriptional Activation; Tumor Suppressor Protein p53 | 2019 |
The Cancer/Testes (CT) Antigen HORMAD1 promotes Homologous Recombinational DNA Repair and Radioresistance in Lung adenocarcinoma cells.
Topics: Adenocarcinoma of Lung; Antineoplastic Agents; Camptothecin; Cell Cycle Proteins; Cell Line, Tumor; Cisplatin; DNA End-Joining Repair; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Radiation, Ionizing; Recombinational DNA Repair | 2018 |
Targeting histones for degradation in cancer cells as a novel strategy in cancer treatment.
Topics: Acetylation; Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Cycle; Cell Line, Tumor; DNA Damage; Drug Therapy, Combination; Etoposide; Gamma Rays; Histone Deacetylase Inhibitors; Histones; Homeostasis; Humans; Hydroxamic Acids; Methyl Methanesulfonate; Mice; Valproic Acid; Vorinostat | 2019 |
Sustained Remission After Maintenance Irinotecan in Patient With Multiply Relapsed Hepatoblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chemotherapy, Adjuvant; Disease-Free Survival; Etoposide; Hepatoblastoma; Humans; Ifosfamide; Infant; Irinotecan; Liver Neoplasms; Male; Neoplasm Recurrence, Local; Remission Induction | 2020 |
The ARK Assay Is a Sensitive and Versatile Method for the Global Detection of DNA-Protein Crosslinks.
Topics: Camptothecin; Cross-Linking Reagents; DNA; DNA Repair; DNA-Binding Proteins; Etoposide; Fanconi Anemia; Gene Knockout Techniques; Genetic Techniques; HeLa Cells; Humans; Topoisomerase I Inhibitors | 2020 |
Pausing sites of RNA polymerase II on actively transcribed genes are enriched in DNA double-stranded breaks.
Topics: Camptothecin; DNA Breaks, Double-Stranded; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Etoposide; HeLa Cells; Humans; RNA Polymerase II; Transcription Initiation Site; Transcriptional Activation | 2020 |
Water-Templated, Polysaccharide-rich Bioartificial 3D Microarchitectures as Extra-Cellular Matrix Bioautomatons.
Topics: Acrylates; Antineoplastic Agents; Biomimetic Materials; Camptothecin; Cell Line, Tumor; Drug Screening Assays, Antitumor; Etoposide; Extracellular Matrix; Humans; Hydrogels; Mannans; Methacrylates; Polymerization; Porosity; Reproducibility of Results; Spheroids, Cellular; Tissue Engineering; Tissue Scaffolds | 2020 |
The Indenoisoquinoline LMP517: A Novel Antitumor Agent Targeting both TOP1 and TOP2.
Topics: Animals; Camptothecin; Carcinoma, Small Cell; Cell Line, Tumor; Chickens; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Etoposide; Female; Histones; Humans; Indans; Isoquinolines; Lung Neoplasms; Lymphoma; Mice; Mice, Nude; Molecular Targeted Therapy; Neoplasm Proteins; Poultry Diseases; Random Allocation; Recombinant Proteins; Substrate Specificity; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Xenograft Model Antitumor Assays | 2020 |
Ancient Sturgeons Possess Effective DNA Repair Mechanisms: Influence of Model Genotoxicants on Embryo Development of Sterlet,
Topics: Animals; Benzo(a)pyrene; Camptothecin; Comet Assay; DNA Damage; DNA Fragmentation; DNA Repair; Embryo, Nonmammalian; Embryonic Development; Etoposide; Female; Fishes; Male; Mutagenicity Tests; Mutagens | 2020 |
Combination chemotherapy consisting of irinotecan, etoposide, and carboplatin for refractory or relapsed neuroblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Etoposide; Humans; Irinotecan; Neoplasm Recurrence, Local; Neuroblastoma; Neutropenia; Retrospective Studies | 2022 |